
<html lang="en"     class="pb-page"  data-request-id="5e50f570-7565-49a1-9d77-f9c0da8b7246"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.8b01147;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2018.61.issue-19;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton’s Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis" /></meta><meta name="dc.Creator" content="Wataru  Kawahata" /></meta><meta name="dc.Creator" content="Tokiko  Asami" /></meta><meta name="dc.Creator" content="Takao  Kiyoi" /></meta><meta name="dc.Creator" content="Takayuki  Irie" /></meta><meta name="dc.Creator" content="Haruka  Taniguchi" /></meta><meta name="dc.Creator" content="Yuko  Asamitsu" /></meta><meta name="dc.Creator" content="Tomoko  Inoue" /></meta><meta name="dc.Creator" content="Takahiro  Miyake" /></meta><meta name="dc.Creator" content="Masaaki  Sawa" /></meta><meta name="dc.Description" content="Bruton’s tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis. A series of novel aminotriazines were..." /></meta><meta name="Description" content="Bruton’s tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis. A series of novel aminotriazines were..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 14, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01147" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01147" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01147" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01147" /></link>
        
    
    

<title>Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton’s Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01147" /></meta><meta property="og:title" content="Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton’s Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0017.jpeg" /></meta><meta property="og:description" content="Bruton’s tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis. A series of novel aminotriazines were identified as highly selective inhibitors of BTK by a scaffold-hopping approach. Subsequent SAR studies of this series using two conformationally different BTK proteins, an activated form of BTK and an unactivated form of BTK, led to the discovery of a highly selective BTK inhibitor, 4b. With significant efficacy in models in vivo and good ADME and safety profiles, 4b was advanced into preclinical studies." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01147"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01147">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01147&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01147&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01147&amp;href=/doi/10.1021/acs.jmedchem.8b01147" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 8917-8933</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01141" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01148" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton’s Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Wataru Kawahata</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wataru Kawahata</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</div></div><span class="conrtib-corresp"><strong>*</strong>Tel.: +81(78)302-7040. E-mail: <a href="/cdn-cgi/l/email-protection#8afdebfeebf8ffa4e1ebfdebe2ebfeebcae9ebf8e4ebe8e3e5a4e9e5e7"><span class="__cf_email__" data-cfemail="730412071201065d181204121b120712331012011d12111a1c5d101c1e">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wataru++Kawahata">Wataru Kawahata</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2305-7363" title="Orcid link">http://orcid.org/0000-0002-2305-7363</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tokiko Asami</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tokiko Asami</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tokiko++Asami">Tokiko Asami</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Takao Kiyoi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takao Kiyoi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takao++Kiyoi">Takao Kiyoi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Takayuki Irie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takayuki Irie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takayuki++Irie">Takayuki Irie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haruka Taniguchi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haruka Taniguchi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haruka++Taniguchi">Haruka Taniguchi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yuko Asamitsu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuko Asamitsu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuko++Asamitsu">Yuko Asamitsu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tomoko Inoue</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tomoko Inoue</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tomoko++Inoue">Tomoko Inoue</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Takahiro Miyake</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Takahiro Miyake</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Takahiro++Miyake">Takahiro Miyake</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Masaaki Sawa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Masaaki Sawa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Masaaki++Sawa">Masaaki Sawa</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0077-2188" title="Orcid link">http://orcid.org/0000-0002-0077-2188</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01147&amp;href=/doi/10.1021%2Facs.jmedchem.8b01147" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 8917–8933</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">September 14, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 July 2018</li><li><span class="item_label"><b>Published</b> online</span>14 September 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 October 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01147" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01147</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8917%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DWataru%2BKawahata%252C%2BTokiko%2BAsami%252C%2BTakao%2BKiyoi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D19%26contentID%3Dacs.jmedchem.8b01147%26title%3DDesign%2Band%2BSynthesis%2Bof%2BNovel%2BAmino-triazine%2BAnalogues%2Bas%2BSelective%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitors%2Bfor%2BTreatment%2Bof%2BRheumatoid%2BArthritis%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8933%26publicationDate%3DOctober%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01147"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2415</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01147" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton’s Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Wataru&quot;,&quot;last_name&quot;:&quot;Kawahata&quot;},{&quot;first_name&quot;:&quot;Tokiko&quot;,&quot;last_name&quot;:&quot;Asami&quot;},{&quot;first_name&quot;:&quot;Takao&quot;,&quot;last_name&quot;:&quot;Kiyoi&quot;},{&quot;first_name&quot;:&quot;Takayuki&quot;,&quot;last_name&quot;:&quot;Irie&quot;},{&quot;first_name&quot;:&quot;Haruka&quot;,&quot;last_name&quot;:&quot;Taniguchi&quot;},{&quot;first_name&quot;:&quot;Yuko&quot;,&quot;last_name&quot;:&quot;Asamitsu&quot;},{&quot;first_name&quot;:&quot;Tomoko&quot;,&quot;last_name&quot;:&quot;Inoue&quot;},{&quot;first_name&quot;:&quot;Takahiro&quot;,&quot;last_name&quot;:&quot;Miyake&quot;},{&quot;first_name&quot;:&quot;Masaaki&quot;,&quot;last_name&quot;:&quot;Sawa&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;8917-8933&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01147&quot;},&quot;abstract&quot;:&quot;Bruton’s tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis. A series of novel aminotriazines were identified as highly selective inhibitors of BTK by a scaffold-hopping approach. Subsequent SAR studies of this series using two conformationally different BTK proteins, an activated form of BTK and an unactivated form of BTK, led to the discovery of a highly selective BTK inhibitor, 4b. With significant efficacy in models in vivo and good ADME and safety profiles, 4b was advanced into preclinical studies.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01147&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01147" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01147&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01147" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01147&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01147" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01147&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01147&amp;href=/doi/10.1021/acs.jmedchem.8b01147" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01147" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01147" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01147%26sid%3Dliteratum%253Aachs%26pmid%3D30216722%26genre%3Darticle%26aulast%3DKawahata%26date%3D2018%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BNovel%2BAmino-triazine%2BAnalogues%2Bas%2BSelective%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitors%2Bfor%2BTreatment%2Bof%2BRheumatoid%2BArthritis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D19%26spage%3D8917%26epage%3D8933%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/jmcmar.2018.61.issue-19/20181011/jmcmar.2018.61.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Bruton’s tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis. A series of novel aminotriazines were identified as highly selective inhibitors of BTK by a scaffold-hopping approach. Subsequent SAR studies of this series using two conformationally different BTK proteins, an activated form of BTK and an unactivated form of BTK, led to the discovery of a highly selective BTK inhibitor, <b>4b</b>. With significant efficacy in models in vivo and good ADME and safety profiles, <b>4b</b> was advanced into preclinical studies.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62848" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62848" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Bruton’s tyrosine kinase (BTK) is a member of the Tec family of nonreceptor tyrosine kinases. It is expressed mainly in all hematopoietic cells, especially in B-cells and myeloid cells, but very low expression levels of BTK are also found in T-cells, natural killer cells, and plasma cells.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> BTK is essential for B-cell maturation by mediating B-cell-receptor (BCR) signaling, and it also plays a crucial role in macrophages and mast-cell activation via the high-affinity IgE receptor (FcεRI), releasing several pro-inflammatory mediators.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4−7)</a> The implication of BTK in a number of pathological processes has been reported, and thus, BTK has emerged as a promising target for new therapeutic interventions in a wide array of diseases involving B-cell or macrophage activation, such as B-cell malignancies, asthma, rheumatoid arthritis, and systemic lupus erythematosus.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> Ibrutinib, the first FDA-approved covalent BTK inhibitor, has demonstrated impressive response rates in patients with mantle-cell lymphoma and chronic lymphocytic leukemia,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and several second-generation covalent BTK inhibitors are currently being evaluated in clinical trials for treating those B-cell malignancies.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> These BTK inhibitors covalently bind to the Cys481 residue in the ATP-binding site of BTK to inhibit BTK enzymatic activity irreversibly. However, there is still a high demand for noncovalent BTK inhibitors for the treatment of autoimmune diseases because of the propensity of Michael acceptors to form reactive metabolites.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> In addition, the use of kinase inhibitors for nononcology indications is thought to be a difficult challenge because of anticipated adverse effects related to off-target activities of inhibitors.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> Hence, it is significantly important to optimize kinase selectivity for producing safer drugs, and a number of selective noncovalent BTK inhibitors are also under evaluation in clinical trials.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> As a part of our effort to develop selective and noncovalent BTK inhibitors, we previously reported a series of novel pyrimidine analogues as highly selective and reversible inhibitors of BTK represented by an initial lead compound, <b>1</b>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Unfortunately, efforts to optimize compound <b>1</b> were unsuccessful because of the hERG-inhibitory activities of this chemical series, which would cause QT prolongation. In this article, we describe the design and synthesis of novel and potent triazine-based inhibitors for BTK to overcome the hERG issue by a scaffold-hopping approach from compound <b>1</b>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23226" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23226" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the course of our work on the pyrimidine-based analogues, those compounds were found to show hERG inhibition, which seemed difficult to eliminate by modifying substituents. Therefore, we turned our attention to exploration of a new scaffold. Namely, we got interested in replacing the pyrimidine core with a N-containing heteroaryl group, in which the nitrogen atom would act as the H-bond acceptor to interact with the hinge region of BTK (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Scaffold hopping of core structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">First, we synthesized heteroaryl analogues <b>2a</b>–<b>2c</b> by replacing the pyrimidine ring of compound <b>1</b> with other possible N-containing heteroaryl rings and tested for the inhibition of two conformationally different recombinant human BTK enzymes, an activated conformation of BTK (BTK[A]) and an unactivated conformation of BTK (BTK[U]), on the basis of the fact that compounds that preferentially bind to BTK[U] show higher kinase selectivity than compounds that bind to BTK[A], as we previously reported.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a></div><div class="NLM_p">It can be seen from the results in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> that all compounds synthesized here exhibited more potent inhibition for BTK[U], as expected, because the parent compound, <b>1</b>, was designed to bind BTK[U] preferentially. The pyrazine (<b>2a</b>), the 1,3,4-triazine (<b>2b</b>), and the 1,3,5-triazine (<b>2c</b>) showed weak inhibition for BTK[A], with IC<sub>50</sub> values in the micromolar range (1.8–5.6 μM). The 1,3,4-triazine (<b>2b</b>) and the 1,3,5-triazine (<b>2c</b>) displayed strong inhibition for BTK[U] (IC<sub>50</sub> = 10 and 6.4 nM, respectively), but the pyrazine (<b>2a</b>) was less potent for BTK[U] (IC<sub>50</sub> = 100 nM). These results suggested that the nitrogen atom at the 3-position of the central heteroaryl ring was important for the inhibitory potency for BTK[U]. In our previous paper, the docking model of the pyrimidine analogue with BTK suggested that the 4-position of the pyrimidine ring seems to be able to interact with the hinge region of BTK.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Therefore, we next examined the effects of substituents at the 4-position of the 1,3,5-triazine ring. Introduction of a methyl group resulted in a decrease in the inhibitory potency (<b>2d</b>, IC<sub>50</sub> = 7800 and 37 nM for BTK[A] and [U], respectively). Incorporation of an amino group into compound <b>2c</b> gave compound <b>2e</b>, which displayed a dramatic improvement in the inhibitory potency for both BTK[A] and [U], with IC<sub>50</sub> values of 190 and 0.67 nM, respectively. The methoxy analogue, <b>2f</b>, was significantly less potent for BTK[U] (IC<sub>50</sub> = 80 nM), and demethylation (<b>2g</b>) led to a further decrease of the inhibitory potency even though <b>2g</b> had a hydrogen-bond donor similar to that of the amino analogue (IC<sub>50</sub> = 8800 nM for BTK[U]).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial SAR Study for the Core Structure and Its Substituents</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Values are the means of two separate experiments. See the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for assay details. All values are rounded to two significant digits.</p></div></div><div></div></div><div class="NLM_p">To probe the binding mode of the 1,3,5-triazine analogue, we determined the X-ray cocrystal structure of <b>2e</b> complexed with BTK. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, <b>2e</b> binds in the ATP-binding pocket of BTK, adopting a Src-like inactive conformation, which has been reported previously.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The <i>t</i>-butylphenyl group of compound <b>2e</b> occupies a back pocket called the H3 pocket. Compound <b>2e</b> also forms several important hydrogen bonds with the hinge region of BTK. The NH at the 2-position and the nitrogen atom at the 3-position of the central triazine ring make two hydrogen bonds with the backbone carbonyl and NH of Met477, respectively. The NH<sub>2</sub> at the 4-position of the triazine ring is engaged in an extra H-bond interaction with the backbone carbonyl of Glu475. The benzene ring at the 6-position of the triazine makes a favorable hydrophobic interaction with Val416, and the methyl substituent on the benzene further enhances this hydrophobic interaction. The X-ray cocrystal structure of <b>2e</b> bound to BTK revealed that more space is available around this methyl group, where Asp539 and Lys430 can provide additional interactions with the compound. Thus, we synthesized <b>2h</b> by introducing a hydroxyl group at the methylbenzene, which is capable of making H-bonds. As expected, this modification further improved the inhibitory potency against both BTK[A] and BTK[U] (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, IC<sub>50</sub> = 43 and <0.3 nM for BTK[A] and [U], respectively). On the basis of those results, we selected <b>2h</b>, which has the 1,3,5-triazine ring, for further optimization.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray cocrystal structure of BTK complexed with <b>2e</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZZ4">5ZZ4</a>). (A) Key interactions of <b>2e</b> in the BTK active site. Hydrogen bonds are shown as green dotted lines. (B) Surface presentation of binding of <b>2e</b> to BTK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Previous work in our laboratory has demonstrated that on the right-hand side (RHS), the benzoylmorpholine moiety can be replaced with the 4-morpholinophenyl, which results in better in vitro ADME properties.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In fact, the 4-morpholinophenyl analogue, <b>3a</b>, showed a 2-fold increase in Caco-2 cell permeability compared with that of the benzoylmorpholine analogue, <b>2h</b> (<i>P</i><sub>app</sub> = 7.4 × 10<sup>6</sup> and 16.3 × 10<sup>6</sup> cm<sup>–1</sup> s<sup>–1</sup> for <b>2h</b> and <b>3a</b>, respectively), whereas the kinase-inhibitory potency against BTK of <b>3a</b> was comparable to that of <b>2h</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Thus, we initiated our efforts to explore the SAR on the left-hand side (LHS), which would interact with the H3 hydrophobic pocket of BTK, while keeping the central aminotriazine ring unchanged and the RHS constant as 4-morpholinophenyl. Realizing the metabolic lability of the terminal <i>t</i>-butyl group in <b>3a</b> as we previously described,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> we focused our efforts on exploring replacement of the <i>t</i>-butyl group to improve the metabolic stability. Replacement with isopropyl (<b>3b</b>) or cyclopropyl (<b>3c</b>) resulted in a slight decrease of potency for both BTK[A] and [U], although cyclopropyl analogue <b>3c</b> showed improved metabolic stability in human liver microsomes. Introduction of a dimethylamino group (<b>3d</b>) led to further improvements in stability in both human and mouse microsome, whereas the inhibitory potency for BTK[A] was maintained. However, a 6-fold decrease in the inhibitory potency for BTK[U] was observed, suggesting the H3 pocket in BTK[A] and BTK[U] have different sensitivities to substituents at the terminal benzene. Replacement of the benzene ring with thiazole (<b>3e</b>) or thiophene (<b>3f</b>) resulted in a significant decrease in potency against BTK[A], whereas the decrease in the potency against BTK[U] was modest. Compound <b>3g</b>, having tetrahydrobenzothiophene, was equipotent to compound <b>3a</b>, but this substitution did not improve the metabolic stability.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of H3-Pocket Binder with Simple Amide</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Values are the means of two separate experiments. See the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_001.pdf" class="ext-link">Supporting Information</a> for assay details. NT, not tested. All values are rounded to two significant digits.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Remaining percentage of parent compounds after a 30 min treatment of liver microsomes.</p></div></div><div></div></div><div class="NLM_p">Up to this point, all compounds synthesized showed poor metabolic stability, presumably because of the lability of the amide bond linking the terminal benzene in addition to the <i>t</i>-butyl-group metabolism that was reported previously.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In an attempt to improve the metabolic lability by modifying the terminal benzene on the LHS, we next designed various cyclic amide analogues (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Cyclization of <b>3a</b> or <b>3c</b> led to deterioration of the potency against both BTK[A] and [U] (compounds <b>3h</b>–<b>3j</b>), but this cyclization resulted in a significant improvement of the metabolic stabilities in both human and mouse liver microsomes (compound <b>3i</b>). Introduction of a fluorine atom and a cyano group into the terminal <i>t</i>-butyl benzene (<b>3k</b>) improved the potency while maintaining the metabolic stability. Replacement of the cyanopropane group in <b>3k</b> with a cyclopropyl group (<b>3l</b>) further improved the BTK-inhibitory potency (70 nM for BTK[A]) but resulted in poor stability in mouse liver microsomes. Incorporation of a double bond into the cyclic amide (<b>3m</b>) resulted in a remarkable improvement of BTK inhibition (4.1-fold and 5.3-fold for BTK[A] and BTK[U], respectively, vs <b>3l</b>) but moderate metabolic stability. Compound <b>3n</b>, having dihydropyrrolopyrazine, retained potency, but the switch was not sufficient because of the metabolic instability. Thus, it was concluded that the dihydroisoquinolone core with the cyclopropyl group and fluorine atom were optimal for potency and resulted in acceptable metabolic stability, as was the case of our previous report.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Exploration of H3-Pocket Binder with Cyclic Amide Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Values are the means of two separate experiments. See the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_001.pdf" class="ext-link">Supporting Information</a> for assay details. NT, not tested. All values are rounded to two significant digits.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Remaining percentage of parent compounds after a 30 min treatment of liver microsomes.</p></div></div><div></div></div><div class="NLM_p">Exploration of the SAR on the RHS was conducted to optimize the potency and physicochemical properties. On the basis of the SAR results on the pyrimidine-based inhibitors described in a previous study,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> we focused our efforts on exploring substitution on the pyrazole and pyrrole ring. Thus, a small set of N-substituted pyrazole and pyrrole analogues was synthesized to evaluate the potency and physicochemical properties (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Replacement of the morpholinobenzene with pyrazole as in compound <b>4a</b> resulted in an approximately 2-fold improvement of the inhibitory potency for BTK[A] with substantial metabolic stabilities and aqueous solubility, as compared with those of <b>3m</b>. The methyl substitution on the pyrazole (<b>4b</b>) led to further improvement of the potency against both BTK[A] and BTK[U] while maintaining good metabolic stabilities and aqueous solubility. Further substitution of the pyrazole ring with bulky aliphatic groups, such as cyclopropyl (<b>4c</b>) or cyclopropylethyl (<b>4d</b>), sustained BTK-inhibitory potency, but the metabolic stabilities and aqueous solubilities were reduced. Substituted cyanopyrrole (<b>4e</b>–<b>4i</b>) exhibited similar inhibitory potencies but did not show improvement in the metabolic stabilities and aqueous solubilities.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR Study of Pyrazole and Cyanopyrrole Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0015.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0016.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Values are the means of two separate experiments. See <a href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_001.pdf" class="ext-link">Supporting Information</a> for assay details. NT, not tested. All values are rounded to two significant digits.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Remaining percentage of parent compounds after a 30 min treatment of liver microsomes.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Solubility values of compounds were determined by the kinetic-solubility-measurement method.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">IC<sub>50</sub> values of hERG inhibition were determined by the patch-clamp method.</p></div></div><div></div></div><div class="NLM_p">Compound <b>4b</b> and <b>4e</b>, having <i>N</i>-methyl-pyrazole and <i>N</i>-methyl-cyanopyrrole, respectively, were screened over a panel of 312 kinases to evaluate the kinase selectivity (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_001.pdf" class="ext-link">Table S1</a>). Both compounds demonstrated excellent kinase selectivity with similar profiles; only two Tec-family kinases were inhibited at 0.3 μM concentrations (BMX, 80 and 84.3% inhibition with <b>4b</b> and <b>4e</b>, respectively; TEC, 99.5 and 99.2% inhibition with <b>4b</b> and <b>4e</b>, respectively). TEC and BMX have been reported as being implicated in inflammation;<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> this selectivity profile might be beneficial for the treatment of RA. On the other hand, ibrutinib was found to inhibit both BTK[A] and BTK[U] strongly (0.54 and 0.33 nM, respectively). Ibrutinib showed a moderate selectivity profile (34 kinases were inhibited more than 50% at 0.3 μM), supporting our strategy of obtaining selective BTK inhibitors by increasing the BTK[A]/BTK[U] ratio.</div><div class="NLM_p">As described previously, the pyrimidine-based analogues showed hERG inhibition. Therefore, safety profiling of those compounds was conducted against hERG channels (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). All triazine analogues tested showed moderate to no effects on hERG. Importantly, <b>4b</b>, <b>4g</b>, and <b>4h</b> showed greatly reduced activities in the hERG assay. Methylpyrazole analogue <b>4b</b> showed improved hERG inhibition (IC<sub>50</sub> = 24 μM) compared with those of the corresponding pyrimidine-based analogues (IC<sub>50</sub> = 14 μM).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Methylpyrazole analogue <b>4b</b> met all of our in vitro assay criteria and thus was selected for the further evaluations.</div><div class="NLM_p">We next evaluated the cellular potency of <b>4b</b> by measuring anti-IgM-stimulated phosphorylation of BTK and PLCγ2 in Ramos cells. Upon BCR activation by anti-IgM treatment, Tyr551 is phosphorylated by upstream signal kinases, such as LYN and SYK, followed by autophosphorylation of Tyr223 to activate BTK; then, the activated BTK phosphorylates PLCγ2, which induces intracellular calcium mobilization. As shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, compound <b>4b</b> potently inhibited those phosphorylations with IC<sub>50</sub> values of 19, 14, and 26 nM, respectively. Furthermore, <b>4b</b> significantly inhibited anti-IgM-induced B-cell activation (CD86 expression) in human PBMC with an IC<sub>50</sub> value of 13 nM.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of anti-IgM-stimulated phosphorylation of BTK and PLCγ2 in Ramos cells. Ramos cells were treated with <b>4b</b> at various concentrations for 1 h and then stimulated with anti-IgM for 10 min. The phosphorylation levels of BTK (Tyr223 and Tyr551) and PLCγ2 (Tyr1217) were analyzed by Western blotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With its strong cellular potency and excellent kinase-selectivity profile, compound <b>4b</b> was further evaluated in vivo. In pharmacokinetics (PK) studies of <b>4b</b> using multiple species, <b>4b</b> exhibited good PK profiles with oral bioavailabilities of 65% in mice, 44% in rats, and 43% in dogs (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). On the basis of its adequate exposure in animals, <b>4b</b> was advanced into several mouse models of inflammatory and autoimmune diseases to examine its in vivo efficacy. For those animal models, we used the following vehicle to solubilize <b>4b</b>: DMSO/PEG400/30% (w/v) HP-β-CD (5:30:65).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetic Parameters of <b>4b</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dosage and route</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–<i>t</i>)</sub> (ng/mL·h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>(0–∞)</sub> (ng/mL·h)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>d</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center">CL (L/h/kg)</th><th class="colsep0 rowsep0" align="center">MRT<sub>(0–∞)</sub> (h)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="10" align="center">Mice</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">iv, 2 mg/kg<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">3.27</td><td class="colsep0 rowsep0" align="center">—</td><td class="colsep0 rowsep0" align="center">2887</td><td class="colsep0 rowsep0" align="center">3107</td><td class="colsep0 rowsep0" align="center">3114</td><td class="colsep0 rowsep0" align="center">3.03</td><td class="colsep0 rowsep0" align="center">0.64</td><td class="colsep0 rowsep0" align="center">1.30</td><td class="colsep0 rowsep0" align="center">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">po, 10 mg/kg<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">0.95</td><td class="colsep0 rowsep0" align="center">0.50</td><td class="colsep0 rowsep0" align="center">4619</td><td class="colsep0 rowsep0" align="center">10 208</td><td class="colsep0 rowsep0" align="center">10 242</td><td class="colsep0 rowsep0" align="center">—</td><td class="colsep0 rowsep0" align="center">—</td><td class="colsep0 rowsep0" align="center">1.56</td><td class="colsep0 rowsep0" align="center">65. 8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="10" align="center">Rats</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">iv, 1 mg/kg<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">1.51</td><td class="colsep0 rowsep0" align="center">—</td><td class="colsep0 rowsep0" align="center">1376</td><td class="colsep0 rowsep0" align="center">1917</td><td class="colsep0 rowsep0" align="center">1960</td><td class="colsep0 rowsep0" align="center">1.10</td><td class="colsep0 rowsep0" align="center">0.51</td><td class="colsep0 rowsep0" align="center">1.79</td><td class="colsep0 rowsep0" align="center">—</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">po, 10 mg/kg<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">2.44</td><td class="colsep0 rowsep0" align="center">2.00</td><td class="colsep0 rowsep0" align="center">1476</td><td class="colsep0 rowsep0" align="center">8696</td><td class="colsep0 rowsep0" align="center">8706</td><td class="colsep0 rowsep0" align="center">—</td><td class="colsep0 rowsep0" align="center">—</td><td class="colsep0 rowsep0" align="center">4.88</td><td class="colsep0 rowsep0" align="center">44.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="10" align="center">Dogs</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">iv, 1 mg/kg<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">3.91</td><td class="colsep0 rowsep0" align="center">—</td><td class="colsep0 rowsep0" align="center">4963</td><td class="colsep0 rowsep0" align="center">11 321</td><td class="colsep0 rowsep0" align="center">11 479</td><td class="colsep0 rowsep0" align="center">0.29</td><td class="colsep0 rowsep0" align="center">0.088</td><td class="colsep0 rowsep0" align="center">3.31</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center">po, 2 mg/kg<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">3.59</td><td class="colsep0 rowsep0" align="center">2.00</td><td class="colsep0 rowsep0" align="center">2090</td><td class="colsep0 rowsep0" align="center">9851</td><td class="colsep0 rowsep0" align="center">10 032</td><td class="colsep0 rowsep0" align="center">—</td><td class="colsep0 rowsep0" align="center">—</td><td class="colsep0 rowsep0" align="center">—</td><td class="colsep0 rowsep0" align="center">43.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Values are the means of three animals.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Free base, vehicle: 5:30:65 DMSO/PEG400/30% (w/v) HP-β-CD in water.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Sulfate salt, vehicle: 5:5:90 DMSO/solutol HS 15/saline.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Sulfate salt, vehicle: 0.5% MC.</p></div></div></div><div class="NLM_p">First, we examined the effects of <b>4b</b> on FcεRI-mediated type I allergy in a passive-cutaneous-anaphylaxis (PCA) mouse model to evaluate the anti-inflammatory efficacy.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Oral administration of <b>4b</b> at 30 mg/kg significantly inhibited the PCA reaction, and its inhibition rate was 69% as compared with that of vehicle control (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Efficacy of <b>4b</b> in a mouse PCA model. See the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for experimental details. *<i>P</i> < 0.05 according to Dunnett’s test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, we tested <b>4b</b> in a collagen-induced-arthritis (CIA) mouse model to investigate the efficacy on autoimmune disease.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Compound <b>4b</b> was administered orally (15, 30, and 60 mg/kg, b.i.d.) for 19 days, and inhibition of arthritis development was evaluated by measuring the clinical arthritis index (AI), which reflects paw swelling and joint inflammation. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, a marked reduction in the severity of AI was observed in a dose-dependent manner, suggesting compound <b>4b</b> attenuates arthritis development by inhibiting BTK in vivo.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Efficacy of <b>4b</b> in a collagen-induced-arthritis (CIA) mouse model. See the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for experimental details. *<i>P</i> < 0.05, **<i>P</i> < 0.01, ***<i>P</i> < 0.001 according to Dunnett’s test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Syntheses of pyrazine <b>2a</b> and 1,3,5-triazine analogues <b>2b</b>–<b>2h</b> are shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Commercially available 3-amino-2-methylphenylboronic acid pinacol ester, <b>5</b>, was coupled with 4-<i>t</i>-butylbenzoyl chloride to give boronate ester <b>6</b>. (4-Amino-phenyl)(morpholino)methanone, <b>7</b>, was coupled with 2,6-dichloropyrazine by a Buchwald–Hartwig reaction, and then the resulting chloropyrazine, <b>8</b>, was coupled with boronate ester <b>6</b> by a Suzuki–Miyaura cross-coupling reaction to give pyrazine <b>2a</b>. 1,3,5-Triazine analogues <b>2c</b>–<b>2g</b> were obtained in a manner similar to the synthesis of <b>2a</b> using the appropriate dichloro-1,3,5-triazines. Demethylation of <b>2f</b> afforded the corresponding hydroxy triazine derivative, <b>2g</b>.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>2a</b>–<b>2h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-<i>t</i>-butylbenzoyl chloride, pyridine, DCM, rt; (b) 2,6-dichloropyrazine, Pd<sub>2</sub>(dba)<sub>3</sub>, sodium <i>t</i>-butoxide, 90 °C; (c) <b>6</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, NaHCO<sub>3</sub>, DME, water, 110 °C; (d) dichloro-1,3,5-triazines (nonsubstituted, 6-methyl, or 2-amino), DIEA, DMF, 0 °C or 2,4-dichloro-6-methoxy-1,3,5-triazine, DIEA, MeOH, 0 °C; (e) <b>6</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, water, 110 °C; (f) 4 M HCl in dioxane, MeOH, 50 °C; (g) 4-<i>t</i>-butylbenzoyl chloride, TEA, DCM, rt; (h) 1 M NaOH(aq), THF, MeOH, rt; (i) <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride, EDC, HOBt, TEA, DMF, rt; (j) methylmagnesium bromide, THF, 0 °C to rt; (k) selenium oxide, 1,4-dioxane, water, 100 °C; (l) <i>S</i>-methylisothiosemicarbazide hydroiodide, Na<sub>2</sub>CO<sub>3</sub>, ethanol, rt; (m) <b>7</b>, copper(I) 3-methylsalicylate, cesium carbonate, palladium(II) acetate, xantphos, toluene, 180 °C; (n) TBSCl, imidazole, DCM, rt; (o) Fe, NH<sub>4</sub>Cl, 80 °C; (p) 4-<i>t</i>-butylbenzoyl chloride, TEA, THF, rt; (q) bis(pinacolato)diboron, Pd(dppf)Cl<sub>2</sub>–CH<sub>2</sub>Cl<sub>2</sub>, potassium acetate, 1,4-dioxane, 80 °C; (r) <b>9e</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, water, 110 °C; (s) 1 M TBAF in THF, THF, rt.</p></p></figure><div class="NLM_p">1,2,4-Triazine <b>15</b> was synthesized from commercially available methyl 2-amino-benzoate, <b>10</b>. Namely, coupling of <b>10</b> with 4-<i>t</i>-butylbenzoyl chloride, followed by hydrolysis of the methyl ester gave carboxylic acid <b>12</b>. The carboxyl group in <b>12</b> was then converted to an acetyl group using methylmagnesium bromide via Weinreb amide <b>13</b>. The resulting acetophenone, <b>14</b>, was oxidized by selenium oxide, after which cyclization with <i>S</i>-methylisothiosemicarbazide furnished 1,2,4-triazine <b>15</b>.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Finally, desulfurative cross-coupling reaction<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> of <b>15</b> with aniline <b>7</b> gave the desired 1,2,4-triazine, <b>2b</b>.</div><div class="NLM_p">The hydroxymethylbenzene analogue, <b>2h</b>, was synthesized from commercially available (2-bromo-6-nitrophenyl)methanol, <b>16</b>. Protection of the hydroxyl group in <b>16</b> with a TBS group followed by reduction of the nitro group of <b>17</b> afforded aniline <b>18</b>, which was then subjected to amide coupling with 4-<i>t</i>-butylbenzoyl chloride to give <b>19</b>. The bromo group in <b>19</b> was converted to a boronate ester group by treatment with bis(pinacolato)diboron. The resulting boronate ester, <b>20</b>, was then coupled with <b>9e</b> by Suzuki–Miyaura cross-coupling; TBAF treatment then yielded the desired compound, <b>2h</b>.</div><div class="NLM_p">The general procedure for the preparation of the 1,3,5-triazine derivatives with various R<sup>2</sup> groups listed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Tables <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, through Suzuki–Miyaura cross-coupling of the key chloro-triazine intermediate, <b>22</b>. 2-Amino-4,6-dichloro-1,3,5-triazine was treated with 4-morpholinoaniline to give common intermediate <b>22</b>. The required boronate esters, <b>23b</b>–<b>23g</b>, <b>24h</b>–<b>24m</b>, and <b>25</b>, were prepared analogously according to the method reported in the literature (see the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_001.pdf" class="ext-link">Supporting Information</a>). Diamino chlorotriazine <b>22</b> was coupled with the appropriate boronate esters, <b>20</b>, <b>23b</b>–<b>23g</b>, <b>24h</b>–<b>24m</b>, and <b>25</b>, by Suzuki–Miyaura cross-coupling; deprotection of the hydroxyl group then furnished the desired 1,3,5-triazine derivatives. In some cases (<b>3h</b>, <b>3j</b>, and <b>3n</b>), the removal of the acetyl group was observed during the coupling reaction.</div><figure id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>3a</b>–<b>3n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-amino-4,6-dichloro-1,3,5-triazine, DIEA, THF, 0 °C; (b) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, water, 110 °C; (c) 1 M TBAF in THF, THF, rt; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH, THF, rt to 60 °C.</p></p></figure><div class="NLM_p">The five-membered heterocyclic aminotriazine analogues, <b>4a</b>–<b>4i</b>, were synthesized in two steps starting from common intermediate <b>24m</b>, as shown in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. Pyrazole derivatives <b>26a</b>–<b>26d</b> and pyrrole derivatives <b>26e</b>–<b>26i</b> were readily prepared from 2-amino-4,6-dichloro-1,3,5-triazine and the appropriately substituted aminopyrazoles or aminopyrroles, as previously described.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The coupling conditions of <b>24m</b> and chlorotriazines <b>26a</b>–<b>26i</b> were identical to that described above. The acetyl group was successfully removed by transesterification as described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. For <b>4a</b>, THP group was deprotected by treatment with TsOH before transesterification.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>4a</b>–<b>4i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, water, 110 °C; (b) TsOH, MeOH, 60 °C; (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt to 60 °C.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60477" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60477" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A scaffold-hopping strategy to eliminate hERG inhibition was successfully applied to the identification of novel aminotriazine derivatives as potent inhibitors of BTK. Detailed SAR studies using two conformationally different recombinant human BTK enzymes, an activated conformation of BTK and an unactivated conformation of BTK, led to the discovery of <b>4b</b>, which had a significant kinase-selectivity profile. Compound <b>4b</b> exhibited strong inhibitory potency against the BCR activation in B-cells and showed excellent PK profiles in multiple species. In a mouse CIA model, <b>4b</b> significantly reduced paw swelling and joint inflammation in a dose-dependent manner. On the basis of the in vitro potencies, PK profiles, and in vivo efficacies, compound <b>4b</b> was advanced into preclinical development studies.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26743" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26743" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> General Procedures</h3><div class="NLM_p">Reagents and solvents were purchased from commercial sources and used without further purification. All reactions involving air- or moisture-sensitive reagents were performed under a nitrogen atmosphere unless otherwise noted. Microwave reactions were run in a Biotage Initiator set to normal power at the indicated temperature and were performed in sealed microwave-reaction vessels. Thin-layer chromatography (TLC) was carried out using Merck GmbH Precoated silica-gel 60 F254 plates. Silica-gel chromatography refers to the use of an automated medium-pressure flash-chromatography system (Teledyne ISCO or Yamazen Corporation) using prepacked silica-gel cartridges with UV detection at 254 nm. Preparative reverse-phase HPLC (prep-HPLC) was performed on a Waters Autopurification system (dual triggered by target mass and UV 254 nm) using an Imtakt Unison US-C18, 5 mm, 50 × 20 mm i.d. column, eluted with a binary solvent system (A and B) using gradient elution (A, 10 mM aqueous formic acid; B, 10 mM formic acid in MeOH). All yields reported are isolated yields after removal of residual solvents. The purity of a purified compound was determined using a Shimadzu Prominence HPLC system by UV detection (215 nm) with collection of the MS spectra (100–800 <i>m</i>/<i>z</i> scan) of the target peak. The separation method was the following: The column was an Imtakt Cadenza (3 mm, 50 × 2.0 mm i.d.). The mobile phase was acetonitrile in water (10 mM formic acid) from 10 to 90% with a total run-time of 5 min. The flow rate was 0.5 mL/min. <sup>1</sup>H NMR spectra were recorded on a Bruker Ultra Shield 400 Plus; chemical shifts (δ) are reported relative to a signal of TMS. The data format of the NMR spectra is as follows: chemical shift (δ ppm), multiplicity (s, singlet; br, broad signal; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplets; ddd, doublet of doublet of doublets; m, multiplet or overlapping), coupling constant (Hz), and integration. Very broad peaks for protons on hetero atoms are not always indicated. The synthesized compounds for biological assays had over 95% purity unless otherwise noted in the experimental synthesis.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> 4-(<i>t</i>-Butyl)-<i>N</i>-[2-methyl-3-(6-{[4-(morpholine-4-carbonyl)phenyl]amino}pyrazin-2-yl)phenyl]benzamide (<b>2a</b>)</h4><div class="NLM_p last">A mixture of <b>8</b> (53 mg, 0.17 mmol) and <b>6</b> (66 mg, 0.17 mmol) in DME (3 mL) was degassed with N<sub>2</sub> for 5 min. To this mixture, Pd(PPh<sub>3</sub>)<sub>4</sub> (19 mg, 0.017 mmol) was added, and the solution was degassed with N<sub>2</sub> for 5 min. Subsequently, NaHCO<sub>3</sub> (28 mg, 0.34 mmol) in water (1 mL) was added, and the solution was degassed with N<sub>2</sub> for 2 min. The mixture was heated in a microwave reactor at 110 °C for 20 min. The reaction mixture was extracted with ethyl acetate (2 × 40 mL). The combined organic layers were washed with water (5 mL) and concentrated. The residue was purified by flash column chromatography using 50% ethyl acetate in hexane as eluent to afford <b>2a</b> as an off-white solid (65 mg, 0.118 mmol, 69%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.94 (s, 1H), 9.88 (s, 1H), 8.28 (s, 1H), 8.10 (s, 1H), 8.00–7.92 (m, 2H), 7.85–7.76 (m, 2H), 7.60–7.52 (m, 2H), 7.53–7.43 (m, 1H), 7.42–7.34 (m, 4H), 3.62–3.55 (m, 4H), 3.55–3.43 (m, 4H), 2.26 (s, 3H), 1.33 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 169.5, 165.8, 154.9, 151.4, 151.3, 142.6, 138.9, 137.8, 134.3, 133.7, 132.8, 132.2, 128.9, 128.2, 128.0, 128.0, 127.9, 126.3, 125.7, 117.8, 66.6, 35.1, 31.4, 15.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>36</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 550.2818, found: 550.2810, purity 100%.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> 4-(<i>t</i>-Butyl)-<i>N</i>-[2-methyl-3-(3-{[4-(morpholine-4-carbonyl)phenyl]amino}-1,2,4-triazin-5-yl)phenyl]benzamide (<b>2b</b>)</h4><div class="NLM_p last">To a suspension of <b>15</b> (40 mg, 0.10 mmol) in toluene (2 mL) were added <b>7</b> (25 mg, 0.12 mmol), copper(I) 3-methylsalicylate (44 mg, 0.20 mmol), Cs<sub>2</sub>CO<sub>3</sub> (73 mg, 0.22 mmol), PdOAc<sub>2</sub> (2.29 mg, 10.19 nmol), and xantphos (12 mg, 0.02 mmol). The mixture was heated in a microwave reactor at 170 °C for 3 h. The reaction mixture was filtered through a bed of Celite to remove insoluble materials. After removal of the solvent, the residue was purified by prep-HPLC to afford <b>2b</b> as an off-white solid (8 mg, 0.013 mmol, 13%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.47 (s, 1H), 10.03 (s, 1H), 9.09 (s, 1H), 7.96 (d, <i>J</i> = 8.02 Hz, 2H), 7.89 (d, <i>J</i> = 8.31 Hz, 2H), 7.64–7.36 (m, 7H), 3.61 (br, 4H), 3.51 (br, 4H), 2.33 (s, 3H), 1.33 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 169.5, 165.9, 155.4, 155.0, 150.8, 143.0, 141.4, 136.0, 134.6, 133.4, 132.0, 130.7, 129.6, 129.2, 128.7, 128.0, 126.7, 125.7, 119.1, 66.6, 35.2, 31.4, 15.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>35</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 551.2771, found: 551.2759, purity 97%.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> 4-(<i>t</i>-Butyl)-<i>N</i>-[2-methyl-3-(4-{[4-(morpholine-4-carbonyl)phenyl]amino}-1,3,5-triazin-2-yl)phenyl]benzamide (<b>2c</b>)</h4><div class="NLM_p">To a solution of <b>9c</b> (50.0 mg, 0.16 mmol) and <b>6</b> (62 mg, 0.16 mmol) in DME (3 mL), Pd(PPh<sub>3</sub>)<sub>4</sub> (18 mg, 0.016 mmol) and K<sub>2</sub>CO<sub>3</sub> (43 mg, 0.31 mmol) in water (1 mL) were added, and the mixture was heated in a microwave reactor at 110 °C for 20 min. The reaction mixture was extracted with ethyl acetate (2 × 40 mL), and the combined organic layers were washed with water (5 mL), dried over sodium sulfate, filtered, and concentrated. The crude material was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford <b>2c</b> as a colorless solid (25 mg, 0.045 mmol, 29%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.56 (s, 1H), 9.97 (s, 1H), 8.91 (s, 1H), 7.99–7.89 (m, 2H), 7.89–7.82 (m, 2H), 7.68–7.24 (m, 7H), 3.66–3.54 (m, 4H), 3.56–3.40 (m, 4H), 2.39 (s, 3H), 1.33 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.8, 168.8, 166.2, 165.3, 163.2, 154.4, 139.9, 137.3, 133.1, 132.1, 131.9, 131.9, 131.5, 131.4, 131.3, 128.7, 128.6, 127.9, 127.4, 125.5, 125.1, 119.8, 66.0, 34.6, 30.8, 15.4. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>35</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 551.2771, found: 551.2770, purity 97%.</div><div class="NLM_p last">Compounds <b>2d</b>, <b>2e</b>, and <b>2f</b> were synthesized from 4-(<i>t</i>-butyl)-<i>N</i>-[2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzamide (<b>6</b>) and the appropriate chlorotriazines (<b>9d</b>, <b>9e</b>, and <b>9f</b>, respectively) using a procedure similar to the procedure for the synthesis of <b>2c</b>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 4-(<i>t</i>-Butyl)-<i>N</i>-[2-methyl-3-(4-methyl-6-{[4-(morpholine-4-carbonyl)phenyl]amino}-1,3,5-triazin-2-yl)phenyl]benzamide (<b>2d</b>)</h4><div class="NLM_p last">Colorless solid; 66% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.47 (s, 1H), 9.96 (s, 1H), 7.95 (d, <i>J</i> = 8.45 Hz, 2H), 7.87 (d, <i>J</i> = 8.25 Hz, 2H), 7.67–7.33 (m, 7H), 3.60 (br, 4H), 3.50 (br, 4H), 2.52 (s, 3H), 2.37 (s, 3H), 1.33 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 174.4, 169.4, 165.8, 164.1, 154.9, 140.8, 137.8, 133.8, 133.7, 132.5, 132.1, 131.9, 130.0, 129.2, 128.5, 128.0, 126.0, 125.7, 120.1, 66.6, 35.2, 31.4, 26.0, 15.9. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>37</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 565.2927, found: 565.2936, purity 98.4%.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>N</i>-[3-(4-Amino-6-{[4-(morpholine-4-carbonyl)phenyl]amino}-1,3,5-triazin-2-yl)-2-methylphenyl]-4-(<i>t</i>-butyl)benzamide (<b>2e</b>)</h4><div class="NLM_p last">Colorless solid; 30.7% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.95 (s, 1H), 9.84 (s, 1H), 8.01–7.89 (m, 4H), 7.59–7.49 (m, 3H), 7.46–7.25 (m, 6H), 3.60 (br, 4H), 3.51 (br, 4H), 2.37 (s, 3H), 1.33 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 174.7, 169.6, 167.3, 165.8, 164.7, 154.9, 141.9, 139.7, 137.6, 133.2, 132.2, 128.9, 128.4, 128.4, 128.0, 127.5, 125.7, 125.6, 119.5, 66.6, 35.1, 31.4, 15.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>36</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 566.2880, found: 566.2874, purity 98.9%.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 4-(<i>t</i>-Butyl)-<i>N</i>-[3-(4-methoxy-6-{[4-(morpholine-4-carbonyl)phenyl]amino}-1,3,5-triazin-2-yl)-2-methylphenyl]benzamide (<b>2f</b>)</h4><div class="NLM_p last">Colorless solid; 68% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.48 (br, 1H), 9.96 (s, 1H), 8.00–7.90 (m, 2H), 7.92–7.80 (m, 2H), 7.67 (d, <i>J</i> = 7.95 Hz, 1H), 7.58–7.53 (m, 2H), 7.50–7.45 (m, 1H), 7.42 (d, <i>J</i> = 8.26 Hz, 2H), 7.37 (t, <i>J</i> = 7.77 Hz, 1H), 4.01 (s, 3H), 3.60 (br, 4H), 3.50 (br, 4H), 2.39 (s, 3H), 1.33 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 169.4, 165.8, 154.9, 140.7, 138.4, 137.9, 134.0, 132.5, 132.1, 132.0, 131.9, 130.1, 129.2, 128.5, 128.2, 128.0, 126.0, 125.7, 120.2, 66.6, 55.1, 35.2, 31.4, 16.0. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>37</sub>N<sub>6</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 581.2876, found: 581.2883, purity 100%.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-(<i>t</i>-Butyl)-<i>N</i>-[3-(4-hydroxy-6-{[4-(morpholine-4-carbonyl)phenyl]amino}-1,3,5-triazin-2-yl)-2-methylphenyl]benzamide (<b>2g</b>)</h4><div class="NLM_p last">To a solution of <b>2f</b> (50 mg, 0.086 mmol) in MeOH (1 mL) was added 4 N HCl in 1,4-dioxane (1 mL), and the mixture was stirred at 50 °C for 4 h. The reaction mixture was diluted with 1 N NaOH (30 mL) and extracted with ethyl acetate (3 × 25 mL). The combined organic layers were washed successively with water (20 mL) and brine (30 mL), dried over sodium sulfate, and concentrated. The crude material was purified by flash chromatography on silica gel and eluted with chloroform/MeOH to afford <b>2g</b> as a colorless solid (7 mg, 0.012 mmol, 14%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.34 (s, 1H), 10.32 (s, 1H), 10.00 (s, 1H), 8.03–7.81 (m, 3H), 7.61–7.48 (m, 3H), 7.47–7.31 (m, 4H), 3.60 (br, 4H), 3.50 (br, 5H), 2.29 (s, 3H), 1.33 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 169.4, 166.7, 165.9, 163.8, 155.9, 155.0, 140.7, 137.8, 133.7, 132.9, 132.1, 130.3, 129.8, 128.4, 128.1, 127.0, 126.3, 125.7, 120.2, 66.6, 35.2, 31.4, 15.5. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>35</sub>N<sub>6</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 567.2720, found: 567.2706, purity 100%.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> <i>N</i>-[3-(4-Amino-6-{[4-(morpholine-4-carbonyl)phenyl]amino}-1,3,5-triazin-2-yl)-2-(hydroxymethyl)phenyl]-4-(<i>t</i>-butyl)benzamide (<b>2h</b>)</h4><div class="NLM_p">To a solution of <b>9e</b> (256 mg, 0.764 mmol) in DME (11 mL) were added <b>20</b> (400 mg, 0.764 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (88 mg, 0.076 mmol), K<sub>2</sub>CO<sub>3</sub> (211 mg, 1.53 mmol), and water (3.8 mL), and the mixture was heated in a microwave reactor at 110 °C for 20 min. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 × 25 mL). The combined organic layers were washed successively with water (50 mL) and brine (50 mL); then, the organic layers were dried over sodium sulfate and concentrated. The crude material was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford the corresponding TBS-protected intermediate. The obtained intermediate was dissolved in THF (4.1 mL); then, a 1 M TBAF solution in THF (0.4 mL) was added to the solution. The mixture was stirred for 16 h at room temperature. The solvent was evaporated, and the residue was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford <b>2h</b> as a colorless solid (62 mg, 0.11 mmol, 52%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 9.85 (s, 1H), 8.09–7.95 (m, 1H), 7.95–7.83 (m, 4H), 7.65–7.54 (m, 2H), 7.50 (dd, <i>J</i> = 1.44, 7.78 Hz, 1H), 7.42 (t, <i>J</i> = 7.85 Hz, 1H), 7.36 (d, <i>J</i> = 8.63 Hz, 2H), 7.29 (br, 2H), 5.67 (t, <i>J</i> = 5.57 Hz, 1H), 4.83 (d, <i>J</i> = 5.58 Hz, 2H), 3.60 (br, 4H), 3.50 (br, 4H), 1.33 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 174.0, 169.5, 167.0, 165.3, 164.5, 155.2, 141.7, 139.1, 138.5, 132.3, 132.1, 129.1, 128.4, 127.7, 127.5, 126.4, 126.0, 125.3, 119.6, 66.6, 58.4, 35.2, 31.4. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>36</sub>N<sub>7</sub>O<sub>4</sub> [M + H]<sup>+</sup>: 582.2829, found: 582.2833, purity 100%.</div><div class="NLM_p last">Compounds <b>3a</b>–<b>3g</b> were synthesized from 6-chloro-<i>N</i><sup>2</sup>-(4-morpholinophenyl)-1,3,5-triazine-2,4-diamine (<b>22</b>) and the appropriate boronate esters using a procedure similar to the procedure for the synthesis of <b>2h</b>.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-4-(<i>t</i>-butyl)benzamide (<b>3a</b>)</h4><div class="NLM_p last">Off-white solid; 34% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.41 (s, 1H), 9.42 (br, 1H), 7.99 (s, 1H), 7.92 (d, <i>J</i> = 8.12 Hz, 2H), 7.71–7.54 (m, 4H), 7.51 (d, <i>J</i> = 7.43 Hz, 1H), 7.42 (t, <i>J</i> = 7.82 Hz, 1H), 7.16 (br, 2H), 6.89 (d, <i>J</i> = 8.60 Hz, 2H), 5.72 (br, 1H), 4.91–4.74 (m, 2H), 3.86–3.61 (m, 4H), 3.19–2.90 (m, 4H), 1.33 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 178.1, 173.6, 167.0, 165.3, 155.2, 147.2, 139.4, 138.5, 132.3, 131.7, 127.5, 126.5, 126.0, 125.4, 122.0, 120.7, 115.9, 110.0, 66.6, 58.4, 49.5, 35.2, 31.4. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>31</sub>H<sub>36</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 554.2880, found: 554.2877, purity 96%.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-4-isopropylbenzamide (<b>3b</b>)</h4><div class="NLM_p last">Colorless solid; 15% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.40 (s, 1H), 9.40 (br, 1H), 8.04–7.92 (m, 1H), 7.90 (d, <i>J</i> = 7.92 Hz, 2H), 7.71–7.54 (m, 2H), 7.52–7.34 (m, 4H), 7.17 (br, 2H), 6.88 (d, <i>J</i> = 8.53 Hz, 2H), 5.73 (br, 1H), 4.91–4.67 (m, 2H), 3.85–3.59 (m, 4H), 3.12–2.87 (m, 5H), 1.25 (d, <i>J</i> = 6.94 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.6, 167.0, 165.3, 164.4, 153.0, 147.2, 139.4, 138.4, 132.7, 132.3, 127.8, 127.6, 127.1, 126.5, 125.4, 122.0, 119.9, 115.9, 66.6, 58.4, 49.5, 33.9, 24.1. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>30</sub>H<sub>34</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 540.2723, found: 540.2721, purity 100%.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-4-cyclopropylbenzamide (<b>3c</b>)</h4><div class="NLM_p last">Off-white solid; 23% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 9.41 (br, 1H), 8.04–7.90 (m, 1H), 7.90–7.77 (m, 2H), 7.60 (br, 2H), 7.49 (dd, <i>J</i> = 1.44, 7.80 Hz, 1H), 7.40 (t, <i>J</i> = 7.85 Hz, 1H), 7.28–7.21 (m, 2H), 7.15 (br, 2H), 6.95–6.80 (m, 2H), 5.68 (t, <i>J</i> = 5.72 Hz, 1H), 4.78 (d, <i>J</i> = 4.94 Hz, 2H), 3.85–3.63 (m, 4H), 3.15–2.92 (m, 4H), 2.11–1.94 (m, 1H), 1.11–0.96 (m, 2H), 0.82–0.72 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.8, 173.6, 167.0, 165.2, 164.3, 148.8, 147.2, 139.4, 138.4, 132.2, 131.9, 127.7, 127.6, 126.5, 125.9, 125.4, 122.0, 115.9, 66.6, 58.4, 49.5, 15.7, 10.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>30</sub>H<sub>32</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 538.2567, found: 538.2559, purity 100%.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-4-(dimethylamino)benzamide (<b>3d</b>)</h4><div class="NLM_p last">Colorless solid; 31% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.18 (s, 1H), 9.40 (br, 1H), 8.02 (d, <i>J</i> = 7.80 Hz, 1H), 7.88–7.75 (m, 2H), 7.61 (br, 2H), 7.48–7.31 (m, 2H), 7.14 (br, 2H), 6.94–6.84 (m, 2H), 6.84–6.74 (m, 2H), 5.87–5.59 (m, 1H), 4.93–4.70 (m, 2H), 3.79–3.65 (m, 4H), 3.06–3.02 (m, 4H), 3.01 (s, 6H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.7, 167.0, 165.2, 164.3, 153.0, 147.2, 139.3, 139.0, 132.3, 129.0, 127.5, 125.7, 124.8, 121.9, 121.2, 115.9, 115.1, 111.5, 66.6, 58.5, 49.5. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>29</sub>H<sub>33</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 541.2676, found: 541.2668, purity 100%.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-5-(<i>t</i>-butyl)thiazole-2-carboxamide (<b>3e</b>)</h4><div class="NLM_p">Off-white solid; 14% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.44 (s, 1H), 9.45 (br, 1H), 8.39 (s, 1H), 7.70 (d, <i>J</i> = 8.07 Hz, 1H), 7.66–7.47 (m, 3H), 7.41 (t, <i>J</i> = 7.85 Hz, 1H), 7.19 (br, 2H), 6.99–6.78 (m, 2H), 5.50 (br, 1H), 4.70 (s, 2H), 3.81–3.65 (m, 4H), 3.13–2.94 (m, 4H), 1.42 (s, 9H).</div><div class="NLM_p last"><sup>13</sup>C NMR (101 MHz, DMSO) δ 190.3, 185.3, 173.4, 166.8, 164.3, 159.5, 151.1, 147.3, 143.8, 139.6, 137.1, 134.4, 132.1, 127.8, 127.2, 122.1, 115.9, 66.6, 57.9, 49.5, 38.3, 30.8. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>28</sub>H<sub>33</sub>N<sub>8</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: 561.2396, found: 561.2390, purity 100%.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-5-(<i>t</i>-butyl)thiophene-2-carboxamide (<b>3f</b>)</h4><div class="NLM_p last">Colorless solid; 44% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.31 (s, 1H), 9.42 (br, 1H), 7.81 (d, <i>J</i> = 7.91 Hz, 1H), 7.68 (d, <i>J</i> = 3.84 Hz, 1H), 7.60 (br, 2H), 7.51 (dd, <i>J</i> = 1.40, 7.78 Hz, 1H), 7.39 (t, <i>J</i> = 7.85 Hz, 1H), 7.17 (br, 2H), 7.03 (d, <i>J</i> = 3.84 Hz, 1H), 6.93–6.84 (m, 2H), 5.63 (t, <i>J</i> = 5.85 Hz, 1H), 4.74 (d, <i>J</i> = 6.20 Hz, 2H), 3.80–3.63 (m, 4H), 3.12–2.94 (m, 4H), 1.38 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.6, 166.9, 164.3, 163.2, 160.4, 147.2, 139.5, 137.8, 136.6, 132.2, 129.0, 127.7, 126.9, 126.1, 123.5, 122.0, 115.9, 66.6, 58.2, 49.5, 40.6, 35.1, 32.4. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>29</sub>H<sub>34</sub>N<sub>7</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: 560.2444, found: 560.2455, purity 100%.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-4,5,6,7-tetrahydrobenzo[<i>b</i>]thiophene-2-carboxamide (<b>3g</b>)</h4><div class="NLM_p last">Pale-yellow solid; 24% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.30 (s, 1H), 9.43 (br, 1H), 7.88 (s, 1H), 7.68–7.57 (m, 2H), 7.57–7.45 (m, 2H), 7.40 (t, <i>J</i> = 7.83 Hz, 1H), 7.17 (br, 2H), 6.89 (d, <i>J</i> = 8.71 Hz, 2H), 5.86 (br, 1H), 4.78 (s, 2H), 3.83–3.63 (m, 4H), 3.18–2.88 (m, 4H), 2.84–2.69 (m, 2H), 2.69–2.55 (m, 2H), 1.88–1.69 (m, 4H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 167.0, 164.3, 160.4, 160.2, 147.2, 142.1, 139.4, 138.0, 136.6, 135.8, 132.2, 131.8, 130.1, 129.6, 127.6, 126.6, 122.0, 115.9, 66.6, 58.3, 49.5, 27.9, 25.3, 22.9, 22.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>29</sub>H<sub>32</sub>N<sub>7</sub>O<sub>3</sub>S [M + H]<sup>+</sup>: 558.2287, found: 558.2284, purity 95%.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-5-(<i>t</i>-butyl)isoindolin-1-one (<b>3h</b>)</h4><div class="NLM_p last">To a solution of <b>22</b> (146 mg, 0.48 mmol) in DME (7.1 mL) were added <b>24h</b> (220 mg, 0.48 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (27 mg, 0.024 mmol), K<sub>2</sub>CO<sub>3</sub> (131 mg, 0.95 mmol), and water (2.3 mL), and the mixture was stirred at 100 °C for 4 h. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (2 × 25 mL). The combined organic layers were washed successively with water (50 mL) and brine (50 mL); then, the organic layers were dried over sodium sulfate and concentrated. The crude material was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford <b>3h</b> as a pale-yellow powder (35 mg, 0.062 mmol, 13%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.53 (br, 1H), 7.93–7.44 (m, 8H), 7.30 (br, 2H), 6.90 (d, <i>J</i> = 8.49 Hz, 2H), 5.08 (br, 1H), 4.92 (s, 2H), 4.59–4.29 (m, 2H), 3.86–3.59 (m, 4H), 3.20–2.87 (m, 4H), 1.37 (s, 9H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.2, 167.8, 166.9, 155.7, 147.3, 143.0, 140.4, 138.9, 138.7, 132.1, 130.8, 130.0, 129.6, 128.5, 125.9, 123.4, 122.1, 120.6, 115.9, 98.7, 66.6, 57.5, 54.7, 49.5, 35.6, 31.6. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>36</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 566.2880, found: 566.2867, purity 100%.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropylphthalazin-1(2<i>H</i>)-one (<b>3i</b>)</h4><div class="NLM_p">To a mixture of <b>24i</b> (112 mg, 0.24 mmol) and <b>22</b> (74.6 mg, 0.24 mmol) in DME (1.6 mL) was added a solution of K<sub>2</sub>CO<sub>3</sub> (67 mg, 0.49 mmol) in water (0.4 mL), and the solution was degassed with N<sub>2</sub> for 5 min. To this mixture, Pd(PPh<sub>3</sub>)<sub>4</sub> (28.1 mg, 0.024 mmol) was added, and the mixture was heated in a microwave reactor at 110 °C for 20 min. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 × 25 mL). The combined organic layers were washed successively with water (50 mL) and brine (50 mL) and then dried over sodium sulfate. The solvent was evaporated to afford the corresponding acetyl-protected intermediate. The obtained intermediate was dissolved in MeOH/THF (2:1, 6 mL), and K<sub>2</sub>CO<sub>3</sub> (200 mg) were added to the solution. The mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 × 25 mL). The combined organic layers were washed successively with water (50 mL) and brine (50 mL), then dried over sodium sulfate, and concentrated. The crude residue was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford <b>3i</b> as a pale-yellow powder (26 mg, 0.044 mmol, 18%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.50 (br, 1H), 8.46 (s, 1H), 8.18 (d, <i>J</i> = 8.26 Hz, 1H), 7.87 (dd, <i>J</i> = 1.58, 7.64 Hz, 1H), 7.72 (d, <i>J</i> = 1.73 Hz, 1H), 7.69–7.50 (m, 4H), 7.49 (dd, <i>J</i> = 1.56, 7.86 Hz, 1H), 7.24 (br, 2H), 6.90 (d, <i>J</i> = 8.80 Hz, 2H), 5.06 (br, 1H), 4.42 (s, 1H), 4.30 (s, 1H), 3.82–3.66 (m, 4H), 3.11–2.98 (m, 4H), 2.26–2.12 (m, 1H), 1.20–1.11 (m, 2H), 0.99–0.82 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.2, 169.2, 159.2, 153.0, 151.5, 147.3, 141.9, 140.2, 138.7, 137.9, 130.8, 130.4, 130.3, 128.6, 128.2, 127.8, 126.6, 125.4, 123.2, 115.9, 66.6, 57.1, 49.5, 40.4, 16.0, 11.4. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>31</sub>H<sub>31</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 563.2519, found: 563.2516, purity 97%.</div><div class="NLM_p last">Compounds <b>3j</b> and <b>3n</b> were synthesized from 6-chloro-<i>N</i><sup>2</sup>-(4-morpholinophenyl)-1,3,5-triazine-2,4-diamine (<b>22</b>) and the appropriate boronate esters <b>24j</b> and <b>25</b>, respectively, using a procedure similar to the procedure for the preparation of <b>3h</b>. Compounds <b>3k</b>, <b>3l</b> and <b>3m</b> were synthesized from <b>22</b> and the appropriate boronate esters <b>24k</b>, <b>24l</b> and <b>24m</b>, respectively, a procedure similar to the procedure for the preparation of <b>3i</b>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>3j</b>)</h4><div class="NLM_p last">Off-white solids; 5.6% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.50 (br, 1H), 7.86–7.70 (m, 2H), 7.61 (br, 2H), 7.52–7.38 (m, 2H), 7.26 (br, 2H), 7.14–7.03 (m, 2H), 6.95–6.80 (m, 2H), 5.08 (br, 1H), 4.61–4.47 (m, 1H), 4.42–4.27 (m, 1H), 4.00–3.79 (m, 2H), 3.81–3.67 (m, 4H), 3.28–3.15 (m, 2H), 3.13–2.96 (m, 4H), 2.06–1.92 (m, 1H), 1.09–0.97 (m, 2H), 0.82–0.70 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 177.9, 176.4, 165.8, 165.4, 164.0, 153.4, 149.2, 140.4, 139.6, 137.9, 132.1, 130.3, 128.2, 124.5, 124.3, 121.8, 115.9, 115.6, 113.8, 109.7, 66.6, 57.6, 50.4, 49.5, 28.1, 15.8, 10.6. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>34</sub>N<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 564.2723, found: 564.2705, purity 98%.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 2-[2-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-8-fluoro-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl]-2-methylpropanenitrile (<b>3k</b>)</h4><div class="NLM_p last">A pale-yellow powder; 74% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.61 (br, 1H), 7.75 (dd, <i>J</i> = 2.32, 6.83 Hz, 1H), 7.61 (br, 2H), 7.54–7.44 (m, 2H), 7.43 (d, <i>J</i> = 1.86 Hz, 1H), 7.39–7.21 (m, 3H), 6.91 (d, <i>J</i> = 8.83 Hz, 2H), 4.60 (d, <i>J</i> = 12.04 Hz, 1H), 4.37 (d, <i>J</i> = 12.02 Hz, 1H), 4.01–3.77 (m, 2H), 3.76–3.68 (m, 4H), 3.37–3.13 (m, 2H), 3.10–3.01 (m, 4H), 1.74 (s, 6H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 163.3, 160.7, 160.3, 147.8, 147.7, 147.4, 143.7, 143.1, 138.0, 130.4, 129.6, 128.7, 124.3, 122.1, 120.9, 117.2, 117.2, 115.9, 113.2, 112.9, 110.0, 66.6, 57.6, 50.1, 49.5, 37.3, 28.9, 28.3. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>33</sub>H<sub>34</sub>FN<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 609.2738, found: 609.2737, purity 97%.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 2-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoro-3,4-dihydroisoquinolin-1(2<i>H</i>)-one (<b>3l</b>)</h4><div class="NLM_p last">Off-white solids; 63% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.50 (br, 1H), 7.76 (dd, <i>J</i> = 1.81, 7.34 Hz, 1H), 7.73–7.53 (m, 2H), 7.53–7.36 (m, 2H), 7.26 (br, 2H), 7.03–6.75 (m, 4H), 5.07 (br, 1H), 4.68–4.49 (m, 1H), 4.44–4.24 (m, 1H), 3.94–3.77 (m, 2H), 3.76–3.69 (m, 4H), 3.28–3.08 (m, 2H), 3.08–2.94 (m, 4H), 2.06–1.92 (m, 1H), 1.11–0.98 (m, 2H), 0.88–0.75 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.2, 166.9, 164.4, 163.5, 160.9, 151.7, 147.3, 143.4, 142.6, 140.4, 138.0, 132.1, 130.4, 129.6, 128.6, 122.0, 120.6, 115.9, 114.7, 112.4, 66.6, 57.7, 50.2, 49.5, 28.9, 15.7, 11.0, 11.0. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>33</sub>FN<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 582.2629, found: 582.2628, purity 98%.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2<i>H</i>)-one (<b>3m</b>)</h4><div class="NLM_p last">Off-white solids; 68% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.55 (br, 1H), 7.90 (dd, <i>J</i> = 1.43, 7.81 Hz, 1H), 7.73–7.59 (m, 2H), 7.56 (t, <i>J</i> = 7.80 Hz, 1H), 7.45 (dd, <i>J</i> = 1.43, 7.95 Hz, 1H), 7.42–7.14 (m, 4H), 6.99 (dd, <i>J</i> = 1.63, 13.17 Hz, 1H), 6.95–6.86 (m, 2H), 6.62 (dd, <i>J</i> = 2.09, 7.55 Hz, 1H), 5.14 (br, 1H), 4.54 (dd, <i>J</i> = 4.98, 12.14 Hz, 1H), 4.13 (dd, <i>J</i> = 8.88, 12.12 Hz, 1H), 3.81–3.66 (m, 4H), 3.12–2.98 (m, 4H), 2.14–2.00 (m, 1H), 1.14–1.05 (m, 2H), 0.92–0.81 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 173.0, 163.7, 161.1, 158.8, 152.3, 147.3, 141.1, 140.5, 140.4, 137.8, 135.4, 132.1, 130.8, 130.7, 128.7, 122.1, 118.9, 115.9, 112.4, 111.4, 111.2, 104.7, 66.6, 57.2, 49.5, 15.9, 11.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>31</sub>FN<sub>7</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 580.2472, found: 580.2482, purity 97%.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-(3-{4-Amino-6-[(4-morpholinophenyl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1<i>H</i>-cyclopenta[4,5]pyrrolo[1,2-<i>a</i>]pyrazin-1-one (<b>3n</b>)</h4><div class="NLM_p last">Off-white solids; 11% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.48 (br, 1H), 7.74 (dd, <i>J</i> = 1.78, 7.38 Hz, 1H), 7.69–7.50 (m, 2H), 7.50–7.38 (m, 2H), 7.25 (br, 2H), 6.94–6.83 (m, 2H), 6.57–6.43 (m, 1H), 5.04 (br, 1H), 4.54 (d, <i>J</i> = 11.55 Hz, 1H), 4.42–4.31 (m, 1H), 4.25–4.14 (m, 2H), 4.09–3.97 (m, 1H), 3.97–3.85 (m, 1H), 3.80–3.66 (m, 4H), 3.11–2.98 (m, 4H), 2.56 (s, 2H), 2.42 (s, 2H), 1.24–1.19 (m, 6H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 159.1, 147.3, 142.9, 140.5, 140.3, 138.3, 132.1, 132.0, 131.9, 130.5, 129.5, 129.2, 128.4, 126.9, 125.5, 122.1, 115.9, 108.5, 66.6, 57.5, 50.3, 49.5, 45.8, 42.4, 41.3, 39.5, 30.6, 30.6. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>37</sub>N<sub>8</sub>O<sub>3</sub> [M + H]<sup>+</sup>: 581.2989, found: 581.2993, purity 100%.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-(3-{4-[(1<i>H</i>-Pyrazol-4-yl)amino]-6-amino-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2<i>H</i>)-one (<b>4a</b>)</h4><div class="NLM_p last">To a mixture of chlorotriazine <b>26a</b> (124 mg, 0.42 mmol) and boronate ester <b>24m</b> (200 mg, 0.419 mmol) in DME (6 mL) was added a solution of K<sub>2</sub>CO<sub>3</sub> (116 mg, 0.84 mmol) in water (2 mL), and the mixture was degassed with N<sub>2</sub> for 5 min. Pd(PPh<sub>3</sub>)<sub>4</sub> (24.21 mg, 0.021 mmol) was added to the mixture, and the mixture was heated in a microwave reactor at 110 °C for 10 min. The reaction mixture diluted with added water (50 mL) and extracted with ethyl acetate (3 × 25 mL). The combined organic layers were washed successively with water (50 mL) and brine (50 mL) and then dried over sodium sulfate. The solvent was evaporated, and the residue was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford the corresponding acetylated product as a crude mixture. To a solution of the obtained crude product in MeOH (10 mL), <i>p</i>-toluenesulfonic acid monohydrate (179 mg, 0.94 mmol) was added, and the mixture was stirred at 60 °C for 1 h. After cooling to room temperature, the resulting solids were collected by filtration and washed successively with water and diethyl ether to give colorless solids. The obtained solids were dissolved in MeOH (7 mL), and K<sub>2</sub>CO<sub>3</sub> (100 mg) was added to the solution. The mixture was stirred at room temperature for 3 h. The resulting solids were collected by filtration, and washed successively with water and diethyl ether to afford <b>4a</b> as a colorless solid (150 mg, 0.30 mmol, 81%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.55 (s, 1H), 9.71 (s, 1H), 8.16–7.59 (m, 3H), 7.61–7.51 (m, 1H), 7.45 (dd, <i>J</i> = 1.45, 7.82 Hz, 1H), 7.38–7.31 (m, 3H), 7.29–7.22 (m, 1H), 7.00 (dd, <i>J</i> = 1.72, 13.32 Hz, 1H), 6.67–6.56 (m, 1H), 5.33–4.93 (m, 1H), 4.60–4.40 (m, 1H), 4.18–4.01 (m, 1H), 2.15–2.00 (m, 1H), 1.17–1.03 (m, 2H), 0.93–0.81 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 172.7, 167.2, 163.7, 163.3, 161.1, 158.8, 158.7, 152.3, 141.1, 140.5, 140.4, 137.8, 135.4, 130.8, 128.6, 122.1, 118.9, 112.4, 111.4, 111.2, 104.6, 57.2, 15.9, 11.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>25</sub>H<sub>22</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 485.1850, found: 485.1842, purity 97%.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 2-(3-{4-Amino-6-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2<i>H</i>)-one (<b>4b</b>)</h4><div class="NLM_p">To a mixture of boronate ester <b>24m</b> (141 mg, 0.30 mmol) and chlorotriazine <b>26b</b> (67 mg, 0.30 mmol) in DME (5 mL) was added a solution of K<sub>2</sub>CO<sub>3</sub> (82 mg, 0.59 mmol) in water (1.6 mL), and the mixture was degassed with N<sub>2</sub> for 5 min. Pd(PPh<sub>3</sub>)<sub>4</sub> (17 mg, 0.015 mmol) was added to the mixture, and the mixture was heated in a microwave reactor at 110 °C for 20 min. The reaction mixture was diluted with water (50 mL) and extracted with ethyl acetate (3 × 25 mL). The combined organic layers were washed successively with water (50 mL) and brine (50 mL), then dried over sodium sulfate, and concentrated. The residue was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford the corresponding acetylated product as a crude mixture. To a solution of the obtained crude product in MeOH (5 mL), K<sub>2</sub>CO<sub>3</sub> (100 mg) was added, and the mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with water (50 mL), and the resulting solids were collected by filtration and washed successively with water and diethyl ether to afford <b>4b</b> as an off-white solid (85 mg, 0.17 mmol, 57%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.70 (s, 1H), 8.09–7.77 (m, 2H), 7.62–7.41 (m, 3H), 7.37–7.25 (m, 4H), 7.00 (dd, <i>J</i> = 1.68, 13.25 Hz, 1H), 6.62 (dd, <i>J</i> = 2.08, 7.52 Hz, 1H), 5.19 (dd, <i>J</i> = 5.00, 9.08 Hz, 1H), 4.49 (dd, <i>J</i> = 5.05, 12.12 Hz, 1H), 4.14–4.04 (m, 1H), 3.79 (s, 3H), 2.14–2.02 (m, 1H), 1.17–1.01 (m, 2H), 0.92–0.83 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 172.7, 167.2, 163.7, 163.3, 161.1, 158.8, 152.3, 141.2, 140.5, 140.4, 137.8, 135.4, 130.9, 130.7, 128.6, 122.7, 121.9, 118.9, 112.4, 111.3, 104.7, 57.2, 39.2, 15.9, 11.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>26</sub>H<sub>24</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 499.2006, found: 499.2011, purity 100%.</div><div class="NLM_p last">Compounds <b>4c</b>–<b>4i</b> were synthesized from 2-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1<i>H</i>)-yl)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate (<b>24m</b>) and the appropriate chlorotriazines (<b>26c</b>–<b>26i</b>, respectively) using a procedure similar to the procedure for the preparation of <b>4b</b>.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 2-(3-{4-Amino-6-[(1-cyclopropyl-1<i>H</i>-pyrazol-4-yl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2<i>H</i>)-one (<b>4c</b>)</h4><div class="NLM_p last">Colorless solid; 75% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.73 (s, 1H), 8.11 (s, 1H), 7.99–7.83 (m, 1H), 7.70–7.50 (m, 2H), 7.50–7.42 (m, 1H), 7.38 (br, 2H), 7.34 (d, <i>J</i> = 7.34 Hz, 1H), 7.31–7.21 (m, 1H), 7.00 (dd, <i>J</i> = 1.65, 13.24 Hz, 1H), 6.62 (dd, <i>J</i> = 2.06, 7.53 Hz, 1H), 5.22 (dd, <i>J</i> = 5.09, 9.10 Hz, 1H), 4.51 (dd, <i>J</i> = 5.03, 12.10 Hz, 1H), 4.11 (dd, <i>J</i> = 9.16, 12.21 Hz, 1H), 3.75–3.59 (m, 1H), 2.16–2.01 (m, 1H), 1.19–0.69 (m, 8H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 172.7, 167.1, 163.7, 163.2, 161.1, 158.8, 152.3, 141.1, 140.5, 140.3, 137.8, 135.4, 130.8, 130.8, 128.6, 122.4, 121.0, 118.9, 112.4, 111.3, 104.7, 57.2, 33.2, 15.9, 11.2, 6.7. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>28</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 525.2163, found: 525.2160, purity 99%.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 2-[3-(4-Amino-6-{[1-(1-cyclopropylethyl)-1<i>H</i>-pyrazol-4-yl]amino}-1,3,5-triazin-2-yl)-2-(hydroxymethyl)phenyl]-6-cyclopropyl-8-fluoroisoquinolin-1(2<i>H</i>)-one (<b>4d</b>)</h4><div class="NLM_p last">Colorless solid; 83% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.74 (s, 1H), 8.13 (s, 1H), 8.02–7.95 (m, 1H), 7.91 (dd, <i>J</i> = 1.45, 7.88 Hz, 1H), 7.67–7.50 (m, 2H), 7.52–7.42 (m, 1H), 7.42–7.30 (m, 2H), 7.29–7.22 (m, 1H), 7.00 (dd, <i>J</i> = 1.64, 13.24 Hz, 1H), 6.70–6.56 (m, 1H), 5.18 (br, 1H), 4.69–4.41 (m, 1H), 4.30–3.97 (m, 1H), 3.69–3.51 (m, 1H), 2.13–2.01 (m, 1H), 1.57–1.42 (m, 3H), 1.31–1.14 (m, 1H), 1.14–1.04 (m, 2H), 0.92–0.83 (m, 2H), 0.63–0.51 (m, 1H), 0.50–0.38 (m, 1H), 0.39–0.26 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 172.7, 168.7, 167.1, 163.3, 161.1, 158.8, 153.8, 152.2, 141.1, 140.5, 137.8, 135.4, 130.7, 130.5, 128.6, 122.1, 119.3, 118.9, 112.4, 112.4, 104.7, 62.4, 57.3, 21.0, 17.9, 15.9, 11.2, 4.3, 4.0. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>30</sub>H<sub>30</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 553.2476, found: 553.2452, purity 100%.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-({4-Amino-6-[3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1<i>H</i>)-yl)-2-(hydroxymethyl)phenyl]-1,3,5-triazin-2-yl}amino)-1-methyl-1<i>H</i>-pyrrole-2-carbonitrile (<b>4e</b>)</h4><div class="NLM_p last">Off-white solid; 37% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.81 (s, 1H), 7.99–7.79 (m, 1H), 7.65–7.49 (m, 2H), 7.49–7.19 (m, 5H), 7.13–6.83 (m, 2H), 6.62 (dd, <i>J</i> = 2.09, 7.53 Hz, 1H), 5.25–4.95 (m, 1H), 4.62–4.40 (m, 1H), 4.22–3.93 (m, 1H), 3.75 (s, 3H), 2.15–2.00 (m, 1H), 1.16–1.04 (m, 2H), 0.93–0.81 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 172.8, 167.1, 163.5, 161.1, 158.8, 152.3, 141.2, 140.5, 140.3, 137.8, 135.4, 130.8, 128.6, 124.6, 119.8, 118.9, 114.4, 112.4, 111.4, 111.4, 111.2, 104.7, 101.1, 57.2, 35.7, 15.9, 11.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>28</sub>H<sub>24</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 523.2006, found: 523.2003, purity 100%.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-({4-Amino-6-[3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1<i>H</i>)-yl)-2-(hydroxymethyl)phenyl]-1,3,5-triazin-2-yl}amino)-1-ethyl-1<i>H</i>-pyrrole-2-carbonitrile (<b>4f</b>)</h4><div class="NLM_p last">Off-white solid; 79% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.81 (s, 1H), 7.88 (d, <i>J</i> = 7.81 Hz, 1H), 7.67–7.49 (m, 2H), 7.51–7.41 (m, 1H), 7.42–7.30 (m, 3H), 7.30–7.22 (m, 1H), 7.08–6.95 (m, 2H), 6.62 (dd, <i>J</i> = 2.11, 7.48 Hz, 1H), 5.25–5.10 (m, 1H), 4.63–4.43 (m, 1H), 4.22–3.97 (m, 3H), 2.15–1.99 (m, 1H), 1.49–1.28 (m, 3H), 1.16–1.05 (m, 2H), 0.93–0.81 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 172.8, 167.1, 163.5, 161.1, 158.8, 152.3, 141.2, 140.5, 140.3, 137.8, 135.4, 130.8, 129.2, 128.7, 124.7, 118.9, 118.1, 114.4, 112.4, 111.6, 111.3, 104.7, 99.9, 57.2, 43.9, 16.8, 15.9, 11.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>29</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 537.2163, found: 537.2164, purity 100%.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-({4-Amino-6-[3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1<i>H</i>)-yl)-2-(hydroxymethyl)phenyl]-1,3,5-triazin-2-yl}amino)-1-isopropyl-1<i>H</i>-pyrrole-2-carbonitrile (<b>4g</b>)</h4><div class="NLM_p last">Off-white solid; 33% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.79 (s, 1H), 7.88 (d, <i>J</i> = 7.65 Hz, 1H), 7.67 (s, 1H), 7.62–7.50 (m, 1H), 7.48–7.43 (m, 1H), 7.40 (br, 2H), 7.33 (d, <i>J</i> = 7.38 Hz, 1H), 7.31–7.24 (m, 1H), 7.05–6.95 (m, 2H), 6.66–6.57 (m, 1H), 5.17 (s, 1H), 4.66–4.33 (m, 2H), 4.19–4.00 (m, 1H), 2.15–2.00 (m, 1H), 1.48 (d, <i>J</i> = 6.63 Hz, 6H), 1.14–1.06 (m, 2H), 0.92–0.82 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 163.7, 163.3, 140.6, 140.3, 135.4, 130.8, 130.7, 128.7, 118.9, 115.2, 114.5, 113.8, 112.4, 111.5, 111.4, 106.2, 105.1, 104.7, 100.0, 99.3, 87.5, 82.4, 78.1, 51.9, 51.3, 23.4, 15.9, 11.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>30</sub>H<sub>28</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 551.2319, found: 551.2310, purity 100%.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 4-({4-Amino-6-[3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1<i>H</i>)-yl)-2-(hydroxymethyl)phenyl]-1,3,5-triazin-2-yl}amino)-1-cyclopropyl-1<i>H</i>-pyrrole-2-carbonitrile (<b>4h</b>)</h4><div class="NLM_p last">Off-white solid; 16% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.79 (br, 1H), 7.90 (d, <i>J</i> = 7.75 Hz, 1H), 7.64–7.50 (m, 2H), 7.52–7.37 (m, 3H), 7.34 (d, <i>J</i> = 7.36 Hz, 1H), 7.27 (d, <i>J</i> = 1.66 Hz, 1H), 7.06–6.85 (m, 2H), 6.62 (dd, <i>J</i> = 2.08, 7.46 Hz, 1H), 5.20 (br, 1H), 4.66–4.41 (m, 1H), 4.25–4.03 (m, 1H), 3.63–3.46 (m, 1H), 2.15–2.01 (m, 1H), 1.17–0.96 (m, 6H), 0.92–0.83 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 172.7, 167.1, 163.7, 163.3, 161.1, 158.8, 152.3, 141.2, 140.5, 140.3, 137.9, 135.3, 130.8, 128.6, 124.3, 118.9, 118.5, 114.4, 112.4, 112.2, 111.3, 104.7, 102.1, 57.2, 30.0, 15.9, 11.2, 7.0. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>30</sub>H<sub>26</sub>FN<sub>8</sub>O<sub>2</sub> [M + H]<sup>+</sup>: 549.2163, found: 549.2139, purity 100%.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-({4-Amino-6-[3-(6-cyclopropyl-8-fluoro-1-oxoisoquinolin-2(1<i>H</i>)-yl)-2-(hydroxymethyl)phenyl]-1,3,5-triazin-2-yl}amino)-1-[2-(2-methoxyethoxy)ethyl]-1<i>H</i>-pyrrole-2-carbonitrile (<b>4i</b>)</h4><div class="NLM_p last">Off-white solid; 69% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.82 (s, 1H), 8.02–7.83 (m, 1H), 7.67–7.22 (m, 7H), 7.10 (d, <i>J</i> = 1.90 Hz, 1H), 6.99 (dd, <i>J</i> = 1.64, 13.20 Hz, 1H), 6.62 (dd, <i>J</i> = 2.09, 7.57 Hz, 1H), 5.27–5.10 (m, 1H), 4.62–4.44 (m, 1H), 4.24–4.04 (m, 3H), 3.83–3.63 (m, 2H), 3.57–3.46 (m, 2H), 3.47–3.35 (m, 2H), 3.23 (s, 3H), 2.14–2.01 (m, 1H), 1.15–1.04 (m, 2H), 0.92–0.83 (m, 2H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 172.8, 167.1, 163.5, 161.1, 158.8, 152.3, 141.2, 140.5, 140.3, 137.8, 135.4, 130.8, 130.7, 128.6, 124.8, 118.9, 118.7, 114.4, 112.4, 111.7, 111.3, 104.7, 101.0, 71.7, 70.1, 70.1, 58.6, 57.2, 48.9, 15.9, 11.2. HRMS (ESI) <i>m</i>/<i>z</i> calculated for C<sub>32</sub>H<sub>32</sub>FN<sub>8</sub>O<sub>4</sub> requires [M + H]<sup>+</sup>: 611.2531, found: 611.2533, purity 96%.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 4-(<i>t</i>-Butyl)-<i>N</i>-[2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzamide (<b>6</b>)</h4><div class="NLM_p last">Under nitrogen atmosphere, 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline, <b>5</b> (326 mg, 1.49 mmol), was dissolved in DCM (15 mL) and cooled with an ice bath. To this solution, pyridine (0.132 mL, 1.64 mmol) and 4-<i>t</i>-butylbenzoyl chloride (439 mg, 2.23 mmol) were added dropwise, and the mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with chloroform (75 mL), washed successively with water (2 × 30 mL), a 1 N hydrochloric acid solution (30 mL), saturated NaHCO<sub>3</sub>(aq) (30 mL), and brine (30 mL); then, the organic layer was dried over sodium sulfate, filtered, and concentrated to afford <b>6</b> (565 mg, 1.44 mmol, 97%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.80 (s, 1H), 7.92 (d, <i>J</i> = 8.3 Hz, 2H), 7.54 (m, 3H), 7.39 (d, <i>J</i> = 7.6 Hz, 1H), 7.21 (t, <i>J</i> = 7.6 Hz, 1H), 2.37 (s, 3H), 1.32 (s, 9H), 1.32 (s, 12H).LCMS (<i>m</i>/<i>z</i>): mass was calculated for C<sub>24</sub>H<sub>32</sub>BNO<sub>3</sub> requires 393.2, found 394.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> {4-[(6-Chloropyrazin-2-yl)amino]phenyl}(morpholino)methanone (<b>8</b>)</h4><div class="NLM_p last">A mixture of 2,6-dichloropyrazine (250 mg, 1.68 mmol) and (4-aminophenyl)morpholin-4-ylmethanone <b>7</b> (345 mg, 1.68 mmol) in toluene (8 mL) was degassed with N<sub>2</sub> gas for 5 min. Pd<sub>2</sub>dba<sub>3</sub> (15 mg, 0.017 mmol) was added to the solution, and the mixture was degassed again with N<sub>2</sub> for 5 min. To this mixture, sodium <i>t</i>-butoxide (322 mg, 3.35 mmol) was added, and the mixture was degassed with N<sub>2</sub> for 2 min and then heated at 90 °C for 16 h. The solvent was evaporated, and the residue was dissolved in acetone and filtered through Celite. The filtrate was concentrated and the residue was purified by flash column chromatography using 50% ethyl acetate in hexane as eluent to afford <b>8</b> (210 mg, 0.66 mmol, 39%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.08 (s, 1H), 8.22 (s, 1H), 8.05 (s, 1H), 7.70 (d, <i>J</i> = 8.6 Hz, 2H), 7.43 (d, <i>J</i> = 8.6 Hz, 2H), 3.60–3.48 (m, 8H). LCMS (<i>m</i>/<i>z</i>): mass was calculated for C<sub>15</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub> requires 318.1, found 318.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> {4-[(4-Chloro-1,3,5-triazin-2-yl)amino]phenyl}(morpholino)methanone (<b>9c</b>)</h4><div class="NLM_p last">A solution of 2,4-dichloro-1,3,5-triazine (300 mg, 2.0 mmol) in DMF (5 mL) was cooled with an ice bath, and DIEA (0.5 mL, 3.0 mmol) and (4-aminophenyl)morpholin-4-ylmethanone (412 mg, 2.0 mmol) were added to the solution, and the mixture was then stirred at 0 °C for 16 h. The reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed with water (20 mL), dried over sodium sulfate, filtered, and concentrated. The crude material was purified by chromatography on silica gel and eluted with hexane/ethyl acetate to afford <b>9c</b> (270 mg, 0.84 mmol, 42%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.94 (s, 1H), 8.69 (s, 1H), 7.75 (d, <i>J</i> = 7.71 Hz, 3H), 7.44 (d, <i>J</i> = 8.52 Hz, 2H), 3.77–3.35 (m, 8H). LCMS (<i>m</i>/<i>z</i>): mass was calculated for C<sub>14</sub>H<sub>14</sub>ClN<sub>5</sub>O<sub>2</sub> requires 319.1, found 319.8 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> {4-[(4-Chloro-6-methyl-1,3,5-triazin-2-yl)amino]phenyl}(morpholino)methanone (<b>9d</b>)</h4><div class="NLM_p last">Following the procedures described for <b>9c</b>, 2,4-dichloro-6-methyl-1,3,5-triazine (200 mg, 1.22 mmol) and (4-aminophenyl)morpholin-4-ylmethanone (252 mg, 1.22 mmol) were used for the synthesis of <b>9d</b> (120 mg, 0.36 mmol, 29.5%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.83 (s, 1H), 7.76 (br, 2H), 7.43 (d, <i>J</i> = 8.5 Hz, 2H), 3.76–3.34 (m, 8H), 2.44 (s, 3H).</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> {4-[(4-Amino-6-chloro-1,3,5-triazin-2-yl)amino]phenyl}(morpholino)methanone (<b>9e</b>)</h4><div class="NLM_p last">Following the procedures described for <b>9c</b>, 2-amino-4,6-dichloro-1,3,5-triazine (200 mg, 1.21 mmol) and (4-aminophenyl)morpholin-4-ylmethanone (250 mg, 1.21 mmol) were used for the synthesis of <b>9e</b> (325 mg, 0.97 mmol, 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 7.81 (d, <i>J</i> = 8.3 Hz, 2H), 7.68 (br, 2H), 7.40–7.32 (m, 2H), 3.60 (br, 4H), 3.49 (br, 4H).</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> {4-[(4-Chloro-6-methoxy-1,3,5-triazin-2-yl)amino]phenyl}(morpholino)methanone (<b>9f</b>)</h4><div class="NLM_p last">A solution of 2,4-dichloro-6-methoxy-1,3,5-triazine (200 mg, 1.11 mmol) in MeOH (2.8 mL) was cooled with an ice bath, and DIEA (0.21 mL, 1.22 mmol) and (4-aminophenyl)morpholin-4-ylmethanone (229 mg, 1.11 mmol) were added to the solution, and the mixture was then stirred at 0 °C for 10 min. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (2 × 25 mL). The combined organic layers were washed with water (20 mL) and brine (30 mL), dried over sodium sulfate, filtered, and concentrated. The crude material was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford <b>9f</b> (138 mg, 0.395 mmol, 35.5%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) (400 MHz, DMSO) δ 10.85 (s, 1H), 7.76 (br, 2H), 7.58–7.28 (m, 2H), 3.97 (s, 3H), 3.60 (br, 4H), 3.49 (br, 4H).</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Methyl 3-[4-(<i>t</i>-Butyl)benzamido]-2-methylbenzoate (<b>11</b>)</h4><div class="NLM_p last">To a solution of methyl 3-amino-2-methylbenzoate, <b>10</b> (2.7 g, 16.4 mmol), in DCM (50 mL) was added TEA (4.6 mL, 37.7 mmol), and the solution was cooled with an ice bath. To this solution, 4-<i>t</i>-butylbenzoyl chloride (3.5 mL, 17.9 mmol) was added dropwise, and the mixture was stirred at room temperature for 3.5 h. The reaction mixture was diluted with DCM (30 mL) and washed successively with a 1 N hydrochloric acid solution (2 × 40 mL), water (40 mL), saturated NaHCO<sub>3</sub>(aq) (2 × 40 mL), and brine (30 mL); then, the organic layer was dried over sodium sulfate and concentrated. The obtained crude solids were triturated with ether (50 mL) and hexane (50 mL) to afford <b>11</b> (4.5 g, 13.83 mmol, 85%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.98 (s, 1H), 7.93 (d, <i>J</i> = 8.35 Hz, 2H), 7.65 (dd, <i>J</i> = 1.35, 7.85 Hz, 1H), 7.55 (d, <i>J</i> = 8.40 Hz, 2H), 7.53–7.49 (m, 1H), 7.34 (t, <i>J</i> = 7.82 Hz, 1H), 3.85 (s, 3H), 2.34 (s, 3H), 1.33 (s, 9H).</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 3-[4-(<i>t</i>-Butyl)benzamido]-2-methylbenzoic acid (<b>12</b>)</h4><div class="NLM_p last">To a solution of <b>11</b> (300 mg, 0.92 mmol) in MeOH/THF (1:1, 6 mL) was added 1 N NaOH(aq) (3 mL), and the mixture was stirred for 4 h at room temperature. After removal of the solvent, the residue was diluted with water (20 mL), and washed with ethyl acetate (2 × 30 mL). The aqueous layer was acidified (pH ∼2) with 2 N HCl. The resulting solids were collected by filtration, washed with water (2 × 10 mL), and then dried to afford <b>12</b> (300 mg, quantitative yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.97 (br, 1H), 9.96 (s, 1H), 7.93 (d, <i>J</i> = 8.36 Hz, 2H), 7.69–7.62 (m, 1H), 7.58–7.51 (m, 2H), 7.51–7.44 (m, 1H), 7.31 (t, <i>J</i> = 7.81 Hz, 1H), 2.37 (s, 3H), 1.32 (s, 9H).</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 3-[4-(<i>t</i>-Butyl)benzamido]-<i>N</i>-methoxy-<i>N</i>,2-dimethylbenzamide (<b>13</b>)</h4><div class="NLM_p last">To a solution of <b>12</b> (0.5 g, 1.606 mmol) in DMF (5.8 mL) were added 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride (0.37 g, 1.93 mmol) and 1-hydroxybenzotriazole monohydrate (0.3 g, 1.93 mmol), and the mixture was stirred for 1 h at room temperature. Then, TEA (0.56 mL, 4.01 mmol) and <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (0.4 g, 4.01 mmol) were added to the mixture, and the stirring was continued for 16 h at room temperature. The reaction mixture was diluted with water and extracted with ethyl acetate (3 × 25 mL). The combined the organic layers were washed successively with water (40 mL), 1 N NaOH (40 mL), and brine (40 mL) and dried over sodium sulfate. The solvent was evaporated to afford <b>13</b> (570 mg, 1.58 mmol, quantitative yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.88 (s, 1H), 7.93 (d, <i>J</i> = 8.46 Hz, 2H), 7.54 (d, <i>J</i> = 8.41 Hz, 2H), 7.39 (d, <i>J</i> = 7.68 Hz, 1H), 7.28 (t, <i>J</i> = 7.71 Hz, 1H), 7.17 (d, <i>J</i> = 7.46 Hz, 1H), 3.45 (br, 3H), 3.26 (br, 3H), 2.12 (s, 3H), 1.32 (s, 9H).</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(3-Acetyl-2-methylphenyl)-4-(<i>t</i>-butyl)benzamide (<b>14</b>)</h4><div class="NLM_p last">A solution of <b>13</b> (0.5 g, 1.41 mmol) in THF (14 mL) was cooled to 0 °C; then, 3 M methyl magnesium bromide in diethyl ether (3.8 mL, 11.28 mmol) was added dropwise to the solution, and the mixture was stirred for 2 h at room temperature. The reaction was quenched with 1 N HCl (40 mL) and extracted with ethyl acetate (3 × 25 mL). The combined organic layers were washed successively with water (40 mL), saturated NaHCO<sub>3</sub>(aq) (40 mL) and brine (40 mL) and dried over sodium sulfate. The solvent was evaporated, and the residue was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford <b>14</b> (212 mg, 0.685 mmol, 48.6% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.93 (s, 1H), 7.92 (d, <i>J</i> = 8.57 Hz, 2H), 7.67–7.60 (m, 1H), 7.55 (d, <i>J</i> = 8.59 Hz, 2H), 7.49–7.44 (m, 1H), 7.34 (t, <i>J</i> = 7.77 Hz, 1H), 2.57 (s, 3H), 2.25 (s, 3H), 1.32 (s, 9H).</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 4-(<i>t</i>-Butyl)-<i>N</i>-{2-methyl-3-[3-(methylthio)-1,2,4-triazin-5-yl]phenyl}benzamide (<b>15</b>)</h4><div class="NLM_p last">To a solution of <b>14</b> (0.3 g, 0.97 mmol) in 1,4-dioxane (3 mL) were added selenium oxide (0.14 g, 1.26 mmol) and water (0.1 mL), and the mixture was stirred for 18 h at 100 °C. The reaction mixture was filtered through a bed of Celite to remove insoluble materials. The solvent was replaced with ethanol (5 mL), and Na<sub>2</sub>CO<sub>3</sub> (0.15 g, 1.45 mmol) and methyl hydrazinecarbimidothioate hydroiodide (0.27 g, 1.16 mmol) were added to the solution. The mixture was stirred for 3 h at room temperature. The reaction mixture was diluted with water (30 mL), and extracted with ethyl acetate (3 × 25 mL). The combined organic layers were washed successively with water (30 mL) and brine (30 mL), dried over sodium sulfate, and concentrated. The crude material was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford <b>15</b> (131 mg, 0.33 mmol, 34% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.04 (s, 1H), 9.42 (s, 1H), 7.99–7.91 (m, 2H), 7.59–7.52 (m, 4H), 7.49–7.40 (m, 1H), 2.65 (s, 3H), 2.30 (s, 3H), 1.33 (s, 9H).</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> [(2-Bromo-6-nitrobenzyl)oxy](<i>t</i>-butyl)dimethylsilane (<b>17</b>)</h4><div class="NLM_p last">To a solution of <b>16</b> (9.42 g, 40.6 mmol) in DCM (81 mL) were added imidazole (4.15 g, 60.9 mmol) and <i>t</i>-butyldimethylchlorosilane (7.34 g, 48.7 mmol). The mixture was stirred for 4 h at room temperature. The reaction mixture was diluted with water (200 mL) and extracted with DCM (3 × 50 mL). The combined organic layers were washed successively with water (100 mL) and brine (100 mL) and dried over sodium sulfate. The solvent was evaporated to afford <b>17</b> (14.5 g, 41.9 mmol, quantitative yield). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.73 (ddd, <i>J</i> = 8.0, 1.2, 0.5 Hz, 1H), 7.61 (ddd, <i>J</i> = 8.0, 1.3, 0.5 Hz, 1H), 7.25 (t, <i>J</i> = 8.0 Hz, 1H), 5.03 (s, 2H), 0.86 (s, 9H), 0.06 (s, 6H).</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 3-Bromo-2-{[(<i>t</i>-butyldimethylsilyl)oxy]methyl}aniline (<b>18</b>)</h4><div class="NLM_p last">To a solution of <b>17</b> (14.5 g, 41.9 mmol) in ethanol (291 mL) were added iron (23.38 g, 419 mmol), NH<sub>4</sub>Cl (44.8 g, 837 mmol), and water (58.2 mL), and the mixture was stirred for 3 h at 80 °C. The reaction mixture was filtered through a bed of Celite to remove insoluble materials. The solvent was concentrated, and the residue was diluted with water (500 mL) and extracted with chloroform (3 × 300 mL). The combined organic layers were washed successively with water (500 mL) and brine (100 mL) and dried over sodium sulfate. The solvent was evaporated to afford <b>18</b> (12.14 g, 38.4 mmol, 92%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 6.95–6.85 (m, 2H), 6.61–6.56 (m, 1H), 4.95 (s, 2H), 4.48 (s, 2H), 0.89 (s, 9H), 0.10 (s, 6H).</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i>-(3-Bromo-2-{[(<i>t</i>-butyldimethylsilyl)oxy]methyl}phenyl)-4-(<i>t</i>-butyl)benzamide (<b>19</b>)</h4><div class="NLM_p last">Under a nitrogen atmosphere, <b>18</b> (2.0 g, 6.32 mmol) was dissolved in THF (63 mL) and cooled with an ice bath. To this solution, TEA (1.76 mL, 12.65 mmol) and 4-<i>t</i>-butylbenzoyl chloride (1.37 g, 6.96 mmol) were added dropwise, and the mixture was stirred at room temperature for 16 h. The reaction was quenched with water (200 mL) and extracted with ethyl acetate (3 × 100 mL). The combined organic layers were washed successively with 1 N HCl (150 mL), 1 N NaOH (150 mL), and brine (100 mL); then, the organic layers were dried over sodium sulfate and concentrated. The crude material was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford <b>19</b> (2.87 g, 6.02 mmol, 95%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 9.93 (s, 1H), 8.34 (dd, <i>J</i> = 1.18, 8.17 Hz, 1H), 7.95–7.80 (m, 2H), 7.50–7.44 (m, 2H), 7.31 (dd, <i>J</i> = 1.20, 8.08 Hz, 1H), 7.20 (t, <i>J</i> = 8.09 Hz, 1H), 5.10 (s, 2H), 1.36 (s, 9H), 0.89 (s, 9H), 0.16 (s, 6H).</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-(<i>t</i>-Butyl)-<i>N</i>-(2-{[(<i>t</i>-butyldimethylsilyl)oxy]methyl}-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzamide (<b>20</b>)</h4><div class="NLM_p last">To a solution of <b>19</b> (3.2 g, 6.72 mmol) in 1,4-dioxane (32 mL) were added bis(pinacolato)diboron (3.41 g, 13.43 mmol), PdCl<sub>2</sub>(dppf)–CH<sub>2</sub>Cl<sub>2</sub> adduct (548 mg, 0.67 mmol), and potassium acetate (1.98 g, 20.15 mmol), and the mixture was stirred for 16 h at 80 °C. The reaction mixture was diluted with water (100 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic layers were washed successively with water (100 mL) and brine (100 mL); then, the organic layers were dried over sodium sulfate and concentrated. The crude material was purified by flash chromatography on silica gel and eluted with hexane/ethyl acetate to afford <b>20</b> (1.87 g, 3.57 mmol, 53%). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 10.06 (s, 1H), 8.46 (dd, <i>J</i> = 1.36, 8.14 Hz, 1H), 7.96–7.84 (m, 2H), 7.61 (dd, <i>J</i> = 1.38, 7.51 Hz, 1H), 7.53–7.42 (m, 2H), 7.36 (t, <i>J</i> = 7.78 Hz, 1H), 5.27 (s, 2H), 1.38–1.34 (m, 21H), 0.88 (s, 9H), 0.13 (s, 6H).</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 6-Chloro-<i>N</i><sup>2</sup>-(4-morpholinophenyl)-1,3,5-triazine-2,4-diamine (<b>22</b>)</h4><div class="NLM_p last">A solution of 4,6-dichloro-1,3,5-triazin-2-amine (124 mg, 0.75 mmol) in THF (1.2 mL) was cooled with an ice bath, and DIEA (0.18 mL, 1.0 mmol) and 4-morpholinoaniline <b>21</b> (89 mg, 0.5 mmol) were added to the solution. The mixture was stirred at 0 °C for 1 h and then allowed to warm up to room temperature, and the stirring was continued for 16 h. The resulting solids were collected by filtration and washed with ethyl acetate to afford <b>22</b> as a gray powder (124 mg, 0.40 mmol, 81%). <sup>1</sup>H NMR (400 MHz, DMSO-d6) δ9.65 (s, 1H), 7.71–7.15 (m, 4H), 6.99–6.76 (m, 2H), 3.79–3.67 (m, 4H), 3.09–2.99 (m, 4H). LCMS (<i>m</i>/<i>z</i>): mass was calculated for C<sub>13</sub>H<sub>15</sub>ClN<sub>6</sub>O requires 306.1, found 307.1 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> BTK Inhibition Assay</h3><div class="NLM_p last">The recombinant biotinylated human BTK enzymes having N-terminal DYKDDDDK tags were obtained from the Drug Discovery Support Business Division of Carna Biosciences, Inc.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Preparation of the Activated Form of BTK (BTK[A])</h3><div class="NLM_p last">The biotinylated BTK in a buffer solution consisting of 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 10% glycerol, 0.05% Brij 35, and 1 mM DTT was treated with 3 mM ATP at 4 °C overnight. The mixture was then run through the 10-DG column to afford BTK[A].</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Preparation of the Unactivated Form of BTK (BTK[U])</h3><div class="NLM_p last">The biotinylated BTK in the buffer solution was treated with 10 U/μg λ protein phosphatase and 2 mM MnCl<sub>2</sub> at 4 °C overnight. The mixture was purified by a DYKDDDDK-tag-antibody agarose-gel column; then, the buffer was exchanged using the 10-DG column to afford BTK[U].</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Measurement of BTK-Inhibitory Activity</h3><div class="NLM_p">Measurement of BTK activity was carried out using an MSA assay kit (QuickScout Screening Assist Kit, Carna Biosciences, Inc.). Namely, the enzymatic activities of BTK[A] and BTK[U] were measured using 1 mM FITC-labeled Srctide peptide in the presence of compounds in assay buffer consisting of 20 mM HEPES (pH 7.5), 0.01% Triton X-100, 2 mM DTT, and 5 mM MgCl<sub>2</sub>. Then 25 mM ATP or 50 mM ATP was added for a biotinylated BTK[A] or biotinylated BTK[U] assay, respectively. The reaction was terminated by adding EDTA. The quantities of the substrate (<i>S</i>) and the phosphorylated substrate (<i>P</i>) in the reaction solution were measured using a LabChip EZ Reader II system (PerkinElmer, Inc.). The inhibition rate (%) of the test compound was calculated according to the following equation:<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_m001.gif" alt="" id="_i66" /></img></span><i>A</i> represents <i>P</i>/(<i>P</i> + <i>S</i>) for a blank well, <i>B</i> represents <i>P</i>/(<i>P</i> + <i>S</i>) for a solvent well, and <i>C</i> represents <i>P</i>/(<i>P</i> + <i>S</i>) for a compound-added well. <i>S</i> represents the peak heights of the separated substrate, and <i>P</i> represents the phosphorylated substrate.</div><div class="NLM_p last">The IC<sub>50</sub> value was calculated via a regression analysis of the inhibition rate (%), and the test-compound concentration (logarithmic value).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> X-ray Crystallography of <b>2e</b> Complexed with BTK</h3><div class="NLM_p last">Generation of human BTK protein (residues 393 to 656) for crystallography was conducted as previously reported.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Crystallization was carried out using the sitting-drop vapor-diffusion method. Compound <b>2e</b> (1.6 μL in a 10 mM DMSO solution) was added to a solution of hBTK (160 μL, 6 mg/mL) and incubated at 4 °C for 16 h prior to the setting up of the drops. A drop consisted of 1 μL of protein solution and 1 μL of reservoir solution containing 0.1 M imidazole (pH 7.0), 0.1 M potassium thiocyanate, 30% (w/v) PEG MME 2000, and 4% (v/v) polypropylene glycol P 400, and microseeding was performed to initiate crystal growth. The crystals appeared within a few days and continued to grow for 1–2 weeks. Crystals were flash-cooled in liquid nitrogen for data collection with 10% glycerol and 90% reservoir solution as cryoprotectant. Diffraction data were collected by SOSHO, Inc. Cocrystals of hBTK–compound <b>2e</b> belonged to the space group <i>C</i>2: <i>a</i> = 71.3 Å, <i>b</i> = 41.2 Å, <i>c</i> = 587.9 Å, β = 90.006°. The 2.90 Å resolution structure was determined by molecular replacement using the human BTK structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN">3GEN</a>). The structure of hBTK with compound <b>2e</b> has been deposited to RCSB with PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZZ4">5ZZ4</a>.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Measurement of BTK Inhibition in Cells</h3><div class="NLM_p">Ramos cells (2G6.4C10, ATCC Inc., No. CRL-1923) were cultured in a T75 flask in a 5% CO<sub>2</sub> incubator using RPMI-1640 medium (GIBCO Inc.) containing 10% FBS (AusGene Inc.) and 1% penicillin–streptomycin (Nacalai Inc.). Test-compound solution was prepared as a 3× concentration of the final concentration by diluting a 10 mM DMSO stock solution with RPMI-1640 medium.</div><div class="NLM_p">Ramos cells were diluted with RPMI-1640 medium (no serum) to prepare the cell suspension (cell density of 7.5 × 10<sup>6</sup> cells/mL) and then incubated at 37 °C for 45 min.  The test-compound solution (500 μL) was added to 1 mL of the cell suspension in a 2.0 mL tube and incubated at 37 °C for 1 h. Then, anti-IgM Ab (Invitrogen, H15100) was added to the tube (final concentration of 10 μg/mL) and incubated at 37 °C for 10 min. Then, the cells were collected as pellets by centrifugation, and 100 μL of lysis buffer (1× RIPA buffer, Cell Signaling Technology, Inc.) containing 1% phosphatase inhibitor cocktail 3 (Sigma Company, No. P0044), 1% phosphatase inhibitor cocktail (Nacalai Inc., No. 07575), and 1 mM phenylmethylsulfonyl fluoride (PMSF) was added; this was followed by gentle stirring and further standing for 10 min. The supernatant was collected by centrifugation at 15 000 rpm for 15 min. The supernatant was mixed with SDS–sample buffer, and the mixture was heated at 95 °C for 5 min. The sample solution (5 μL each) was applied to each well of a 4–20% gradient acrylamide gel (Cosmo Bio Company, Ltd., No. 414879), and then electrophoresis was carried out. The protein in the gel was transferred to a PVDF membrane using an iBlot gel-transfer system (Life Technologies Corporation).</div><div class="NLM_p last">The transferred PVDF membrane was subjected to a blocking treatment with 2% ECL prime blocking reagent (GE Healthcare Ltd.) and then incubated with a primary antibody at 4 °C overnight. The unbound primary antibody was washed with TBST buffer (10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 0.1% Tween 20), and then the membrane was incubated with a secondary antibody in TBST buffer containing 2% ECL prime blocking reagent at room temperature for 1 h. The unbound secondary antibody was washed with TBST buffer, and the membrane was treated with an ECL Prime Western Blotting Detection System (GE Healthcare Ltd.) according to the manufacturer’s protocol. Each band was detected by chemiluminescence using a CCD camera (ATTO, Light-CaptureII).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> Animal Studies</h3><div class="NLM_p last">All animal experiments in this study were approved by the Carna Biosciences Animal Care and Use Committee and carried out according to the Carna Biosciences Animal Experimentation Regulation.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Efficacy Study of <b>4b</b> in a Mouse PCA Model</h3><div class="NLM_p last">Mice were passively sensitized by intradermal injection of 10 μL of anti-DNP IgE in both ears. After 46 h, diphenhydramine, compound <b>4b</b>, and vehicle (5:30:65 DMSO/PEG400/30% (w/v) HP-β-CD) were administered. Then, the DNP-BSA/dye mixture was administered (0.25 mL per mouse, iv) after 10 min for diphenhydramine or after 2 h for compound <b>4b</b>. The mice were sacrificed 30 min after dye injection, and both ears of each mouse were collected and weighed. Each pair of ears was dissolved by 1 N KOH (0.7 mL) at 37 °C overnight; then, 9.3 mL of an acetone/0.6 N phosphoric acid (13:5) mixture was added to the suspension, and the mixture was shaken. The extracts were centrifuged (3000 rpm, 10 min) to remove precipitates; then, the supernatant was filtered by a 0.2 mm filter. Absorbance at 620 nm was measured to determine the amount of the dye.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Collagen-Induced-Arthritis Mouse Model</h3><div class="NLM_p last">Incomplete Freund’s Adjuvant (Chondrex, Inc., #7002) supplemented with desiccated <i>M. tuberculosis</i> H37 Ra (Beckton Dickinson and Company, #231141) at 2.5 mg/mL and Bovine Type II Collagen in a 2 mg/mL solution (Chondrex, Inc., #20022) were mixed in a 1:1 ratio to form an emulsion. DBA/1J mice (10 animals/group, 6 week old, male) each received 0.1 mL of the emulsion by intradermal injection at the base of the tail on day 0, and the mice were boosted in the same manner on day 21. The compound in DMSO/PEG400/30% (w/v) HP-β-CD (5:30:65) was administered orally twice a day every day from day 18 to day 36 (compound <b>4b</b> at 15, 30, or 60 mg/kg). After the boost on day 21, the development and severity of arthritis in each extremity was scored visually once in 2 or 3 days by the following scheme: +0, normal; +1, swelling or redness of the paw or one finger; +2, swelling of two or more joints; +3, swelling of the entire paw covering more than two joints; and +4, severe arthritis of the paw and entire fingers. The scores of all four extremities were summed for each mouse, and the mean value of the 10 animals in each group was represented as an arthritis score (normal at 0 up to the maximum of 16).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01147" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01147" class="ext-link">10.1021/acs.jmedchem.8b01147</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis methods for intermediates <b>24h</b>–<b>24m</b>, <b>25</b>, and <b>26a</b>–<b>26i</b> and methods for the microsomal-stability assay, aqueous-solubility assay, hERG assay, and kinase-selectivity-panel assay (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular-formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_001.pdf">jm8b01147_si_001.pdf (1.16 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_002.csv">jm8b01147_si_002.csv (2.95 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB code for compound <b>2e</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZZ4">5ZZ4</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.8b01147" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20473" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20473" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wataru Kawahata</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2305-7363" title="Orcid link">http://orcid.org/0000-0002-2305-7363</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f2859386938087dc999385939a938693b29193809c93909b9ddc919d9f"><span class="__cf_email__" data-cfemail="e1968095809394cf8a80968089809580a18280938f8083888ecf828e8c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tokiko Asami</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takao Kiyoi</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takayuki Irie</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haruka Taniguchi</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuko Asamitsu</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomoko Inoue</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takahiro Miyake</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masaaki Sawa</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Carna Biosciences, Inc., 3rd Floor, BMA, 1-5-5 Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0077-2188" title="Orcid link">http://orcid.org/0000-0002-0077-2188</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e4552-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i74">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47262" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47262" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank the scientists at TCG Lifesciences Private Limited for synthetic-chemistry support. We acknowledge Dr. Yuko Uno for in vitro assay support. We also gratefully acknowledge Carna’s Contract Research Department for providing assay kits and performing selectivity profiling.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CIA</td><td class="NLM_def"><p class="first last">collagen-induced arthritis</p></td></tr><tr><td class="NLM_term">PLCγ2</td><td class="NLM_def"><p class="first last">phospholipase Cγ2</p></td></tr><tr><td class="NLM_term">SYK</td><td class="NLM_def"><p class="first last">spleen tyrosine kinase</p></td></tr><tr><td class="NLM_term">Vd</td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">MC</td><td class="NLM_def"><p class="first last">methyl cellulose</p></td></tr><tr><td class="NLM_term">DNP</td><td class="NLM_def"><p class="first last">dinitrophenol</p></td></tr><tr><td class="NLM_term">MTX</td><td class="NLM_def"><p class="first last">methotrexate</p></td></tr><tr><td class="NLM_term">DIEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-(dimethylamino)propyl)carbodiimide</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">HP-β-CD</td><td class="NLM_def"><p class="first last">2-hydroxypropyl-β-cyclodextrin</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i76">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28604" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28604" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 25 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Btk function in B cell development and response</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1006/smim.1998.0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1006%2Fsmim.1998.0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=9695187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=309-316&author=A.+B.+Satterthwaiteauthor=Z.+Liauthor=O.+N.+Witte&title=Btk+function+in+B+cell+development+and+response&doi=10.1006%2Fsmim.1998.0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Btk function in B cell development and response</span></div><div class="casAuthors">Satterthwaite, Anne B.; Li, Zuomei; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-316</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 85 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B cell immunodeficiencies XLA (X-linked agammaglobulinemia) in humans and Xid (X-linked immunodeficiency) in mice.  Both the maintenance of peripheral B cell nos. and their response to B cell antigen receptor (BCR) crosslinking depend on Btk.  Btk integrates signals from multiple cell surface receptors, including BCR and G-protein coupled receptors.  These Btk dependent signals control B cell proliferation and survival by mediating Ca2+ flux, activating JNK and p38 and inducing cell cycle regulatory genes.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrVOyUeT25bVg90H21EOLACvtfcHk0lgMrQ3e_pCa6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D&md5=f03605bc9f39d663d28794c7b7e40138</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1998.0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1998.0123%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DBtk%2520function%2520in%2520B%2520cell%2520development%2520and%2520response%26jtitle%3DSemin.%2520Immunol.%26date%3D1998%26volume%3D10%26spage%3D309%26epage%3D316%26doi%3D10.1006%2Fsmim.1998.0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase</span>. <i>Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1385/IR:23:2-3:147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1385%2FIR%3A23%3A2-3%3A147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=11444380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=147-156&author=W.+N.+Khan&title=Regulation+of+B+lymphocyte+development+and+activation+by+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1385%2FIR%3A23%3A2-3%3A147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase</span></div><div class="casAuthors">Khan, Wasif N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunologic Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2 & 3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">IMRSEB</span>;
        ISSN:<span class="NLM_cas:issn">0257-277X</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review discussed the role of Bruton's tyrosine kinase in B lymphocyte development and activation.  The generation and maintenance of B lymphocytes is controlled by biochem. signals transmitted by the B cell antigen receptor (BCR) complex.  These signals are transduced by multiple cytoplasmic protein tyrosine kinases (PTKs) including Lyn, Syk, and Bruton's tyrosine kinase (BTK).  Upon BCR engagement, these PTKs activate downstream effectors, including transcription factors that modulate gene expression.  In turn, activation of downstream effectors is crit. for B cell survival, cell cycle progression, and antibody prodn.  Our studies focus on the role of BTK in these biol. responses.  We have discovered that BTK is required for activation of the BCR-responsive transcription factor, NF-κB.  Furthermore, BTK-dependent activation of NF-κB is essential for reprogramming the expression of genes that control B cell survival and proliferation.  The biochem. mechanisms by which BTK regulates signaling components that activate NF-κB, and the identification of BTK-responsive genes are under investigation.  Elucidation of these regulatory mechanisms is expected to reveal new therapeutic targets for B cell pathologies involving defects in BTK, including X-linked agammaglobulinemia (XLA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0btKIFSX9LVg90H21EOLACvtfcHk0lgMrQ3e_pCa6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D&md5=564d950f06ab14daff2b45f5a3d863f4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1385%2FIR%3A23%3A2-3%3A147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FIR%253A23%253A2-3%253A147%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DRegulation%2520of%2520B%2520lymphocyte%2520development%2520and%2520activation%2520by%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DImmunol.%2520Res.%26date%3D2001%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1385%2FIR%3A23%3A2-3%3A147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase: structure and functions, expression and mutations</span>. <i>Gene Technol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">106</span>, <span class="refDoi"> DOI: 10.4172/2329-6682.1000106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.4172%2F2329-6682.1000106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=106&author=Y.+Liuauthor=G.+Zhouauthor=B.+Zhangauthor=Y.+Liu&title=Bruton%E2%80%99s+tyrosine+kinase%3A+structure+and+functions%2C+expression+and+mutations&doi=10.4172%2F2329-6682.1000106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4172%2F2329-6682.1000106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2329-6682.1000106%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%253A%2520structure%2520and%2520functions%252C%2520expression%2520and%2520mutations%26jtitle%3DGene%2520Technol.%26date%3D2013%26volume%3D2%26spage%3D106%26doi%3D10.4172%2F2329-6682.1000106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1111%2Fj.1600-065X.2000.imr017504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10933597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2000&pages=120-127&author=A.+B.+Satterthwaiteauthor=O.+N.+Witte&title=The+role+of+Bruton%E2%80%99s+tyrosine+kinase+in+B-cell+development+and+function%3A+a+genetic+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Bruton's tyrosine kinase in B-cell development and function: A genetic perspective</span></div><div class="casAuthors">Satterthwaite, Anne B.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120-127</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 95 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B-cell immunodeficiencies X-linked agammaglobulinemia in humans and X-linked immunodeficiency in mice.  These diseases are characterized by blocks in B-cell development at multiple stages and impaired function of residual mature B cells.  The authors focus here on a series of in vivo genetic studies that have begun to define the mechanism by which Btk regulates B-cell development and function.  The functional interactions between Btk and other signaling mols. defined by this approach are more complex than initially appreciated from in vitro biochem. and cell culture studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpysAcsASekh7Vg90H21EOLACvtfcHk0ljQH4ZvOWeW6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D&md5=8fb36554501b75b645cc2a807c29d6ac</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2000.imr017504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2000.imr017504.x%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DThe%2520role%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B-cell%2520development%2520and%2520function%253A%2520a%2520genetic%2520perspective%26jtitle%3DImmunol.%2520Rev.%26date%3D2000%26volume%3D175%26spage%3D120%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurosaki, T.</span></span> <span> </span><span class="NLM_article-title">Functional dissection of BCR signaling pathways</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">276</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1016/S0952-7915(00)00087-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2FS0952-7915%2800%2900087-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10781408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjsFeqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=276-281&author=T.+Kurosaki&title=Functional+dissection+of+BCR+signaling+pathways&doi=10.1016%2FS0952-7915%2800%2900087-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Functional dissection of BCR signaling pathways</span></div><div class="casAuthors">Kurosaki, Tomohiro</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">276-281</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 54 refs.  Signal transduction by the BCR is crit. for progression through developmental checkpoints as well as for immune responses.  Recent results obtained in mice deficient either in an adaptor mol., BLNK (alternatively named SLP-65 or BASH), or in phosphatidylinositol 3-kinase have revealed similar - though not identical - phenotypes to those of Btk-/- mice, suggesting a functional link between BLNK, Btk and phosphatidylinositol 3-kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOqXLG-jXZS7Vg90H21EOLACvtfcHk0ljQH4ZvOWeW6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjsFeqsb4%253D&md5=ad0404939f3ecc43959a439f20c68546</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2800%2900087-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252800%252900087-X%26sid%3Dliteratum%253Aachs%26aulast%3DKurosaki%26aufirst%3DT.%26atitle%3DFunctional%2520dissection%2520of%2520BCR%2520signaling%2520pathways%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2000%26volume%3D12%26spage%3D276%26epage%3D281%26doi%3D10.1016%2FS0952-7915%2800%2900087-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schebesta, A.</span></span> <span> </span><span class="NLM_article-title">Tec family kinases: regulation of FceRI-mediated mast-cell activation</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">1990</span>– <span class="NLM_lpage">2000</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2011.08073.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1111%2Fj.1742-4658.2011.08073.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=1990-2000&author=W.+Ellmeierauthor=A.+Abramovaauthor=A.+Schebesta&title=Tec+family+kinases%3A+regulation+of+FceRI-mediated+mast-cell+activation&doi=10.1111%2Fj.1742-4658.2011.08073.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2011.08073.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2011.08073.x%26sid%3Dliteratum%253Aachs%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DAbramova%26aufirst%3DA.%26aulast%3DSchebesta%26aufirst%3DA.%26atitle%3DTec%2520family%2520kinases%253A%2520regulation%2520of%2520FceRI-mediated%2520mast-cell%2520activation%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26spage%3D1990%26epage%3D2000%26doi%3D10.1111%2Fj.1742-4658.2011.08073.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pal
Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammeijer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in B cells and malignancies</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0779-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1186%2Fs12943-018-0779-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=29455639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=57&author=S.+Pal%0ASinghauthor=F.+Dammeijerauthor=R.+W.+Hendriks&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+B+cells+and+malignancies&doi=10.1186%2Fs12943-018-0779-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in B cells and malignancies</span></div><div class="casAuthors">Pal Singh Simar; Dammeijer Floris; Hendriks Rudi W; Pal Singh Simar; Pal Singh Simar; Dammeijer Floris; Dammeijer Floris</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies.  BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells.  Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR).  More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies.  In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions.  Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016.  To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies.  BTK inhibition has molecular effects beyond its classic role in BCR signaling.  These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches.  Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment.  As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors.  Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses.  In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp0F3T0LEJd4vKgEt20y1XfW6udTcc2eZmIlS5zCL_crntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D&md5=de1ba14dc19e6a123c21b89f1f4133f4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0779-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0779-z%26sid%3Dliteratum%253Aachs%26aulast%3DPal%2BSingh%26aufirst%3DS.%26aulast%3DDammeijer%26aufirst%3DF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cells%2520and%2520malignancies%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26spage%3D57%26doi%3D10.1186%2Fs12943-018-0779-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuvaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L. P.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton’s tyrosine kinase in B cell malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/nrc3702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1038%2Fnrc3702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=24658273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=219-232&author=R.+W.+Hendriksauthor=S.+Yuvarajauthor=L.+P.+Kil&title=Targeting+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+malignancies&doi=10.1038%2Fnrc3702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton's tyrosine kinase in B cell malignancies</span></div><div class="casAuthors">Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies.  Small-mol. inhibitors of BTK have shown antitumor activity in animal models and, recently, in clin. studies.  High response rates were reported in patients with chronic lymphocytic leukemia and mantle cell lymphoma.  Remarkably, BTK inhibitors have mol. effects that cannot be explained by the classic role of BTK in BCR signalling.  In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9z_6SqjcVYLVg90H21EOLACvtfcHk0lhvtt6jmWTF-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D&md5=ed615772c752b64360d0b5c51780e93e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc3702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3702%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26aulast%3DYuvaraj%26aufirst%3DS.%26aulast%3DKil%26aufirst%3DL.%2BP.%26atitle%3DTargeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D219%26epage%3D232%26doi%3D10.1038%2Fnrc3702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horwood, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbaniak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danks, L.</span></span> <span> </span><span class="NLM_article-title">Tec family kinases in inflammation and disease</span>. <i>Int. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.3109/08830185.2012.670334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.3109%2F08830185.2012.670334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=22449071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1Omurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=87-103&author=N.+J.+Horwoodauthor=A.+M.+Urbaniakauthor=L.+Danks&title=Tec+family+kinases+in+inflammation+and+disease&doi=10.3109%2F08830185.2012.670334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tec Family Kinases in Inflammation and Disease</span></div><div class="casAuthors">Horwood, Nicole J.; Urbaniak, Ania M.; Danks, Lynett</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-103</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Over the last decade, the Tec family of nonreceptor tyrosine kinases (Btk, Tec, Bmx, Itk, and Rlk) have been shown to play a key role in inflammation and bone destruction.  Bruton's tyrosine kinase (Btk) has been the most widely studied due to the crit. role of this kinase in B-cell development and recent evidence showing that blocking Btk signaling is effective in ameliorating lymphoma progression and exptl. arthritis.  This review will examine the role of TFK in myeloid cell function and the potential of targeting these kinases as a therapeutic intervention in autoimmune disorders such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdTCQbHJ62BbVg90H21EOLACvtfcHk0lhvtt6jmWTF-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1Omurc%253D&md5=0b1c148cac968ab20e4447848eb19c02</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3109%2F08830185.2012.670334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08830185.2012.670334%26sid%3Dliteratum%253Aachs%26aulast%3DHorwood%26aufirst%3DN.%2BJ.%26aulast%3DUrbaniak%26aufirst%3DA.%2BM.%26aulast%3DDanks%26aufirst%3DL.%26atitle%3DTec%2520family%2520kinases%2520in%2520inflammation%2520and%2520disease%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2012%26volume%3D31%26spage%3D87%26epage%3D103%26doi%3D10.3109%2F08830185.2012.670334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musuka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span> <span> </span><span class="NLM_article-title">Btk Regulates Localization, In vivo activation, and class switching of anti-DNA B cells</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2008.08.278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.molimm.2008.08.278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=18849077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWhtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2008&pages=233-241&author=K.+E.+Halcombauthor=S.+Musukaauthor=T.+Gutierrezauthor=H.+L.+Wrightauthor=A.+B.+Satterthwaite&title=Btk+Regulates+Localization%2C+In+vivo+activation%2C+and+class+switching+of+anti-DNA+B+cells&doi=10.1016%2Fj.molimm.2008.08.278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells</span></div><div class="casAuthors">Halcomb, Kristina E.; Musuka, Sandirai; Gutierrez, Toni; Wright, Heather L.; Satterthwaite, Anne B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-241</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The autoimmune disease systemic lupus erythematosus (SLE) is characterized by loss of tolerance to nuclear antigens such as chromatin, DNA, and RNA.  This focused autoreactivity is thought to arise from the ability of DNA or RNA specific B cells to receive dual signals from the BCR and TLR9 or TLR7, resp.  The Tec kinase Btk is necessary for the prodn. of anti-DNA antibodies in several murine models of SLE.  To assess the role of Btk in the fate of DNA reactive B cells, the authors generated Btk-/- mice carrying the 56R anti-DNA Ig transgene on the C57BL/6 background.  DsDNA specific B cells were present in 56R.Btk-/- mice, although they were not preferentially localized to the marginal zone.  These cells were able to proliferate in response to large CpG DNA contg. fragments that require BCR-induced internalization to access TLR9.  However, anti-DNA antibodies were not obsd. in the serum of 56R.Btk-/- mice.  A transgene expressing a low level of Btk in B cells (Btklo) restored anti-DNA IgM in these mice.  This correlated with partial rescue of proliferative response to BCR engagement and TLR9-induced IL-10 secretion in Btklo B cells.  Anti-DNA IgG was not obsd. in 56R.Btklo mice, however.  This was likely due, at least in part, to a role for Btk in controlling the expression of T-bet and AID in cells stimulated with CpG DNA.  Thus, Btk is required for the initial loss of tolerance to DNA and the subsequent prodn. of pathogenic autoantibodies once tolerance is breached.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4xJJLOaR6YrVg90H21EOLACvtfcHk0lhvtt6jmWTF-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWhtLvF&md5=2efbed09279bf25f4fb2c3668502cecc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2008.08.278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2008.08.278%26sid%3Dliteratum%253Aachs%26aulast%3DHalcomb%26aufirst%3DK.%2BE.%26aulast%3DMusuka%26aufirst%3DS.%26aulast%3DGutierrez%26aufirst%3DT.%26aulast%3DWright%26aufirst%3DH.%2BL.%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26atitle%3DBtk%2520Regulates%2520Localization%252C%2520In%2520vivo%2520activation%252C%2520and%2520class%2520switching%2520of%2520anti-DNA%2520B%2520cells%26jtitle%3DMol.%2520Immunol.%26date%3D2008%26volume%3D46%26spage%3D233%26epage%3D241%26doi%3D10.1016%2Fj.molimm.2008.08.278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.2217/fon.14.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.2217%2Ffon.14.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=24941982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=957-967&author=M.+S.+Davidsauthor=J.+R.+Brown&title=Ibrutinib%3A+a+first+in+class+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.2217%2Ffon.14.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase</span></div><div class="casAuthors">Davids, Matthew S.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is crit. for B-cell survival and proliferation.  In preclin. studies, ibrutinib bound to Bruton's tyrosine kinase with high affinity, leading to inhibition of B-cell receptor signaling, decreased B-cell activation and induction of apoptosis.  In clin. studies, ibrutinib has been well-tolerated and has demonstrated profound anti-tumor activity in a variety of hematol. malignancies, most notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), leading to US FDA approval for relapsed CLL and MCL.  Ongoing studies are evaluating ibrutinib in other types of non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and Waldenstroem's macrogobulinemia, in larger Phase III studies in CLL and MCL, and in combination studies with monoclonal antibodies and chemotherapy.  Future studies will combine ibrutinib with other promising novel agents currently in development in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3o_pMnFVskLVg90H21EOLACvtfcHk0lj0gBjSlEPtfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D&md5=345b4e839a830be822d474f62755a022</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.51%26sid%3Dliteratum%253Aachs%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIbrutinib%253A%2520a%2520first%2520in%2520class%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D957%26epage%3D967%26doi%3D10.2217%2Ffon.14.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Second-generation inhibitors of Bruton tyrosine kinase</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0313-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1186%2Fs13045-016-0313-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=27590878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=80-86&author=J.+Wuauthor=C.+Liuauthor=S.+T.+Tsuiauthor=D.+Liu&title=Second-generation+inhibitors+of+Bruton+tyrosine+kinase&doi=10.1186%2Fs13045-016-0313-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation inhibitors of Bruton tyrosine kinase</span></div><div class="casAuthors">Wu, Jingjing; Liu, Christina; Tsui, Stella T.; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80/1-80/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase (BTK) is a crit. effector mol. for B cell development and plays a major role in lymphoma genesis.  Ibrutinib is the first-generation BTK inhibitor.  Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib.  Resistance to ibrutinib was also reported.  The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib.  This review summarizes the clin. development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb086cwyJYLrVg90H21EOLACvtfcHk0lj0gBjSlEPtfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L&md5=b6140d9f7a24665131f5e772d55f29eb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0313-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0313-y%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DSecond-generation%2520inhibitors%2520of%2520Bruton%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D80%26epage%3D86%26doi%3D10.1186%2Fs13045-016-0313-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6243</span>– <span class="NLM_lpage">6262</span>, <span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lj0gBjSlEPtfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent Ibrutinib</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-10-606038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1182%2Fblood-2014-10-606038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=25700432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=2497-506&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=Y.+Shawauthor=E.+Bilottiauthor=C.+Zhouauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Three-year+follow-up+of+treatment-naive+and+previously+treated+patients+with+CLL+and+SLL+receiving+single-agent+Ibrutinib&doi=10.1182%2Fblood-2014-10-606038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Burger, Jan A.; Blum, Kristie A.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Shaw, Yun; Bilotti, Elizabeth; Zhou, Cathy; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling.  In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL).  The durable responses obsd. with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period.  We report on median 3-yr follow-up of 132 patients with symptomatic treatment- naive and relapsed/refractory CLL or small lymphocytic lymphoma.  Longer treatment with ibrutinib was assocd. with improvement in response quality over time and durable remissions.  Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections.  Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease.  Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 yr and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better.  Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbUSbfHjGYebVg90H21EOLACvtfcHk0lhANC1kQidPSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D&md5=1bedfb4e6798a3f51320d8b8054c13aa</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-10-606038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-10-606038%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DY.%26aulast%3DBilotti%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DThree-year%2520follow-up%2520of%2520treatment-naive%2520and%2520previously%2520treated%2520patients%2520with%2520CLL%2520and%2520SLL%2520receiving%2520single-agent%2520Ibrutinib%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D2497%26epage%3D506%26doi%3D10.1182%2Fblood-2014-10-606038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+Ibrutinib+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0lhANC1kQidPSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berglöf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamasy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krstic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Månsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Österborg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I.</span></span> <span> </span><span class="NLM_article-title">Targets for Ibrutinib beyond B cell malignancies</span>. <i>Scand. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1111/sji.12333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1111%2Fsji.12333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=26111359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A280%3ADC%252BC2MbmvFWqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2015&pages=208-17&author=A.+Bergl%C3%B6fauthor=A.+Hamasyauthor=S.+Meinkeauthor=M.+Palmaauthor=A.+Krsticauthor=R.+M%C3%A5nssonauthor=E.+Kimbyauthor=A.+%C3%96sterborgauthor=C.+I.+Smith&title=Targets+for+Ibrutinib+beyond+B+cell+malignancies&doi=10.1111%2Fsji.12333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targets for Ibrutinib Beyond B Cell Malignancies</span></div><div class="casAuthors">Berglof A; Hamasy A; Smith C I E; Meinke S; Palma M; Osterborg A; Palma M; Krstic A; Mansson R; Kimby E</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian journal of immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ibrutinib (Imbruvica®) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK).  Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies, a truly remarkable feat.  Few, if any medicines are monospecific and ibrutinib is no exception; already during ibrutinib's initial characterization, it was found that it could bind also to other kinases.  In this review, we discuss the implications of such interactions, which go beyond the selective effect on BTK in B cell malignancies.  In certain cases, the outcome of ibrutinib treatment likely results from the combined inhibition of BTK and other kinases, causing additive or synergistic, effects.  Conversely, there are also examples when the clinical outcome seems unrelated to inhibition of BTK.  Thus, more specifically, adverse effects such as enhanced bleeding or arrhythmias could potentially be explained by different interactions.  We also predict that during long-term treatment bone homoeostasis might be affected due to the inhibition of osteoclasts.  Moreover, the binding of ibrutinib to molecular targets other than BTK or effects on cells other than B cell-derived malignancies could be beneficial and result in new indications for clinical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTIAzlx77-clWmbXvSEQle5fW6udTcc2eY4p73q424Xd7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbmvFWqsQ%253D%253D&md5=004b34b6f5cb196b65eb11002042d5a6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fsji.12333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fsji.12333%26sid%3Dliteratum%253Aachs%26aulast%3DBergl%25C3%25B6f%26aufirst%3DA.%26aulast%3DHamasy%26aufirst%3DA.%26aulast%3DMeinke%26aufirst%3DS.%26aulast%3DPalma%26aufirst%3DM.%26aulast%3DKrstic%26aufirst%3DA.%26aulast%3DM%25C3%25A5nsson%26aufirst%3DR.%26aulast%3DKimby%26aufirst%3DE.%26aulast%3D%25C3%2596sterborg%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26atitle%3DTargets%2520for%2520Ibrutinib%2520beyond%2520B%2520cell%2520malignancies%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D2015%26volume%3D82%26spage%3D208%26epage%3D17%26doi%3D10.1111%2Fsji.12333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thareja, S.</span></span> <span> </span><span class="NLM_article-title">The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.ejmech.2018.03.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=29631132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=315-326&author=C.+Liangauthor=D.+Tianauthor=X.+Renauthor=S.+Dingauthor=M.+Jiaauthor=M.+Xinauthor=S.+Thareja&title=The+development+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+from+2012+to+2017%3A+A+mini-review&doi=10.1016%2Fj.ejmech.2018.03.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span></div><div class="casAuthors">Liang, Chengyuan; Tian, Danni; Ren, Xiaodong; Ding, Shunjun; Jia, Minyi; Xin, Minhang; Thareja, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-326</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies and autoimmune diseases related to B lymphocytes.  This review focuses on the diverse, small-mol. inhibitors of BTK kinase that have shown good prospects for clin. application.  Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed.  Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK.  The present review also surveys the pharmacol. advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire crit. thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNAsX0qwSHLVg90H21EOLACvtfcHk0lgIn21KnDnL9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D&md5=1ea0bf36d8ebadbfba624f858911b182</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.062%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DThareja%26aufirst%3DS.%26atitle%3DThe%2520development%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520from%25202012%2520to%25202017%253A%2520A%2520mini-review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D315%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2018.03.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawahata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.bmcl.2017.11.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=29198867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=145-151&author=W.+Kawahataauthor=T.+Asamiauthor=T.+Irieauthor=M.+Sawa&title=Design+and+synthesis+of+novel+pyrimidine+analogs+as+highly+selective%2C+non-covalent+BTK+inhibitors&doi=10.1016%2Fj.bmcl.2017.11.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors</span></div><div class="casAuthors">Kawahata, Wataru; Asami, Tokiko; Irie, Takayuki; Sawa, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-151</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BTK is a promising target for the treatment of multiple diseases such as B cell malignances, asthma, and rheumatoid arthritis.  Here, the authors report the discovery of a series of novel pyrimidine analogs as potent, highly selective, non-covalent inhibitors of BTK.  Compd. I demonstrated higher affinity to an unactivated conformation of BTK that resulted in an excellent kinase selectivity.  Compd. I showed a good oral bioavailability in mice, and significantly inhibits the PCA reaction in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpVaSuT25WJ7Vg90H21EOLACvtfcHk0lgIn21KnDnL9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhur7I&md5=f77ce613ad2c95fe4d34abb41f5c5ea9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DKawahata%26aufirst%3DW.%26aulast%3DAsami%26aufirst%3DT.%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520pyrimidine%2520analogs%2520as%2520highly%2520selective%252C%2520non-covalent%2520BTK%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D145%26epage%3D151%26doi%3D10.1016%2Fj.bmcl.2017.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">TR-FRET binding assay targeting unactivated form of Bruton’s tyrosine kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2033</span>– <span class="NLM_lpage">2036</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.bmcl.2015.04.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2033-2036&author=T.+Asamiauthor=W.+Kawahataauthor=M.+Sawa&title=TR-FRET+binding+assay+targeting+unactivated+form+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1016%2Fj.bmcl.2015.04.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DAsami%26aufirst%3DT.%26aulast%3DKawahata%26aufirst%3DW.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3DTR-FRET%2520binding%2520assay%2520targeting%2520unactivated%2520form%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2033%26epage%3D2036%26doi%3D10.1016%2Fj.bmcl.2015.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawahata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">’Turn On/Off’ fluorescence probe for the screening of unactivated Bruton’s tyrosine kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2141</span>– <span class="NLM_lpage">2145</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.bmcl.2015.03.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2141-2145&author=W.+Kawahataauthor=T.+Asamiauthor=I.+Fujiiauthor=M.+Sawa&title=%E2%80%99Turn+On%2FOff%E2%80%99+fluorescence+probe+for+the+screening+of+unactivated+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1016%2Fj.bmcl.2015.03.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.063%26sid%3Dliteratum%253Aachs%26aulast%3DKawahata%26aufirst%3DW.%26aulast%3DAsami%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DI.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3D%25E2%2580%2599Turn%2520On%252FOff%25E2%2580%2599%2520fluorescence%2520probe%2520for%2520the%2520screening%2520of%2520unactivated%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2141%26epage%3D2145%26doi%3D10.1016%2Fj.bmcl.2015.03.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lj8KAz0X4sQhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frauchiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewdney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=512-516&author=Y.+Louauthor=X.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-based+drug+design+of+RN486%2C+a+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Lou, Yan; Han, Xiaochun; Kuglstatter, Andreas; Kondru, Rama K.; Sweeney, Zachary K.; Soth, Michael; McIntosh, Joel; Litman, Renee; Suh, Judy; Kocer, Buelent; Davis, Dana; Park, Jaehyeon; Frauchiger, Sandra; Dewdney, Nolan; Zecic, Hasim; Taygerly, Joshua P.; Sarma, Keshab; Hong, Junbae; Hill, Ronald J.; Gabriel, Tobias; Goldstein, David M.; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">512-516</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis.  Highlights include the introduction of a benzyl alc. group and a fluorine substitution, each of which resulted in over 10-fold increase in activity.  Concurrent optimization of drug-like properties led to compd. I (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclin. characterization based on its favorable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdHX9-PE5I7Vg90H21EOLACvtfcHk0lj8KAz0X4sQhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D&md5=dc3c069b0e876f44846a30e3aa6a894a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-based%2520drug%2520design%2520of%2520RN486%252C%2520a%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francesco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolove, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magadala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">R115</span>, <span class="refDoi"> DOI: 10.1186/ar3400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1186%2Far3400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=21752263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFGltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=R115&author=B.+Y.+Changauthor=M.+M.+Huangauthor=M.+Francescoauthor=J.+Chenauthor=J.+Sokoloveauthor=P.+Magadalaauthor=W.+H.+Robinsonauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+ameliorates+autoimmune+arthritis+by+inhibition+of+multiple+effector+cells&doi=10.1186%2Far3400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells</span></div><div class="casAuthors">Chang, Betty Y.; Huang, Min Mei; Francesco, Michelle; Chen, Jun; Sokolove, Jeremy; Magadala, Padmaja; Robinson, William H.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">R115</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: The aim was to det. the effect of the Bruton tyrosine kinase (Btk)-selective inhibitor PCI-32765, currently in Phase I/II studies in lymphoma trials, in arthritis and immune-complex (IC) based animal models and describe the underlying cellular mechanisms.  Methods: PCI-32765 was administered in a series of murine IC disease models including collagen-induced arthritis (CIA), collagen antibody-induced arthritis (CAIA), reversed passive anaphylactic reaction (RPA), and passive cutaneous anaphylaxis (PCA).  Clin. and pathol. features characteristic of each model were examd. following treatment.  PCI-32765 was then examd. in assays using immune cells relevant to the pathogenesis of arthritis, and where Btk is thought to play a functional role.  These included proliferation and calcium mobilization in B cells, cytokine and chemokine prodn. in monocytes/macrophages, degranulation of mast cells and its subsequent cytokine/chemokine prodn.  Results: PCI-32765 dose-dependently and potently reversed arthritic inflammation in a therapeutic CIA model with an ED50 of 2.6 mg/kg/day.  PCI-32765 also prevented clin. arthritis in CAIA models.  In both models, infiltration of monocytes and macrophages into the synovium was completely inhibited and importantly, the bone and cartilage integrity of the joints were preserved.  PCI-32765 reduced inflammation in the Arthus and PCA assays.  In vitro, PCI-32765 inhibited BCR-activated primary B cell proliferation (IC50 = 8 nM).  Following FcγR stimulation, PCI-32765 inhibited TNFα, IL-1β and IL-6 prodn. in primary monocytes (IC50 = 2.6, 0.5, 3.9 nM, resp.).  Following Fc.vepsiln.RI stimulation of cultured human mast cells, PCI-32765 inhibited release of histamine, PGD2, TNF-α, IL-8 and MCP-1.  Conclusions: PCI-32765 is efficacious in CIA, and in IC models that do not depend upon autoantibody prodn. from B cells.  Thus PCI-32765 targets not only B lymphocytes but also monocytes, macrophages and mast cells, which are important Btk-expressing effector cells in arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQLy1_wdvr7rVg90H21EOLACvtfcHk0liFFp5b6g-i8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFGltrs%253D&md5=ab0d3df5dc8816194c4087a131125744</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2Far3400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far3400%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DHuang%26aufirst%3DM.%2BM.%26aulast%3DFrancesco%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSokolove%26aufirst%3DJ.%26aulast%3DMagadala%26aufirst%3DP.%26aulast%3DRobinson%26aufirst%3DW.%2BH.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520ameliorates%2520autoimmune%2520arthritis%2520by%2520inhibition%2520of%2520multiple%2520effector%2520cells%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2011%26volume%3D13%26spage%3DR115%26doi%3D10.1186%2Far3400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajbi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzenet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khouili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaumet, G.</span></span> <span> </span><span class="NLM_article-title">Polysubstituted 2,3-dihydrofuro[2,3-b]pyridines and 3,4-dihydro-2<i>H</i>-pyrano[2,3-b]pyridines via microwave-activated Inverse electron demand Diels-Alder reactions</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8286</span>– <span class="NLM_lpage">8297</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2007.05.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.tet.2007.05.112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=8286-8297&author=Y.+Hajbiauthor=F.+Suzenetauthor=M.+Khouiliauthor=S.+Lazarauthor=G.+Guillaumet&title=Polysubstituted+2%2C3-dihydrofuro%5B2%2C3-b%5Dpyridines+and+3%2C4-dihydro-2H-pyrano%5B2%2C3-b%5Dpyridines+via+microwave-activated+Inverse+electron+demand+Diels-Alder+reactions&doi=10.1016%2Fj.tet.2007.05.112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2007.05.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2007.05.112%26sid%3Dliteratum%253Aachs%26aulast%3DHajbi%26aufirst%3DY.%26aulast%3DSuzenet%26aufirst%3DF.%26aulast%3DKhouili%26aufirst%3DM.%26aulast%3DLazar%26aufirst%3DS.%26aulast%3DGuillaumet%26aufirst%3DG.%26atitle%3DPolysubstituted%25202%252C3-dihydrofuro%255B2%252C3-b%255Dpyridines%2520and%25203%252C4-dihydro-2H-pyrano%255B2%252C3-b%255Dpyridines%2520via%2520microwave-activated%2520Inverse%2520electron%2520demand%2520Diels-Alder%2520reactions%26jtitle%3DTetrahedron%26date%3D2007%26volume%3D63%26spage%3D8286%26epage%3D8297%26doi%3D10.1016%2Fj.tet.2007.05.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellegatti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedrenne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span> <span> </span><span class="NLM_article-title">New heteroaromatic aminations on 5-aryl-1,2,4-triazines and 1,2,4,5-tetrazines by palladium catalysis</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">4389</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2010.03.099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.tet.2010.03.099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtF2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=4383-4389&author=L.+Pellegattiauthor=E.+Vedrenneauthor=J.+M.+Legerauthor=C.+Jarryauthor=S.+Routier&title=New+heteroaromatic+aminations+on+5-aryl-1%2C2%2C4-triazines+and+1%2C2%2C4%2C5-tetrazines+by+palladium+catalysis&doi=10.1016%2Fj.tet.2010.03.099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">New heteroaromatic aminations on 5-aryl-1,2,4-triazines and 1,2,4,5-tetrazines by palladium catalysis</span></div><div class="casAuthors">Pellegatti, Laurent; Vedrenne, Emeline; Leger, Jean-Michel; Jarry, Christian; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4383-4389</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The efficient and original palladium-catalyzed amination of 5-aryl-1,2,4-triazines and 1,2,4,5-tetrazines is reported.  This Buchwald-Hartwig type reaction leads to the formation of aminated heterocycles via methylsulfur release.  The reaction is optimized and a wide range of amines is used to det. the scope and limitations of this methodol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHHZgix8tAWrVg90H21EOLACvtfcHk0ljke_CHP8glyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtF2jtbw%253D&md5=d0037874d57b7052144967c67abf44b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2010.03.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2010.03.099%26sid%3Dliteratum%253Aachs%26aulast%3DPellegatti%26aufirst%3DL.%26aulast%3DVedrenne%26aufirst%3DE.%26aulast%3DLeger%26aufirst%3DJ.%2BM.%26aulast%3DJarry%26aufirst%3DC.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DNew%2520heteroaromatic%2520aminations%2520on%25205-aryl-1%252C2%252C4-triazines%2520and%25201%252C2%252C4%252C5-tetrazines%2520by%2520palladium%2520catalysis%26jtitle%3DTetrahedron%26date%3D2010%26volume%3D66%26spage%3D4383%26epage%3D4389%26doi%3D10.1016%2Fj.tet.2010.03.099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bin Ma, Tonika Bohnert, Kevin L. Otipoby, Eric Tien, Million Arefayene, Judy Bai, Bekim Bajrami, Eris Bame, Timothy R. Chan, Michael Humora, J. Michael MacPhee, Douglas Marcotte, Devangi Mehta, Claire M. Metrick, George Moniz, Evelyne Polack, Urjana Poreci, Annick Prefontaine, Sarah Sheikh, Patricia Schroeder, Karen Smirnakis, Lei Zhang, Fengmei Zheng, <span class="NLM_string-name hlFld-ContribAuthor">Brian T. Hopkins</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12526-12541. <a href="https://doi.org/10.1021/acs.jmedchem.0c00702" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00702%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBIIB068%25253A%252BA%252BSelective%25252C%252BPotent%25252C%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252Bas%252Ban%252BOrally%252BEfficacious%252BAgent%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27042020%26date%3D06082020%26date%3D22072020%26volume%3D63%26issue%3D21%26spage%3D12526%26epage%3D12541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Peng Zhao, You Zhou, Xiao-Xiao Yu, Chun Huang, Yan-Dong Wu, Guodong Yin, <span class="NLM_string-name hlFld-ContribAuthor">An-Xin Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Iodine-Promoted Multicomponent Synthesis of 2,4-Diamino-1,3,5-triazines. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (21)
                                     , 8528-8532. <a href="https://doi.org/10.1021/acs.orglett.0c03130" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c03130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c03130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c03130%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DIodine-Promoted%252BMulticomponent%252BSynthesis%252Bof%252B2%25252C4-Diamino-1%25252C3%25252C5-triazines%26aulast%3DZhao%26aufirst%3DPeng%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17092020%26date%3D13102020%26volume%3D22%26issue%3D21%26spage%3D8528%26epage%3D8532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Bin    Ma    </span><span class="hlFld-ContribAuthor "> Chaomin    Li </span><span class="hlFld-ContribAuthor "> Brian T.    Hopkins </span><span class="hlFld-ContribAuthor "> Lloyd    Franklin </span><span class="hlFld-ContribAuthor "> Robbie    Chen    </span><span class="hlFld-ContribAuthor "> Tamera    Mack </span><span class="hlFld-ContribAuthor "> Daniel    Patience </span><span class="hlFld-ContribAuthor "> William F.    Kiesman </span><span class="hlFld-ContribAuthor "> Erin M.    O’Brien    </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Process Development of BIIB068: A Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 313-337. <a href="https://doi.org/10.1021/bk-2020-1369.ch010" title="DOI URL">https://doi.org/10.1021/bk-2020-1369.ch010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2020-1369.ch010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2020-1369.ch010%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BProcess%252BDevelopment%252Bof%252BBIIB068%25253A%252BA%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26spage%3D313%26epage%3D337%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B3%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2020%26date%3D2020%26volume%3D1369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ahmad Junaid, Felicia Phei Lin Lim, Edward R. T. Tiekink, <span class="NLM_string-name hlFld-ContribAuthor">Anton V. Dolzhenko</span>. </span><span class="cited-content_cbyCitation_article-title">New One-Pot Synthesis of 1,3,5-Triazines: Three-Component Condensation, Dimroth Rearrangement, and Dehydrogenative Aromatization. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2019,</strong> <em>21 </em>
                                    (7)
                                     , 548-555. <a href="https://doi.org/10.1021/acscombsci.9b00079" title="DOI URL">https://doi.org/10.1021/acscombsci.9b00079</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.9b00079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.9b00079%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DNew%252BOne-Pot%252BSynthesis%252Bof%252B1%25252C3%25252C5-Triazines%25253A%252BThree-Component%252BCondensation%25252C%252BDimroth%252BRearrangement%25252C%252Band%252BDehydrogenative%252BAromatization%26aulast%3DJunaid%26aufirst%3DAhmad%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D18042019%26date%3D21052019%26date%3D10062019%26volume%3D21%26issue%3D7%26spage%3D548%26epage%3D555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian T.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Eris  Bame</span>, <span class="hlFld-ContribAuthor ">Noah  Bell</span>, <span class="hlFld-ContribAuthor ">Tonika  Bohnert</span>, <span class="hlFld-ContribAuthor ">Jon K.  Bowden-Verhoek</span>, <span class="hlFld-ContribAuthor ">Minna  Bui</span>, <span class="hlFld-ContribAuthor ">Mark T.  Cancilla</span>, <span class="hlFld-ContribAuthor ">Patrick  Conlon</span>, <span class="hlFld-ContribAuthor ">Patrick  Cullen</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Junfa  Fan</span>, <span class="hlFld-ContribAuthor ">Tarra  Fuchs-Knotts</span>, <span class="hlFld-ContribAuthor ">Stig  Hansen</span>, <span class="hlFld-ContribAuthor ">Stacey  Heumann</span>, <span class="hlFld-ContribAuthor ">Tracy J.  Jenkins</span>, <span class="hlFld-ContribAuthor ">Chuck  Gua</span>, <span class="hlFld-ContribAuthor ">Ying  Liu</span>, <span class="hlFld-ContribAuthor ">YuTing  Liu</span>, <span class="hlFld-ContribAuthor ">Mukush  Lulla</span>, <span class="hlFld-ContribAuthor ">Douglas  Marcotte</span>, <span class="hlFld-ContribAuthor ">Isaac  Marx</span>, <span class="hlFld-ContribAuthor ">Bob  McDowell</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Mertsching</span>, <span class="hlFld-ContribAuthor ">Ella  Negrou</span>, <span class="hlFld-ContribAuthor ">Michael J.  Romanowski</span>, <span class="hlFld-ContribAuthor ">Daniel  Scott</span>, <span class="hlFld-ContribAuthor ">Laura  Silvian</span>, <span class="hlFld-ContribAuthor ">Wenjin  Yang</span>, <span class="hlFld-ContribAuthor ">Min  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>44 </em>, 116275. <a href="https://doi.org/10.1016/j.bmc.2021.116275" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116275%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DUtilizing%252Bstructure%252Bbased%252Bdrug%252Bdesign%252Band%252Bmetabolic%252Bsoft%252Bspot%252Bidentification%252Bto%252Boptimize%252Bthe%252Bin%252Bvitro%252Bpotency%252Band%252Bin%252Bvivo%252Bpharmacokinetic%252Bproperties%252Bleading%252Bto%252Bthe%252Bdiscovery%252Bof%252Bnovel%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DHopkins%26aufirst%3DBrian%2BT.%26date%3D2021%26volume%3D44%26spage%3D116275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad Syafiq  Bin Shahari</span>, <span class="hlFld-ContribAuthor ">Ahmad  Junaid</span>, <span class="hlFld-ContribAuthor ">Edward R. T.  Tiekink</span>, <span class="hlFld-ContribAuthor ">Anton V.  Dolzhenko</span>. </span><span class="cited-content_cbyCitation_article-title">A New One-Pot Three-Component Synthesis of 4-Aryl-6-cycloamino-1,3,5-triazin-2-amines under Microwave Irradiation. </span><span class="cited-content_cbyCitation_journal-name">Synthesis</span><span> <strong>2021,</strong> <em>53 </em>
                                    (14)
                                     , 2457-2468. <a href="https://doi.org/10.1055/a-1401-2795" title="DOI URL">https://doi.org/10.1055/a-1401-2795</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/a-1401-2795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fa-1401-2795%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthesis%26atitle%3DA%252BNew%252BOne-Pot%252BThree-Component%252BSynthesis%252Bof%252B4-Aryl-6-cycloamino-1%25252C3%25252C5-triazin-2-amines%252Bunder%252BMicrowave%252BIrradiation%26aulast%3DBin%2BShahari%26aufirst%3DMuhammad%2BSyafiq%26date%3D2021%26date%3D2021%26volume%3D53%26issue%3D14%26spage%3D2457%26epage%3D2468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Qiu</span>, <span class="hlFld-ContribAuthor ">Zahid  Ali</span>, <span class="hlFld-ContribAuthor ">Andrew  Bender</span>, <span class="hlFld-ContribAuthor ">Richard  Caldwell</span>, <span class="hlFld-ContribAuthor ">Yi-Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Zhizhou  Fang</span>, <span class="hlFld-ContribAuthor ">Anna  Gardberg</span>, <span class="hlFld-ContribAuthor ">Nina  Glaser</span>, <span class="hlFld-ContribAuthor ">Anja  Goettsche</span>, <span class="hlFld-ContribAuthor ">Andreas  Goutopoulos</span>, <span class="hlFld-ContribAuthor ">Roland  Grenningloh</span>, <span class="hlFld-ContribAuthor ">Bettina  Hanschke</span>, <span class="hlFld-ContribAuthor ">Jared  Head</span>, <span class="hlFld-ContribAuthor ">Theresa  Johnson</span>, <span class="hlFld-ContribAuthor ">Christopher  Jones</span>, <span class="hlFld-ContribAuthor ">Reinaldo  Jones</span>, <span class="hlFld-ContribAuthor ">Shashank  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Christine  Maurer</span>, <span class="hlFld-ContribAuthor ">Federica  Morandi</span>, <span class="hlFld-ContribAuthor ">Constantin  Neagu</span>, <span class="hlFld-ContribAuthor ">Sven  Poetzsch</span>, <span class="hlFld-ContribAuthor ">Justin  Potnick</span>, <span class="hlFld-ContribAuthor ">Ralf  Schmidt</span>, <span class="hlFld-ContribAuthor ">Katherine  Roe</span>, <span class="hlFld-ContribAuthor ">Ariele  Viacava Follis</span>, <span class="hlFld-ContribAuthor ">Carolyn  Wing</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Zhu</span>, <span class="hlFld-ContribAuthor ">Brian  Sherer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>40 </em>, 116163. <a href="https://doi.org/10.1016/j.bmc.2021.116163" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116163%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Band%252Bselective%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DQiu%26aufirst%3DHui%26date%3D2021%26volume%3D40%26spage%3D116163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiakuo  Liu</span>, <span class="hlFld-ContribAuthor ">Chengjuan  Chen</span>, <span class="hlFld-ContribAuthor ">Dongmei  Wang</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Tiantai  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>217 </em>, 113329. <a href="https://doi.org/10.1016/j.ejmech.2021.113329" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113329%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEmerging%252Bsmall-molecule%252Binhibitors%252Bof%252Bthe%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252B%252528BTK%252529%25253A%252BCurrent%252Bdevelopment%26aulast%3DLiu%26aufirst%3DJiakuo%26date%3D2021%26volume%3D217%26spage%3D113329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ab  Majeed Ganai</span>, <span class="hlFld-ContribAuthor ">Tabasum  Khan Pathan</span>, <span class="hlFld-ContribAuthor ">Girish A.  Hampannavar</span>, <span class="hlFld-ContribAuthor ">Chandrakant  Pawar</span>, <span class="hlFld-ContribAuthor ">Vincent A.  Obakachi</span>, <span class="hlFld-ContribAuthor ">Babita  Kushwaha</span>, <span class="hlFld-ContribAuthor ">Narva  Deshwar Kushwaha</span>, <span class="hlFld-ContribAuthor ">Rajshekhar  Karpoormath</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances on the s‐Triazine Scaffold with Emphasis on Synthesis, Structure‐Activity and Pharmacological Aspects: A Concise Review. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (7)
                                     , 1616-1660. <a href="https://doi.org/10.1002/slct.202004591" title="DOI URL">https://doi.org/10.1002/slct.202004591</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202004591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202004591%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DRecent%252BAdvances%252Bon%252Bthe%252Bs%2525E2%252580%252590Triazine%252BScaffold%252Bwith%252BEmphasis%252Bon%252BSynthesis%25252C%252BStructure%2525E2%252580%252590Activity%252Band%252BPharmacological%252BAspects%25253A%252BA%252BConcise%252BReview%26aulast%3DMajeed%2BGanai%26aufirst%3DAb%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D7%26spage%3D1616%26epage%3D1660" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramil F.  Fatykhov</span>, <span class="hlFld-ContribAuthor ">Oleg N.  Chupakhin</span>, <span class="hlFld-ContribAuthor ">Vladimir L.  Rusinov</span>, <span class="hlFld-ContribAuthor ">Igor A.  Khalymbadzha</span>. </span><span class="cited-content_cbyCitation_article-title">Copper catalysis for triazines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 161-220. <a href="https://doi.org/10.1016/B978-0-12-821263-9.00005-9" title="DOI URL">https://doi.org/10.1016/B978-0-12-821263-9.00005-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-821263-9.00005-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-821263-9.00005-9%26sid%3Dliteratum%253Aachs%26atitle%3DCopper%252Bcatalysis%252Bfor%252Btriazines%26aulast%3DFatykhov%26aufirst%3DRamil%2BF.%26date%3D2021%26spage%3D161%26epage%3D220%26pub%3DElsevier%26atitle%3DCopper%252Bin%252BN-Heterocyclic%252BChemistry%26date%3D2021%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marie-Aude  Hiebel</span>, <span class="hlFld-ContribAuthor ">Franck  Suzenet</span>. </span><span class="cited-content_cbyCitation_article-title">Triazines, Tetrazines, and Fused Ring Polyaza Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 505-531. <a href="https://doi.org/10.1016/B978-0-12-819962-6.00014-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-819962-6.00014-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-819962-6.00014-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-819962-6.00014-2%26sid%3Dliteratum%253Aachs%26atitle%3DTriazines%25252C%252BTetrazines%25252C%252Band%252BFused%252BRing%252BPolyaza%252BSystems%26aulast%3DHiebel%26aufirst%3DMarie-Aude%26date%3D2020%26spage%3D505%26epage%3D531%26pub%3DElsevier%26date%3D2020%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhai</span>, <span class="hlFld-ContribAuthor ">Ridong  Li</span>, <span class="hlFld-ContribAuthor ">Xinyu  Bai</span>, <span class="hlFld-ContribAuthor ">Xianling  Ning</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Lin</span>, <span class="hlFld-ContribAuthor ">Xuyang  Zhao</span>, <span class="hlFld-ContribAuthor ">Yan  Jin</span>, <span class="hlFld-ContribAuthor ">Yuxin  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (18)
                                     , 4124-4142. <a href="https://doi.org/10.1016/j.bmc.2019.07.043" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.07.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.07.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.07.043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bdithiocarbamate-substituted%252Bdiphenylaminopyrimidine%252Bderivatives%252Bas%252BBTK%252Binhibitors%26aulast%3DZhai%26aufirst%3DZheng%26date%3D2019%26volume%3D27%26issue%3D18%26spage%3D4124%26epage%3D4142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian T.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Eris  Bame</span>, <span class="hlFld-ContribAuthor ">Noah  Bell</span>, <span class="hlFld-ContribAuthor ">Tonika  Bohnert</span>, <span class="hlFld-ContribAuthor ">Jon K.  Bowden-Verhoek</span>, <span class="hlFld-ContribAuthor ">Minna  Bui</span>, <span class="hlFld-ContribAuthor ">Mark T.  Cancilla</span>, <span class="hlFld-ContribAuthor ">Patrick  Conlon</span>, <span class="hlFld-ContribAuthor ">Patrick  Cullen</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Junfa  Fan</span>, <span class="hlFld-ContribAuthor ">Tarra  Fuchs-Knotts</span>, <span class="hlFld-ContribAuthor ">Stig  Hansen</span>, <span class="hlFld-ContribAuthor ">Stacey  Heumann</span>, <span class="hlFld-ContribAuthor ">Tracy J.  Jenkins</span>, <span class="hlFld-ContribAuthor ">Douglas  Marcotte</span>, <span class="hlFld-ContribAuthor ">Bob  McDowell</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Mertsching</span>, <span class="hlFld-ContribAuthor ">Ella  Negrou</span>, <span class="hlFld-ContribAuthor ">Kevin L.  Otipoby</span>, <span class="hlFld-ContribAuthor ">Urjana  Poreci</span>, <span class="hlFld-ContribAuthor ">Michael J.  Romanowski</span>, <span class="hlFld-ContribAuthor ">Daniel  Scott</span>, <span class="hlFld-ContribAuthor ">Laura  Silvian</span>, <span class="hlFld-ContribAuthor ">Wenjin  Yang</span>, <span class="hlFld-ContribAuthor ">Min  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using Tethering-fragment-based screens. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (13)
                                     , 2905-2913. <a href="https://doi.org/10.1016/j.bmc.2019.05.021" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.05.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.05.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252Bnovel%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%252Bidentified%252Busing%252BTethering-fragment-based%252Bscreens%26aulast%3DHopkins%26aufirst%3DBrian%2BT.%26date%3D2019%26volume%3D27%26issue%3D13%26spage%3D2905%26epage%3D2913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michele  Montaruli</span>, <span class="hlFld-ContribAuthor ">Domenico  Alberga</span>, <span class="hlFld-ContribAuthor ">Fulvio  Ciriaco</span>, <span class="hlFld-ContribAuthor ">Daniela  Trisciuzzi</span>, <span class="hlFld-ContribAuthor ">Anna Rita  Tondo</span>, <span class="hlFld-ContribAuthor ">Giuseppe Felice  Mangiatordi</span>, <span class="hlFld-ContribAuthor ">Orazio  Nicolotti</span>. </span><span class="cited-content_cbyCitation_article-title">Accelerating Drug Discovery by Early Protein Drug Target Prediction Based on a Multi-Fingerprint Similarity Search †. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (12)
                                     , 2233. <a href="https://doi.org/10.3390/molecules24122233" title="DOI URL">https://doi.org/10.3390/molecules24122233</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24122233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24122233%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAccelerating%252BDrug%252BDiscovery%252Bby%252BEarly%252BProtein%252BDrug%252BTarget%252BPrediction%252BBased%252Bon%252Ba%252BMulti-Fingerprint%252BSimilarity%252BSearch%252B%2525E2%252580%2525A0%26aulast%3DMontaruli%26aufirst%3DMichele%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D12%26spage%3D2233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Scaffold hopping of core structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. X-ray cocrystal structure of BTK complexed with <b>2e</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZZ4">5ZZ4</a>). (A) Key interactions of <b>2e</b> in the BTK active site. Hydrogen bonds are shown as green dotted lines. (B) Surface presentation of binding of <b>2e</b> to BTK.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibition of anti-IgM-stimulated phosphorylation of BTK and PLCγ2 in Ramos cells. Ramos cells were treated with <b>4b</b> at various concentrations for 1 h and then stimulated with anti-IgM for 10 min. The phosphorylation levels of BTK (Tyr223 and Tyr551) and PLCγ2 (Tyr1217) were analyzed by Western blotting.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Efficacy of <b>4b</b> in a mouse PCA model. See the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for experimental details. *<i>P</i> < 0.05 according to Dunnett’s test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Efficacy of <b>4b</b> in a collagen-induced-arthritis (CIA) mouse model. See the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for experimental details. *<i>P</i> < 0.05, **<i>P</i> < 0.01, ***<i>P</i> < 0.001 according to Dunnett’s test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>2a</b>–<b>2h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-<i>t</i>-butylbenzoyl chloride, pyridine, DCM, rt; (b) 2,6-dichloropyrazine, Pd<sub>2</sub>(dba)<sub>3</sub>, sodium <i>t</i>-butoxide, 90 °C; (c) <b>6</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, NaHCO<sub>3</sub>, DME, water, 110 °C; (d) dichloro-1,3,5-triazines (nonsubstituted, 6-methyl, or 2-amino), DIEA, DMF, 0 °C or 2,4-dichloro-6-methoxy-1,3,5-triazine, DIEA, MeOH, 0 °C; (e) <b>6</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, water, 110 °C; (f) 4 M HCl in dioxane, MeOH, 50 °C; (g) 4-<i>t</i>-butylbenzoyl chloride, TEA, DCM, rt; (h) 1 M NaOH(aq), THF, MeOH, rt; (i) <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride, EDC, HOBt, TEA, DMF, rt; (j) methylmagnesium bromide, THF, 0 °C to rt; (k) selenium oxide, 1,4-dioxane, water, 100 °C; (l) <i>S</i>-methylisothiosemicarbazide hydroiodide, Na<sub>2</sub>CO<sub>3</sub>, ethanol, rt; (m) <b>7</b>, copper(I) 3-methylsalicylate, cesium carbonate, palladium(II) acetate, xantphos, toluene, 180 °C; (n) TBSCl, imidazole, DCM, rt; (o) Fe, NH<sub>4</sub>Cl, 80 °C; (p) 4-<i>t</i>-butylbenzoyl chloride, TEA, THF, rt; (q) bis(pinacolato)diboron, Pd(dppf)Cl<sub>2</sub>–CH<sub>2</sub>Cl<sub>2</sub>, potassium acetate, 1,4-dioxane, 80 °C; (r) <b>9e</b>, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, water, 110 °C; (s) 1 M TBAF in THF, THF, rt.</p></p></figure><figure data-id="sch2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>3a</b>–<b>3n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2-amino-4,6-dichloro-1,3,5-triazine, DIEA, THF, 0 °C; (b) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, water, 110 °C; (c) 1 M TBAF in THF, THF, rt; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH, THF, rt to 60 °C.</p></p></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/medium/jm-2018-01147c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>4a</b>–<b>4i</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-19/acs.jmedchem.8b01147/20181004/images/large/jm-2018-01147c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01147&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, DME, water, 110 °C; (b) TsOH, MeOH, 60 °C; (c) K<sub>2</sub>CO<sub>3</sub>, MeOH, rt to 60 °C.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i76">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50703" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50703" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 25 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Btk function in B cell development and response</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1006/smim.1998.0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1006%2Fsmim.1998.0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=9695187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=309-316&author=A.+B.+Satterthwaiteauthor=Z.+Liauthor=O.+N.+Witte&title=Btk+function+in+B+cell+development+and+response&doi=10.1006%2Fsmim.1998.0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Btk function in B cell development and response</span></div><div class="casAuthors">Satterthwaite, Anne B.; Li, Zuomei; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-316</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 85 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B cell immunodeficiencies XLA (X-linked agammaglobulinemia) in humans and Xid (X-linked immunodeficiency) in mice.  Both the maintenance of peripheral B cell nos. and their response to B cell antigen receptor (BCR) crosslinking depend on Btk.  Btk integrates signals from multiple cell surface receptors, including BCR and G-protein coupled receptors.  These Btk dependent signals control B cell proliferation and survival by mediating Ca2+ flux, activating JNK and p38 and inducing cell cycle regulatory genes.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrVOyUeT25bVg90H21EOLACvtfcHk0lgvF9FmKodZVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D&md5=f03605bc9f39d663d28794c7b7e40138</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1998.0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1998.0123%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DBtk%2520function%2520in%2520B%2520cell%2520development%2520and%2520response%26jtitle%3DSemin.%2520Immunol.%26date%3D1998%26volume%3D10%26spage%3D309%26epage%3D316%26doi%3D10.1006%2Fsmim.1998.0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of B lymphocyte development and activation by Bruton’s tyrosine kinase</span>. <i>Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1385/IR:23:2-3:147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1385%2FIR%3A23%3A2-3%3A147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=11444380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=147-156&author=W.+N.+Khan&title=Regulation+of+B+lymphocyte+development+and+activation+by+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1385%2FIR%3A23%3A2-3%3A147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase</span></div><div class="casAuthors">Khan, Wasif N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunologic Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2 & 3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">IMRSEB</span>;
        ISSN:<span class="NLM_cas:issn">0257-277X</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review discussed the role of Bruton's tyrosine kinase in B lymphocyte development and activation.  The generation and maintenance of B lymphocytes is controlled by biochem. signals transmitted by the B cell antigen receptor (BCR) complex.  These signals are transduced by multiple cytoplasmic protein tyrosine kinases (PTKs) including Lyn, Syk, and Bruton's tyrosine kinase (BTK).  Upon BCR engagement, these PTKs activate downstream effectors, including transcription factors that modulate gene expression.  In turn, activation of downstream effectors is crit. for B cell survival, cell cycle progression, and antibody prodn.  Our studies focus on the role of BTK in these biol. responses.  We have discovered that BTK is required for activation of the BCR-responsive transcription factor, NF-κB.  Furthermore, BTK-dependent activation of NF-κB is essential for reprogramming the expression of genes that control B cell survival and proliferation.  The biochem. mechanisms by which BTK regulates signaling components that activate NF-κB, and the identification of BTK-responsive genes are under investigation.  Elucidation of these regulatory mechanisms is expected to reveal new therapeutic targets for B cell pathologies involving defects in BTK, including X-linked agammaglobulinemia (XLA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0btKIFSX9LVg90H21EOLACvtfcHk0lg9i47V1uTVSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D&md5=564d950f06ab14daff2b45f5a3d863f4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1385%2FIR%3A23%3A2-3%3A147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FIR%253A23%253A2-3%253A147%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DRegulation%2520of%2520B%2520lymphocyte%2520development%2520and%2520activation%2520by%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DImmunol.%2520Res.%26date%3D2001%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1385%2FIR%3A23%3A2-3%3A147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase: structure and functions, expression and mutations</span>. <i>Gene Technol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">106</span>, <span class="refDoi"> DOI: 10.4172/2329-6682.1000106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.4172%2F2329-6682.1000106" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=106&author=Y.+Liuauthor=G.+Zhouauthor=B.+Zhangauthor=Y.+Liu&title=Bruton%E2%80%99s+tyrosine+kinase%3A+structure+and+functions%2C+expression+and+mutations&doi=10.4172%2F2329-6682.1000106"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4172%2F2329-6682.1000106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4172%252F2329-6682.1000106%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%253A%2520structure%2520and%2520functions%252C%2520expression%2520and%2520mutations%26jtitle%3DGene%2520Technol.%26date%3D2013%26volume%3D2%26spage%3D106%26doi%3D10.4172%2F2329-6682.1000106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">The role of Bruton’s tyrosine kinase in B-cell development and function: a genetic perspective</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1111%2Fj.1600-065X.2000.imr017504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10933597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2000&pages=120-127&author=A.+B.+Satterthwaiteauthor=O.+N.+Witte&title=The+role+of+Bruton%E2%80%99s+tyrosine+kinase+in+B-cell+development+and+function%3A+a+genetic+perspective"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Bruton's tyrosine kinase in B-cell development and function: A genetic perspective</span></div><div class="casAuthors">Satterthwaite, Anne B.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120-127</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 95 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B-cell immunodeficiencies X-linked agammaglobulinemia in humans and X-linked immunodeficiency in mice.  These diseases are characterized by blocks in B-cell development at multiple stages and impaired function of residual mature B cells.  The authors focus here on a series of in vivo genetic studies that have begun to define the mechanism by which Btk regulates B-cell development and function.  The functional interactions between Btk and other signaling mols. defined by this approach are more complex than initially appreciated from in vitro biochem. and cell culture studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpysAcsASekh7Vg90H21EOLACvtfcHk0lg9i47V1uTVSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D&md5=8fb36554501b75b645cc2a807c29d6ac</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2000.imr017504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2000.imr017504.x%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DThe%2520role%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B-cell%2520development%2520and%2520function%253A%2520a%2520genetic%2520perspective%26jtitle%3DImmunol.%2520Rev.%26date%3D2000%26volume%3D175%26spage%3D120%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kurosaki, T.</span></span> <span> </span><span class="NLM_article-title">Functional dissection of BCR signaling pathways</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">276</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1016/S0952-7915(00)00087-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2FS0952-7915%2800%2900087-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10781408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BD3cXjsFeqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2000&pages=276-281&author=T.+Kurosaki&title=Functional+dissection+of+BCR+signaling+pathways&doi=10.1016%2FS0952-7915%2800%2900087-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Functional dissection of BCR signaling pathways</span></div><div class="casAuthors">Kurosaki, Tomohiro</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">276-281</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with 54 refs.  Signal transduction by the BCR is crit. for progression through developmental checkpoints as well as for immune responses.  Recent results obtained in mice deficient either in an adaptor mol., BLNK (alternatively named SLP-65 or BASH), or in phosphatidylinositol 3-kinase have revealed similar - though not identical - phenotypes to those of Btk-/- mice, suggesting a functional link between BLNK, Btk and phosphatidylinositol 3-kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOqXLG-jXZS7Vg90H21EOLACvtfcHk0ljnuiwfVWidFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXjsFeqsb4%253D&md5=ad0404939f3ecc43959a439f20c68546</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0952-7915%2800%2900087-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0952-7915%252800%252900087-X%26sid%3Dliteratum%253Aachs%26aulast%3DKurosaki%26aufirst%3DT.%26atitle%3DFunctional%2520dissection%2520of%2520BCR%2520signaling%2520pathways%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D2000%26volume%3D12%26spage%3D276%26epage%3D281%26doi%3D10.1016%2FS0952-7915%2800%2900087-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schebesta, A.</span></span> <span> </span><span class="NLM_article-title">Tec family kinases: regulation of FceRI-mediated mast-cell activation</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">1990</span>– <span class="NLM_lpage">2000</span>, <span class="refDoi"> DOI: 10.1111/j.1742-4658.2011.08073.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1111%2Fj.1742-4658.2011.08073.x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2011&pages=1990-2000&author=W.+Ellmeierauthor=A.+Abramovaauthor=A.+Schebesta&title=Tec+family+kinases%3A+regulation+of+FceRI-mediated+mast-cell+activation&doi=10.1111%2Fj.1742-4658.2011.08073.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1111%2Fj.1742-4658.2011.08073.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1742-4658.2011.08073.x%26sid%3Dliteratum%253Aachs%26aulast%3DEllmeier%26aufirst%3DW.%26aulast%3DAbramova%26aufirst%3DA.%26aulast%3DSchebesta%26aufirst%3DA.%26atitle%3DTec%2520family%2520kinases%253A%2520regulation%2520of%2520FceRI-mediated%2520mast-cell%2520activation%26jtitle%3DFEBS%2520J.%26date%3D2011%26volume%3D278%26spage%3D1990%26epage%3D2000%26doi%3D10.1111%2Fj.1742-4658.2011.08073.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pal
Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammeijer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in B cells and malignancies</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0779-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1186%2Fs12943-018-0779-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=29455639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=57&author=S.+Pal%0ASinghauthor=F.+Dammeijerauthor=R.+W.+Hendriks&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+B+cells+and+malignancies&doi=10.1186%2Fs12943-018-0779-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in B cells and malignancies</span></div><div class="casAuthors">Pal Singh Simar; Dammeijer Floris; Hendriks Rudi W; Pal Singh Simar; Pal Singh Simar; Dammeijer Floris; Dammeijer Floris</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies.  BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells.  Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR).  More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies.  In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions.  Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016.  To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies.  BTK inhibition has molecular effects beyond its classic role in BCR signaling.  These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches.  Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment.  As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors.  Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses.  In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp0F3T0LEJd4vKgEt20y1XfW6udTcc2eZJtJLR07CkPLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D&md5=de1ba14dc19e6a123c21b89f1f4133f4</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0779-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0779-z%26sid%3Dliteratum%253Aachs%26aulast%3DPal%2BSingh%26aufirst%3DS.%26aulast%3DDammeijer%26aufirst%3DF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cells%2520and%2520malignancies%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26spage%3D57%26doi%3D10.1186%2Fs12943-018-0779-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuvaraj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kil, L. P.</span></span> <span> </span><span class="NLM_article-title">Targeting Bruton’s tyrosine kinase in B cell malignancies</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/nrc3702</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1038%2Fnrc3702" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=24658273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=219-232&author=R.+W.+Hendriksauthor=S.+Yuvarajauthor=L.+P.+Kil&title=Targeting+Bruton%E2%80%99s+tyrosine+kinase+in+B+cell+malignancies&doi=10.1038%2Fnrc3702"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Bruton's tyrosine kinase in B cell malignancies</span></div><div class="casAuthors">Hendriks, Rudi W.; Yuvaraj, Saravanan; Kil, Laurens P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">219-232</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) is a key component of B cell receptor (BCR) signalling and functions as an important regulator of cell proliferation and cell survival in various B cell malignancies.  Small-mol. inhibitors of BTK have shown antitumor activity in animal models and, recently, in clin. studies.  High response rates were reported in patients with chronic lymphocytic leukemia and mantle cell lymphoma.  Remarkably, BTK inhibitors have mol. effects that cannot be explained by the classic role of BTK in BCR signalling.  In this Review, we highlight the importance of BTK in various signalling pathways in the context of its therapeutic inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9z_6SqjcVYLVg90H21EOLACvtfcHk0ljnuiwfVWidFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkslCqsL4%253D&md5=ed615772c752b64360d0b5c51780e93e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc3702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3702%26sid%3Dliteratum%253Aachs%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26aulast%3DYuvaraj%26aufirst%3DS.%26aulast%3DKil%26aufirst%3DL.%2BP.%26atitle%3DTargeting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cell%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D219%26epage%3D232%26doi%3D10.1038%2Fnrc3702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Horwood, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbaniak, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danks, L.</span></span> <span> </span><span class="NLM_article-title">Tec family kinases in inflammation and disease</span>. <i>Int. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.3109/08830185.2012.670334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.3109%2F08830185.2012.670334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=22449071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1Omurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=87-103&author=N.+J.+Horwoodauthor=A.+M.+Urbaniakauthor=L.+Danks&title=Tec+family+kinases+in+inflammation+and+disease&doi=10.3109%2F08830185.2012.670334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Tec Family Kinases in Inflammation and Disease</span></div><div class="casAuthors">Horwood, Nicole J.; Urbaniak, Ania M.; Danks, Lynett</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-103</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Over the last decade, the Tec family of nonreceptor tyrosine kinases (Btk, Tec, Bmx, Itk, and Rlk) have been shown to play a key role in inflammation and bone destruction.  Bruton's tyrosine kinase (Btk) has been the most widely studied due to the crit. role of this kinase in B-cell development and recent evidence showing that blocking Btk signaling is effective in ameliorating lymphoma progression and exptl. arthritis.  This review will examine the role of TFK in myeloid cell function and the potential of targeting these kinases as a therapeutic intervention in autoimmune disorders such as rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdTCQbHJ62BbVg90H21EOLACvtfcHk0lh5LdKGyEd-oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1Omurc%253D&md5=0b1c148cac968ab20e4447848eb19c02</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3109%2F08830185.2012.670334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08830185.2012.670334%26sid%3Dliteratum%253Aachs%26aulast%3DHorwood%26aufirst%3DN.%2BJ.%26aulast%3DUrbaniak%26aufirst%3DA.%2BM.%26aulast%3DDanks%26aufirst%3DL.%26atitle%3DTec%2520family%2520kinases%2520in%2520inflammation%2520and%2520disease%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2012%26volume%3D31%26spage%3D87%26epage%3D103%26doi%3D10.3109%2F08830185.2012.670334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halcomb, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musuka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutierrez, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span> <span> </span><span class="NLM_article-title">Btk Regulates Localization, In vivo activation, and class switching of anti-DNA B cells</span>. <i>Mol. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1016/j.molimm.2008.08.278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.molimm.2008.08.278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=18849077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWhtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2008&pages=233-241&author=K.+E.+Halcombauthor=S.+Musukaauthor=T.+Gutierrezauthor=H.+L.+Wrightauthor=A.+B.+Satterthwaite&title=Btk+Regulates+Localization%2C+In+vivo+activation%2C+and+class+switching+of+anti-DNA+B+cells&doi=10.1016%2Fj.molimm.2008.08.278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells</span></div><div class="casAuthors">Halcomb, Kristina E.; Musuka, Sandirai; Gutierrez, Toni; Wright, Heather L.; Satterthwaite, Anne B.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-241</span>CODEN:
                <span class="NLM_cas:coden">MOIMD5</span>;
        ISSN:<span class="NLM_cas:issn">0161-5890</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The autoimmune disease systemic lupus erythematosus (SLE) is characterized by loss of tolerance to nuclear antigens such as chromatin, DNA, and RNA.  This focused autoreactivity is thought to arise from the ability of DNA or RNA specific B cells to receive dual signals from the BCR and TLR9 or TLR7, resp.  The Tec kinase Btk is necessary for the prodn. of anti-DNA antibodies in several murine models of SLE.  To assess the role of Btk in the fate of DNA reactive B cells, the authors generated Btk-/- mice carrying the 56R anti-DNA Ig transgene on the C57BL/6 background.  DsDNA specific B cells were present in 56R.Btk-/- mice, although they were not preferentially localized to the marginal zone.  These cells were able to proliferate in response to large CpG DNA contg. fragments that require BCR-induced internalization to access TLR9.  However, anti-DNA antibodies were not obsd. in the serum of 56R.Btk-/- mice.  A transgene expressing a low level of Btk in B cells (Btklo) restored anti-DNA IgM in these mice.  This correlated with partial rescue of proliferative response to BCR engagement and TLR9-induced IL-10 secretion in Btklo B cells.  Anti-DNA IgG was not obsd. in 56R.Btklo mice, however.  This was likely due, at least in part, to a role for Btk in controlling the expression of T-bet and AID in cells stimulated with CpG DNA.  Thus, Btk is required for the initial loss of tolerance to DNA and the subsequent prodn. of pathogenic autoantibodies once tolerance is breached.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4xJJLOaR6YrVg90H21EOLACvtfcHk0lh5LdKGyEd-oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWhtLvF&md5=2efbed09279bf25f4fb2c3668502cecc</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.molimm.2008.08.278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molimm.2008.08.278%26sid%3Dliteratum%253Aachs%26aulast%3DHalcomb%26aufirst%3DK.%2BE.%26aulast%3DMusuka%26aufirst%3DS.%26aulast%3DGutierrez%26aufirst%3DT.%26aulast%3DWright%26aufirst%3DH.%2BL.%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26atitle%3DBtk%2520Regulates%2520Localization%252C%2520In%2520vivo%2520activation%252C%2520and%2520class%2520switching%2520of%2520anti-DNA%2520B%2520cells%26jtitle%3DMol.%2520Immunol.%26date%3D2008%26volume%3D46%26spage%3D233%26epage%3D241%26doi%3D10.1016%2Fj.molimm.2008.08.278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase</span>. <i>Future Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">957</span>– <span class="NLM_lpage">967</span>, <span class="refDoi"> DOI: 10.2217/fon.14.51</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.2217%2Ffon.14.51" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=24941982" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=957-967&author=M.+S.+Davidsauthor=J.+R.+Brown&title=Ibrutinib%3A+a+first+in+class+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.2217%2Ffon.14.51"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase</span></div><div class="casAuthors">Davids, Matthew S.; Brown, Jennifer R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">957-967</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is crit. for B-cell survival and proliferation.  In preclin. studies, ibrutinib bound to Bruton's tyrosine kinase with high affinity, leading to inhibition of B-cell receptor signaling, decreased B-cell activation and induction of apoptosis.  In clin. studies, ibrutinib has been well-tolerated and has demonstrated profound anti-tumor activity in a variety of hematol. malignancies, most notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), leading to US FDA approval for relapsed CLL and MCL.  Ongoing studies are evaluating ibrutinib in other types of non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and Waldenstroem's macrogobulinemia, in larger Phase III studies in CLL and MCL, and in combination studies with monoclonal antibodies and chemotherapy.  Future studies will combine ibrutinib with other promising novel agents currently in development in hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3o_pMnFVskLVg90H21EOLACvtfcHk0lh5LdKGyEd-oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpvFCrtbc%253D&md5=345b4e839a830be822d474f62755a022</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.51&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.51%26sid%3Dliteratum%253Aachs%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26atitle%3DIbrutinib%253A%2520a%2520first%2520in%2520class%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D957%26epage%3D967%26doi%3D10.2217%2Ffon.14.51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Second-generation inhibitors of Bruton tyrosine kinase</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0313-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1186%2Fs13045-016-0313-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=27590878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=80-86&author=J.+Wuauthor=C.+Liuauthor=S.+T.+Tsuiauthor=D.+Liu&title=Second-generation+inhibitors+of+Bruton+tyrosine+kinase&doi=10.1186%2Fs13045-016-0313-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation inhibitors of Bruton tyrosine kinase</span></div><div class="casAuthors">Wu, Jingjing; Liu, Christina; Tsui, Stella T.; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80/1-80/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase (BTK) is a crit. effector mol. for B cell development and plays a major role in lymphoma genesis.  Ibrutinib is the first-generation BTK inhibitor.  Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib.  Resistance to ibrutinib was also reported.  The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib.  This review summarizes the clin. development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb086cwyJYLrVg90H21EOLACvtfcHk0ljAPzusOv1aGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L&md5=b6140d9f7a24665131f5e772d55f29eb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0313-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0313-y%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DSecond-generation%2520inhibitors%2520of%2520Bruton%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D80%26epage%3D86%26doi%3D10.1186%2Fs13045-016-0313-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6243</span>– <span class="NLM_lpage">6262</span>, <span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0ljAPzusOv1aGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilotti, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent Ibrutinib</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">2497</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1182/blood-2014-10-606038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1182%2Fblood-2014-10-606038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=25700432" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2015&pages=2497-506&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=Y.+Shawauthor=E.+Bilottiauthor=C.+Zhouauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Three-year+follow-up+of+treatment-naive+and+previously+treated+patients+with+CLL+and+SLL+receiving+single-agent+Ibrutinib&doi=10.1182%2Fblood-2014-10-606038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Burger, Jan A.; Blum, Kristie A.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Shaw, Yun; Bilotti, Elizabeth; Zhou, Cathy; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2497-2506</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling.  In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL).  The durable responses obsd. with ibrutinib relate in part to a modest toxicity profile that allows the majority of patients to receive continuous therapy for an extended period.  We report on median 3-yr follow-up of 132 patients with symptomatic treatment- naive and relapsed/refractory CLL or small lymphocytic lymphoma.  Longer treatment with ibrutinib was assocd. with improvement in response quality over time and durable remissions.  Toxicity with longer follow-up diminished with respect to occurrence of grade 3 or greater cytopenias, fatigue, and infections.  Progression remains uncommon, occurring primarily in some patients with relapsed del(17)(p13.1) and/or del(11)(q22.3) disease.  Treatment-related lymphocytosis remains largely asymptomatic even when persisting >1 yr and does not appear to alter longer-term PFS and overall survival compared with patients with partial response or better.  Collectively, these data provide evidence that ibrutinib controls CLL disease manifestations and is well tolerated for an extended period; this information can help direct potential treatment options for different subgroups to diminish the long-term risk of relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbUSbfHjGYebVg90H21EOLACvtfcHk0ljAPzusOv1aGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotV2hs7c%253D&md5=1bedfb4e6798a3f51320d8b8054c13aa</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1182%2Fblood-2014-10-606038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2014-10-606038%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DShaw%26aufirst%3DY.%26aulast%3DBilotti%26aufirst%3DE.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DThree-year%2520follow-up%2520of%2520treatment-naive%2520and%2520previously%2520treated%2520patients%2520with%2520CLL%2520and%2520SLL%2520receiving%2520single-agent%2520Ibrutinib%26jtitle%3DBlood%26date%3D2015%26volume%3D125%26spage%3D2497%26epage%3D506%26doi%3D10.1182%2Fblood-2014-10-606038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in relapsed chronic lymphocytic leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+BTK+with+Ibrutinib+in+relapsed+chronic+lymphocytic+leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0lips9-ODFU-Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520relapsed%2520chronic%2520lymphocytic%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berglöf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamasy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krstic, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Månsson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Österborg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I.</span></span> <span> </span><span class="NLM_article-title">Targets for Ibrutinib beyond B cell malignancies</span>. <i>Scand. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1111/sji.12333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1111%2Fsji.12333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=26111359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A280%3ADC%252BC2MbmvFWqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2015&pages=208-17&author=A.+Bergl%C3%B6fauthor=A.+Hamasyauthor=S.+Meinkeauthor=M.+Palmaauthor=A.+Krsticauthor=R.+M%C3%A5nssonauthor=E.+Kimbyauthor=A.+%C3%96sterborgauthor=C.+I.+Smith&title=Targets+for+Ibrutinib+beyond+B+cell+malignancies&doi=10.1111%2Fsji.12333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targets for Ibrutinib Beyond B Cell Malignancies</span></div><div class="casAuthors">Berglof A; Hamasy A; Smith C I E; Meinke S; Palma M; Osterborg A; Palma M; Krstic A; Mansson R; Kimby E</div><div class="citationInfo"><span class="NLM_cas:title">Scandinavian journal of immunology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-17</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ibrutinib (Imbruvica®) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK).  Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies, a truly remarkable feat.  Few, if any medicines are monospecific and ibrutinib is no exception; already during ibrutinib's initial characterization, it was found that it could bind also to other kinases.  In this review, we discuss the implications of such interactions, which go beyond the selective effect on BTK in B cell malignancies.  In certain cases, the outcome of ibrutinib treatment likely results from the combined inhibition of BTK and other kinases, causing additive or synergistic, effects.  Conversely, there are also examples when the clinical outcome seems unrelated to inhibition of BTK.  Thus, more specifically, adverse effects such as enhanced bleeding or arrhythmias could potentially be explained by different interactions.  We also predict that during long-term treatment bone homoeostasis might be affected due to the inhibition of osteoclasts.  Moreover, the binding of ibrutinib to molecular targets other than BTK or effects on cells other than B cell-derived malignancies could be beneficial and result in new indications for clinical applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTIAzlx77-clWmbXvSEQle5fW6udTcc2ebTqUip_iHGgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbmvFWqsQ%253D%253D&md5=004b34b6f5cb196b65eb11002042d5a6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fsji.12333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fsji.12333%26sid%3Dliteratum%253Aachs%26aulast%3DBergl%25C3%25B6f%26aufirst%3DA.%26aulast%3DHamasy%26aufirst%3DA.%26aulast%3DMeinke%26aufirst%3DS.%26aulast%3DPalma%26aufirst%3DM.%26aulast%3DKrstic%26aufirst%3DA.%26aulast%3DM%25C3%25A5nsson%26aufirst%3DR.%26aulast%3DKimby%26aufirst%3DE.%26aulast%3D%25C3%2596sterborg%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26atitle%3DTargets%2520for%2520Ibrutinib%2520beyond%2520B%2520cell%2520malignancies%26jtitle%3DScand.%2520J.%2520Immunol.%26date%3D2015%26volume%3D82%26spage%3D208%26epage%3D17%26doi%3D10.1111%2Fsji.12333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thareja, S.</span></span> <span> </span><span class="NLM_article-title">The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.ejmech.2018.03.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=29631132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=315-326&author=C.+Liangauthor=D.+Tianauthor=X.+Renauthor=S.+Dingauthor=M.+Jiaauthor=M.+Xinauthor=S.+Thareja&title=The+development+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+from+2012+to+2017%3A+A+mini-review&doi=10.1016%2Fj.ejmech.2018.03.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span></div><div class="casAuthors">Liang, Chengyuan; Tian, Danni; Ren, Xiaodong; Ding, Shunjun; Jia, Minyi; Xin, Minhang; Thareja, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-326</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies and autoimmune diseases related to B lymphocytes.  This review focuses on the diverse, small-mol. inhibitors of BTK kinase that have shown good prospects for clin. application.  Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed.  Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK.  The present review also surveys the pharmacol. advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire crit. thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNAsX0qwSHLVg90H21EOLACvtfcHk0lips9-ODFU-Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D&md5=1ea0bf36d8ebadbfba624f858911b182</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.062%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DThareja%26aufirst%3DS.%26atitle%3DThe%2520development%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520from%25202012%2520to%25202017%253A%2520A%2520mini-review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D315%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2018.03.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawahata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">151</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.11.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.bmcl.2017.11.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=29198867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWhur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=145-151&author=W.+Kawahataauthor=T.+Asamiauthor=T.+Irieauthor=M.+Sawa&title=Design+and+synthesis+of+novel+pyrimidine+analogs+as+highly+selective%2C+non-covalent+BTK+inhibitors&doi=10.1016%2Fj.bmcl.2017.11.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors</span></div><div class="casAuthors">Kawahata, Wataru; Asami, Tokiko; Irie, Takayuki; Sawa, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-151</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BTK is a promising target for the treatment of multiple diseases such as B cell malignances, asthma, and rheumatoid arthritis.  Here, the authors report the discovery of a series of novel pyrimidine analogs as potent, highly selective, non-covalent inhibitors of BTK.  Compd. I demonstrated higher affinity to an unactivated conformation of BTK that resulted in an excellent kinase selectivity.  Compd. I showed a good oral bioavailability in mice, and significantly inhibits the PCA reaction in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpVaSuT25WJ7Vg90H21EOLACvtfcHk0ljMXnicbmH3uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWhur7I&md5=f77ce613ad2c95fe4d34abb41f5c5ea9</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.11.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.11.037%26sid%3Dliteratum%253Aachs%26aulast%3DKawahata%26aufirst%3DW.%26aulast%3DAsami%26aufirst%3DT.%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520pyrimidine%2520analogs%2520as%2520highly%2520selective%252C%2520non-covalent%2520BTK%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D145%26epage%3D151%26doi%3D10.1016%2Fj.bmcl.2017.11.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">TR-FRET binding assay targeting unactivated form of Bruton’s tyrosine kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2033</span>– <span class="NLM_lpage">2036</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.bmcl.2015.04.001" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2033-2036&author=T.+Asamiauthor=W.+Kawahataauthor=M.+Sawa&title=TR-FRET+binding+assay+targeting+unactivated+form+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1016%2Fj.bmcl.2015.04.001"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DAsami%26aufirst%3DT.%26aulast%3DKawahata%26aufirst%3DW.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3DTR-FRET%2520binding%2520assay%2520targeting%2520unactivated%2520form%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2033%26epage%3D2036%26doi%3D10.1016%2Fj.bmcl.2015.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawahata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">’Turn On/Off’ fluorescence probe for the screening of unactivated Bruton’s tyrosine kinase</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2141</span>– <span class="NLM_lpage">2145</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.03.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.bmcl.2015.03.063" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2141-2145&author=W.+Kawahataauthor=T.+Asamiauthor=I.+Fujiiauthor=M.+Sawa&title=%E2%80%99Turn+On%2FOff%E2%80%99+fluorescence+probe+for+the+screening+of+unactivated+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1016%2Fj.bmcl.2015.03.063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.03.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.03.063%26sid%3Dliteratum%253Aachs%26aulast%3DKawahata%26aufirst%3DW.%26aulast%3DAsami%26aufirst%3DT.%26aulast%3DFujii%26aufirst%3DI.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3D%25E2%2580%2599Turn%2520On%252FOff%25E2%2580%2599%2520fluorescence%2520probe%2520for%2520the%2520screening%2520of%2520unactivated%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2141%26epage%3D2145%26doi%3D10.1016%2Fj.bmcl.2015.03.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0ljMXnicbmH3uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frauchiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewdney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Structure-based drug design of RN486, a potent and selective Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=512-516&author=Y.+Louauthor=X.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-based+drug+design+of+RN486%2C+a+potent+and+selective+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor%2C+for+the+treatment+of+rheumatoid+arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Lou, Yan; Han, Xiaochun; Kuglstatter, Andreas; Kondru, Rama K.; Sweeney, Zachary K.; Soth, Michael; McIntosh, Joel; Litman, Renee; Suh, Judy; Kocer, Buelent; Davis, Dana; Park, Jaehyeon; Frauchiger, Sandra; Dewdney, Nolan; Zecic, Hasim; Taygerly, Joshua P.; Sarma, Keshab; Hong, Junbae; Hill, Ronald J.; Gabriel, Tobias; Goldstein, David M.; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">512-516</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis.  Highlights include the introduction of a benzyl alc. group and a fluorine substitution, each of which resulted in over 10-fold increase in activity.  Concurrent optimization of drug-like properties led to compd. I (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclin. characterization based on its favorable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdHX9-PE5I7Vg90H21EOLACvtfcHk0li7lHrXPgeN_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D&md5=dc3c069b0e876f44846a30e3aa6a894a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-based%2520drug%2520design%2520of%2520RN486%252C%2520a%2520potent%2520and%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%252C%2520for%2520the%2520treatment%2520of%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francesco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolove, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magadala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">R115</span>, <span class="refDoi"> DOI: 10.1186/ar3400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1186%2Far3400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=21752263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFGltrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=R115&author=B.+Y.+Changauthor=M.+M.+Huangauthor=M.+Francescoauthor=J.+Chenauthor=J.+Sokoloveauthor=P.+Magadalaauthor=W.+H.+Robinsonauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+ameliorates+autoimmune+arthritis+by+inhibition+of+multiple+effector+cells&doi=10.1186%2Far3400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells</span></div><div class="casAuthors">Chang, Betty Y.; Huang, Min Mei; Francesco, Michelle; Chen, Jun; Sokolove, Jeremy; Magadala, Padmaja; Robinson, William H.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">R115</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: The aim was to det. the effect of the Bruton tyrosine kinase (Btk)-selective inhibitor PCI-32765, currently in Phase I/II studies in lymphoma trials, in arthritis and immune-complex (IC) based animal models and describe the underlying cellular mechanisms.  Methods: PCI-32765 was administered in a series of murine IC disease models including collagen-induced arthritis (CIA), collagen antibody-induced arthritis (CAIA), reversed passive anaphylactic reaction (RPA), and passive cutaneous anaphylaxis (PCA).  Clin. and pathol. features characteristic of each model were examd. following treatment.  PCI-32765 was then examd. in assays using immune cells relevant to the pathogenesis of arthritis, and where Btk is thought to play a functional role.  These included proliferation and calcium mobilization in B cells, cytokine and chemokine prodn. in monocytes/macrophages, degranulation of mast cells and its subsequent cytokine/chemokine prodn.  Results: PCI-32765 dose-dependently and potently reversed arthritic inflammation in a therapeutic CIA model with an ED50 of 2.6 mg/kg/day.  PCI-32765 also prevented clin. arthritis in CAIA models.  In both models, infiltration of monocytes and macrophages into the synovium was completely inhibited and importantly, the bone and cartilage integrity of the joints were preserved.  PCI-32765 reduced inflammation in the Arthus and PCA assays.  In vitro, PCI-32765 inhibited BCR-activated primary B cell proliferation (IC50 = 8 nM).  Following FcγR stimulation, PCI-32765 inhibited TNFα, IL-1β and IL-6 prodn. in primary monocytes (IC50 = 2.6, 0.5, 3.9 nM, resp.).  Following Fc.vepsiln.RI stimulation of cultured human mast cells, PCI-32765 inhibited release of histamine, PGD2, TNF-α, IL-8 and MCP-1.  Conclusions: PCI-32765 is efficacious in CIA, and in IC models that do not depend upon autoantibody prodn. from B cells.  Thus PCI-32765 targets not only B lymphocytes but also monocytes, macrophages and mast cells, which are important Btk-expressing effector cells in arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQLy1_wdvr7rVg90H21EOLACvtfcHk0li7lHrXPgeN_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFGltrs%253D&md5=ab0d3df5dc8816194c4087a131125744</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2Far3400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far3400%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DHuang%26aufirst%3DM.%2BM.%26aulast%3DFrancesco%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSokolove%26aufirst%3DJ.%26aulast%3DMagadala%26aufirst%3DP.%26aulast%3DRobinson%26aufirst%3DW.%2BH.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520ameliorates%2520autoimmune%2520arthritis%2520by%2520inhibition%2520of%2520multiple%2520effector%2520cells%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2011%26volume%3D13%26spage%3DR115%26doi%3D10.1186%2Far3400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajbi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzenet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khouili, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillaumet, G.</span></span> <span> </span><span class="NLM_article-title">Polysubstituted 2,3-dihydrofuro[2,3-b]pyridines and 3,4-dihydro-2<i>H</i>-pyrano[2,3-b]pyridines via microwave-activated Inverse electron demand Diels-Alder reactions</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8286</span>– <span class="NLM_lpage">8297</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2007.05.112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.tet.2007.05.112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2007&pages=8286-8297&author=Y.+Hajbiauthor=F.+Suzenetauthor=M.+Khouiliauthor=S.+Lazarauthor=G.+Guillaumet&title=Polysubstituted+2%2C3-dihydrofuro%5B2%2C3-b%5Dpyridines+and+3%2C4-dihydro-2H-pyrano%5B2%2C3-b%5Dpyridines+via+microwave-activated+Inverse+electron+demand+Diels-Alder+reactions&doi=10.1016%2Fj.tet.2007.05.112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2007.05.112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2007.05.112%26sid%3Dliteratum%253Aachs%26aulast%3DHajbi%26aufirst%3DY.%26aulast%3DSuzenet%26aufirst%3DF.%26aulast%3DKhouili%26aufirst%3DM.%26aulast%3DLazar%26aufirst%3DS.%26aulast%3DGuillaumet%26aufirst%3DG.%26atitle%3DPolysubstituted%25202%252C3-dihydrofuro%255B2%252C3-b%255Dpyridines%2520and%25203%252C4-dihydro-2H-pyrano%255B2%252C3-b%255Dpyridines%2520via%2520microwave-activated%2520Inverse%2520electron%2520demand%2520Diels-Alder%2520reactions%26jtitle%3DTetrahedron%26date%3D2007%26volume%3D63%26spage%3D8286%26epage%3D8297%26doi%3D10.1016%2Fj.tet.2007.05.112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pellegatti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedrenne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Routier, S.</span></span> <span> </span><span class="NLM_article-title">New heteroaromatic aminations on 5-aryl-1,2,4-triazines and 1,2,4,5-tetrazines by palladium catalysis</span>. <i>Tetrahedron</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">4383</span>– <span class="NLM_lpage">4389</span>, <span class="refDoi"> DOI: 10.1016/j.tet.2010.03.099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=10.1016%2Fj.tet.2010.03.099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtF2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=4383-4389&author=L.+Pellegattiauthor=E.+Vedrenneauthor=J.+M.+Legerauthor=C.+Jarryauthor=S.+Routier&title=New+heteroaromatic+aminations+on+5-aryl-1%2C2%2C4-triazines+and+1%2C2%2C4%2C5-tetrazines+by+palladium+catalysis&doi=10.1016%2Fj.tet.2010.03.099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">New heteroaromatic aminations on 5-aryl-1,2,4-triazines and 1,2,4,5-tetrazines by palladium catalysis</span></div><div class="casAuthors">Pellegatti, Laurent; Vedrenne, Emeline; Leger, Jean-Michel; Jarry, Christian; Routier, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4383-4389</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The efficient and original palladium-catalyzed amination of 5-aryl-1,2,4-triazines and 1,2,4,5-tetrazines is reported.  This Buchwald-Hartwig type reaction leads to the formation of aminated heterocycles via methylsulfur release.  The reaction is optimized and a wide range of amines is used to det. the scope and limitations of this methodol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHHZgix8tAWrVg90H21EOLACvtfcHk0lgk10SkRYF5eA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtF2jtbw%253D&md5=d0037874d57b7052144967c67abf44b4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2010.03.099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2010.03.099%26sid%3Dliteratum%253Aachs%26aulast%3DPellegatti%26aufirst%3DL.%26aulast%3DVedrenne%26aufirst%3DE.%26aulast%3DLeger%26aufirst%3DJ.%2BM.%26aulast%3DJarry%26aufirst%3DC.%26aulast%3DRoutier%26aufirst%3DS.%26atitle%3DNew%2520heteroaromatic%2520aminations%2520on%25205-aryl-1%252C2%252C4-triazines%2520and%25201%252C2%252C4%252C5-tetrazines%2520by%2520palladium%2520catalysis%26jtitle%3DTetrahedron%26date%3D2010%26volume%3D66%26spage%3D4383%26epage%3D4389%26doi%3D10.1016%2Fj.tet.2010.03.099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZZ4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZZ4','PDB','5ZZ4'); return false;">PDB: 5ZZ4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3GEN','PDB','3GEN'); return false;">PDB: 3GEN</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i72"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01147">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_35144"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01147">10.1021/acs.jmedchem.8b01147</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis methods for intermediates <b>24h</b>–<b>24m</b>, <b>25</b>, and <b>26a</b>–<b>26i</b> and methods for the microsomal-stability assay, aqueous-solubility assay, hERG assay, and kinase-selectivity-panel assay (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular-formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_001.pdf">jm8b01147_si_001.pdf (1.16 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01147/suppl_file/jm8b01147_si_002.csv">jm8b01147_si_002.csv (2.95 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The PDB code for compound <b>2e</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZZ4">5ZZ4</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01147%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-19%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01147" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799510ecfc93d42","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
